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ABSTRACT 
 
Pancreatic cancer is characterised by an intense fibrotic, or desmoplastic, stroma, 
which contributes to tumour progression. Three-dimensional in vitro culture 
models incorporating this non-tumour component may more closely recapitulate 
the complex in vivo situation. The aim of my project was to develop a 
physiologically relevant, three-dimensional organotypic culture model of 
pancreatic cancer to study the tumour-stroma interactions and its modulation by 
novel therapeutic agents.  
 
Cancer cells cultured on top of collagen/Matrigel gels, embedded with or without 
stromal cells (hTERT immortalised PS1 stellate cells or MRC5 fibroblasts), 
differentiated into luminal structures, exhibiting a central apoptotic core with a 
proliferating peripheral rim and apicobasal polarity. Stromal cells induced a 
reduction in total tumour cell number, which was associated with a decrease in 
E-cadherin expression, upregulated β-catenin expression and translocation of 
ezrin from the apical to the basal aspect of cancer cells, where it was associated 
with invasive activity.  
 
Subsequently, this organotypic model was raised to an air-liquid interface to 
study the direct and indirect effects of all-trans retinoic acid (ATRA), which 
rendered stellate cells back to their quiescent phenotype. Indirect effects of 
quiescent stellate cells on pancreatic cancer cells included changes in 
proliferation (decrease), apoptosis (increase), invasion (decrease), Wnt/β-catenin 
signalling (decrease) and an altered morphology. The Wnt/β-catenin signalling 
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perturbations were mediated by restoration of sFRP4 (secreted frizzled-related 
protein 4) secretion by quiescent stellate cells, resulting in reduced cancer cell 
invasion (reporter and invasion assays). All such observations could be validated 
in human pancreatic cancer tissue samples. 
 
Taken together, pancreatic organotypic culture offers a reproducible, in vitro 
three-dimensional culture model, which allows the study of tumour-stroma 
interactions in a physiologically relevant system. For treatment of pancreatic 
cancer, a tumour characterised by a poor response to conventional 
chemotherapeutic drugs, targeting the tumour-stroma cross-talk with agents such 
as ATRA offers an exciting novel therapeutic strategy.  
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1.CHAPTER I  INTRODUCTION 
 
1.1. Pancreatic cancer 
1.1.1. Classification of pancreatic neoplasms 
The pancreas is composed of exocrine and endocrine compartments, regulating 
two major physiological functions: digestion and glucose metabolism. The 
exocrine pancreas consists of many small glands (acini) formed by acinar cells 
that drain into small ducts, which anastomose to form the pancreatic ductal 
system that ultimately drains into the duodenum. Acinar cells produce inactive 
enzymes, such as trypsin, elastase, amylase and lipase, within membrane-bound 
zymogen granules, which are released upon stimulation into the small duct 
draining the acini. The smallest ductal cells have a cuboidal epithelium, which 
gradually becomes a tall, columnar, electrolyte- and mucus-secreting epithelium 
in the larger ducts. The endocrine cells are organised into compact islets, which 
are interspersed within the exocrine tissue. The classification of neoplasms of the 
pancreas is based mainly on the cellular differentiation along these three main 
epithelial cell types (ductal, acinar and endocrine cells) as well as the gross 
configuration of the tumour (solid, cystic or intraductal)1. The term pancreatic 
cancer generally refers to pancreatic ductal adenocarcinoma (PDAC), which is 
by far the most common neoplasm of the pancreas (> 80%), and the terms 
pancreatic cancer and PDAC are used synonymously. Although the classification 
of pancreatic neoplasms is based on the cellular phenotype, it does not reflect the 
true cell of origin of PDAC. One emerging hypothesis regarding the cell of 
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origin in pancreatic cancer is the existence of a small population of self-
renewing, cancer-initiating cells known as cancer stem cells2, 3. Cancer stem 
cells have been identified in multiple solid tumours, such as those of colon, liver, 
prostate, skin and breast4. Also in pancreatic cancer there is increasing evidence 
of the existence of cancer stem cells, identified on the basis of the expression of 
different cell surface markers (CD133, CD24, CD44 and epithelial specific 
antigen (ESA)) and their ability to initiate tumours in immunocompromised 
mice. These cells demonstrated increased migratory capacity as well as higher 
resistance to the standard chemotherapeutic drug gemcitabine5-7. However, the 
origin of these cancer stem cells remains unknown. Although there is no 
convincing evidence for the presence of stem cells in the normal pancreas, they 
may arise from genetic alterations in somatic stem or progenitor cells. Another 
possibility is that lineage-committed cells have (re-)acquired stem cell 
characteristics through dysregulation of critical self-renewal pathways. In 
addition to these advances, transgenic animal models have provided important 
insights into the cellular origin of pancreatic cancer by demonstrating that, in the 
presence of activated KRAS, both acini and insulin-positive cells can give rise to 
PanINs and in some cases PDAC8. These transgenic models, and the acinar-to-
ductal transdifferentiation, will be discussed in more detail in paragraph 1.6.2. 
 
Pancreatic cancer most commonly arises in the head of the pancreas 
(approximately 65%, versus 15% in the body, 10% in the tail and 10% of 
tumours are multifocal) and infiltrates into surrounding tissue including 
lymphatics and nerves. Perineural and lympho-vascular invasion can already be 
seen in very small primary lesions (40–75% of primary tumours less than 2 cm 
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demonstrate lymph node metastasis and perineural invasion), suggesting a 
tendency for early spread. Indeed, most patients present already with distant 
metastasis, most commonly in the liver and peritoneal cavity9, 10. 
 
1.1.2. Epidemiology 
Pancreatic cancer is a disease with a dire prognosis. In 2008 there were 
approximately 37,000 patients diagnosed with pancreatic cancer in the USA with 
nearly an equal number of deaths from it, which makes it the fourth most 
common cause of cancer-related death11. A similar pattern is seen in the UK, 
where the annual incidence of pancreatic cancer is about 12/100,000 with 
roughly 7,600 newly diagnosed cases in 2007 and 7,700 deaths from the disease 
in 2008, making it the fifth most common cause of cancer death in the UK12, 13. 
These incidence and mortality patterns clearly reflect the poor survival of 
patients with pancreatic cancer. The mortality rates of pancreatic cancer vary 
among countries14; over the last 30 years of the 20th century survival from 
pancreatic cancer has improved very slightly in the UK to a 5-year survival for 
patients with localised, resectable disease of 15-18%, with a decrease to only 2% 
in the presence of metastatic disease14. At present, only pancreatic resection can 
improve survival significantly. However, due to late presentation and aggressive 
tumour behaviour, only a minority (5-10%) of patients can undergo potentially 
curative surgery12.  
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1.1.3. Environmental and genetic risk factors for pancreatic cancer 
Pancreatic cancer is a disease of the elderly, with a peak incidence in the 65-75 
year age group, and a similar prevalence in men and women14. The only other 
consistently reported exogenous risk factor for pancreatic cancer is cigarette 
smoking; it is estimated that one in four cases of pancreatic cancer can be 
attributed to cigarette smoking and a recent meta-analysis of 82 studies published 
between 1950 and 2007 found that current smokers have a 1.74-fold (95% 
confidence interval 1.61-1.87) increased risk of developing pancreatic cancer15, 
16. Other factors that have been associated with an increased risk of pancreatic 
cancer, but whose exact role still is unclear due to inconsistent results, include 
alcohol intake17, diets high in meats and fat, low serum folate levels, obesity18, 
diabetes mellitus19 and chronic pancreatitis20. Additionally, it is estimated that 5-
10% of all pancreatic cancer cases have an inherited component21, 22. In familial 
pancreatic cancer, where there are at least two first-degree relatives with 
pancreatic cancer without the presence of other inherited cancer syndromes, the 
risk of pancreatic cancer increases with the number of first-degree relatives 
affected, suggesting an autosomal dominant inheritance of a rare allele9, 23. 
Although a number of germ-line mutations have been associated with an 
increased risk of pancreatic cancer, in the majority of families the genetic basis 
for the familial occurrence of pancreatic cancer remains unknown. Mutations in 
BRCA2 can be found in 6 to 12% of families with two or more cases of 
pancreatic cancer, with an increased frequency of BRCA2 mutations in families 
with many (three or more) cases of pancreatic cancer24. Other inherited cancer 
syndromes associated with pancreatic cancer are hereditary pancreatitis (caused 
by mutations in the PRSS1 gene), Peutz-Jeghers syndrome (mutations in the 
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STK11/LKB1 gene), familial atypical multiple mole melanoma (FAMMM) 
syndrome (caused by mutations in INK4A), familial breast cancer syndrome 
(BRCA1 and BRCA2 mutations) and hereditary nonpolyposis colorectal cancer 
syndrome (caused by mutations in hMLH1 or hMSH2)25.  
 
1.2. Pathophysiology of pancreatic cancer 
1.2.1. Preneoplastic lesions 
Three histologically different forms of non-invasive pancreatic neoplasia have 
been described: pancreatic intraepithelial neoplasia (PanIN), mucinous cystic 
neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs), and 
each of these, potentially, can have a distinct sequence of molecular/genetic 
aberrations leading to pancreatic ductal adenocarcinoma (PDAC)26. PanINs are 
the microscopic precursor lesions (< 5 mm), defined as neoplastic epithelial 
proliferations in the small pancreatic ducts. Based on their degree of 
differentiation PanINs are classified into three grades, PanIN-1, PanIN-2 and 
PanIN-3. The lower grade PanIN lesions can be flat (PanIN-1A) or papillary 
(PanIN-1B) and have abundant supranuclear mucin, no nuclear atypia and 
maintained polarity. PanIN-2 lesions are mostly papillary with evidence of 
nuclear abnormalities and, infrequently, some mitoses (non luminal and not 
atypical). PanIN-3 lesions are characterised by loss of nuclear polarity, nuclear 
atypia and frequent mitoses that may occasionally be abnormal. PanIN-3 lesions 
resemble carcinoma but, importantly, invasion through the basement membrane 
is absent (carcinoma in situ)27, 28. Comparing normal pancreata with pancreata 
with invasive cancer, clinical studies showed a progressive increase in the 
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number and grade of PanINs. Additionally, a few case-reports have documented 
patients with PanINs who later developed invasive pancreatic cancer28. In 
contrast to PanINs, which cannot be detected with the currently available 
imaging techniques, the larger macroscopic MCNs and IPMNs (both larger than 
1 cm) can be seen radiographically.  
 
MCNs, defined as mucin-producing epithelial neoplasms with a characteristic 
ovarian-type stroma, arise predominantly in the tail of the pancreas and affect 
mainly women26. In addition to the “ovarian-type” stroma, MCNs are 
characterised histologically by columnar mucin-producing cells with varying 
degrees of differentiation, based on which they can be classified into 4 possible 
categories: mucinous cystadenomas (without significant atypia and with uniform 
nuclei), borderline MCNs (moderate cytological and architectural atypia); MCNs 
with carcinoma in situ (significant high-grade dysplasia) and invasive mucinous 
cystadenocarcinoma29. Approximately one third of the MCNs have an associated 
invasive carcinoma, which usually is a ductal type of adenocarcinoma30.  
 
The third distinct precursor lesion in the pancreas is the intraductal papillary 
mucinous neoplasm (IPMN). IPMNs arise in the larger pancreatic ducts, mainly 
in the head of the pancreas and produce mucin MUC2 (whereas most of the 
PanINs express MUC1)27. In contrast to MCNs, the cystic lesions of IPMNs by 
definition communicate with and involve pancreatic ducts (either the main 
pancreatic duct, its branches or both) and, similar to MCNs, the degree of 
cellular atypia can be heterogeneous. Distinction between IPMNs arising in the 
main pancreatic duct (“main duct IPMN”) or in the branches of the main 
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pancreatic duct (“branch duct IPMN”) is clinically important, since branch duct 
IPMNs are less likely to harbour or progress to invasive carcinoma compared to 
main duct IPMNs30. Additionally, microscopic morphological classification is of 
prognostic importance. Two types of invasive carcinoma have been shown to 
arise in association with IPMNs: a tubular/ductal type of invasive 
adenocarcinoma (mostly associated with a “pancreato-biliary-type IPMN”), 
which is identical to PDAC not arising with IPMNs, and the colloid or 
muconodular type of invasive cancer (mostly associated with an “intestinal-type 
IPMN”), which appears to have a significantly better prognosis26, 30, 31.  
 
All three noninvasive entities demonstrate a multistep morphologic and genetic 
progression that ultimately culminates in invasive adenocarcinoma. Each 
precursor lesion however is characterised by a unique repertoire of 
clinicopathologic and genetic alterations that has an impact on natural history 
and prognosis of these lesions (Table 1.1, Figure 1.1)26, 27, 30. 
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 MCN IPMN PanIN PDAC 
Age at 
diagnosis 
Noninvasive,  
55 years;  
invasive,  
65 years 
Noninvasive,  
63 years;  
invasive,  
68 years 
Increasing  
with age 
Increasing  
with age,  
peak between  
65-75 years 
Gender 90% F 40% F 50% F 50% F 
Location in 
pancreas Tail Head Head Head 
Growth within 
larger 
pancreatic ducts 
No Yes No  
Clinically 
detected Yes Yes No  
Grossly visible Yes Yes No  
Mucin oozing 
from ampulla No Yes No  
Ovarian-type 
stroma Yes No No  
Extra-
pancreatic 
neoplasms 
No Yes No  
Presenting 
symptoms 
Asymptomatic or 
vague abdominal 
symptoms (pain, 
anorexia) 
Abdominal pain, 
weight loss, 
steatorrhea, 
pancreatitis 
Asymptomatic 
Jaundice, back or 
abdominal pain, 
nausea, weight 
loss, anorexia, 
malabsorption or 
diabetes mellitus 
 
Table 1.1 Features of different precursor lesions for invasive pancreatic 
ductal adenocarcinoma and the presenting symptoms.  
Adjusted from Maitra et al. Adv Anat Pathol 200526. MCN, mucinous cystic neoplasm; 
IPMN, intraductal papillary mucinous neoplasm; PanIN, pancreatic intraepithelial 
neoplasia; PDAC, pancreatic ductal adenocarcinoma. 
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Figure 1.1 Progression model of pancreatic cancer 
Early genetic alterations include telomere shortening and mutations in the KRAS 
oncogene, shown to be the initiating genetic alteration leading to the development of 
PanIN lesions and PDAC; development of invasive PDAC is accelerated by further loss 
of INK4A/ARF and inactivation of the TP53 and SMAD4 tumour suppressor genes. 
These genetic alterations in epithelial cells are accompanied by stromal alterations 
resulting in an increased desmoplastic tumour microenvironment, which can be seen in 
the histogical images of haematoxylin and eosin (H&E) stained pancreatic tissues. 
PanIN, pancreatic intraepithelial neoplasia; MCN, mucinous cystic neoplasm; IPMN, 
intraductal papillary mucinous neoplasm; PDAC, pancreatic ductal adenocarcinoma. 
Cartoon adjusted from Morris IV et al. Nat Rev Cancer 20108; histological images of 
H&E stained sections are from The Sol Goldman Pancreatic Cancer Research Center, 
http://pathology.jhu.edu/pc/professionals/DuctLesions.php (normal pancreas and all 
precursor lesions) and provided by Mr Hemant M Kocher (pancreatic cancer).  
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1.2.2. Major genetic events 
Molecular analyses of PanINs and invasive pancreatic cancer have shown that 
PanINs share many of the genetic alterations seen in pancreatic cancer, 
confirming the hypothesis that PanINs are precursor lesions to pancreatic cancer, 
and that these genetic alterations accumulate during the consecutive stages of 
tumour progression (Figure 1.1)28. 
 
Activating point mutations in the oncogene KRAS can be found in more than 
90% of pancreatic cancers and are thought to be an initiating event; mutations in 
KRAS can be found in 10-30% of PanIN-1, 45% of PanIN-2 and 85% of PanIN-3 
lesions32. KRAS is a member of the RAS superfamily of guanosine triphosphate 
(GTP)-binding proteins, which possess a very low intrinsic guanosine 
diphosphate (GDP)/GTP exchange and GTP hydrolytic activity. RAS activity is 
regulated by guanine nucleotide exchange factors (GEFs), which promote the 
exchange of GDP for GTP resulting in active RAS, and GTPase activating 
proteins (GAPs), which accelerate the low intrinsic GTPase activity of RAS 
proteins by stimulating GTP hydrolysis to GDP and therefore attenuate RAS 
signalling. In response to a variety of stimuli, such as activation of receptor and 
non-receptor tyrosine kinases, active RAS mediates a wide range of cellular 
functions, including proliferation, differentiation, survival among others33, 34.  
 
Point mutations at codon 12 (from GGT to GAT or GTT, and more rarely CGT) 
result in substitution of glycine with aspartate (G12D), valine (G12V), or alanine 
(G12A), leading to a constitutively active form of KRAS, which has decreased 
intrinsic GTPase activity and is refractory to extrinsic GAPs, hence insensitive 
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for GTP hydrolysis35. Activated KRAS transforms cells through the activation of 
multiple downstream pathways; three main downstream signalling pathways are 
implicated in pancreatic cancer and these are the RAF – mitogen-activated 
protein kinase (MAPK), the phosphoinositide-3-kinase (PI3K), and the RalGDS 
pathways. Moreover, activation of KRAS induces autocrine activation of 
epidermal growth factor receptor (EGFR) family ligands, with upregulated 
expression of EGF and transforming growth factor-α (TGFα) and their receptors 
EGFR, ErbB2 and ErbB336.   
 
In more advanced lesions, additional inactivation of the tumour suppressor genes 
p16/CDKN2A (or INK4A) and TP53 occur in 80-95% and 50-75% of PDAC 
cases respectively, and mutations in SMAD4 occur in nearly 60%27. The INK4A 
product, p16INK4A, inhibits the phosphorylation of retinoblastoma by cyclin-
dependent kinases, thereby blocking the entry into the S phase of the cell-cycle 
(DNA synthesis). Interestingly, the INK4A locus also encodes another tumour 
suppressor, ARF, via distinct first exons and alternative reading frames in shared 
exons. Its product, p19ARF, exerts its tumour suppressive role through the 
stabilisation of p53 by inhibiting Mdm2-mediated ubiquitination. Loss of INK4A, 
through deletion, intragenic mutations or promoter methylation, has been 
associated with the development of pancreatic cancer, since mutations have been 
identified that target INK4A but spare ARF; approximately 40% of pancreatic 
cancers demonstrate a loss of both INK4A and ARF 9, 35. Moreover, germline 
mutations in INK4A are associated with the FAMMM syndrome, in which it is 
associated with a 13-fold increased risk of pancreatic cancer, whereas FAMMM 
kindreds with other mutations do not share this enhanced risk25.  
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More than 50% of pancreatic cancers demonstrate loss of p53 function through 
mutations in the TP53 gene, with loss of the second allele. In cellular stress, such 
as oncogene activation, the p53 protein is stabilised and regulates a transcription 
response resulting in cell-cycle arrest and the induction of apoptosis. Hence, loss 
of this function will allow cells with damaged DNA to survive and divide and 
therefore increase genetic abnormalities and malignant progression35.  
 
Inactivation of SMAD4, either by homozygous deletion or by intragenic 
mutations, affects the transforming growth factor-β (TGFβ) signalling pathway. 
Briefly, binding of TGFβ to its cell surface receptor results in the 
phosphorylation of Smad2 and Smad3, which form a complex with Smad4 and 
subsequently enter the nucleus to modulate the transcription of target genes that 
control many cellular processes, including the cell-cycle and apoptosis. In 
normal epithelial cells TGFβ functions as a tumour suppressor, partly by 
inhibiting proliferation, promoting apoptosis and enhancing genomic stability. 
The loss of Smad4 not only is associated with a growth advantage of pancreatic 
cancer cells, but also has important effects on the tumour microenvironment; this 
aspect of TGFβ signalling will be discussed in paragraph 1.4.137, 38. 
 
In addition to mutated oncogenes and tumour suppressor genes, mutations in 
DNA repair genes are observed in pancreatic cancer, including BRCA2, related 
Fanconi anaemia (FANC) genes, hMLH1 and hMSH2 genes27, 39. Although these 
genes are inactivated only infrequently, they are important mainly because of 
their association with hereditary forms of pancreatic cancer as discussed earlier.  
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Increasing evidence is also emerging for reactivation of embryological signalling 
pathways, such as Hedgehog and Wnt/β-catenin signalling8, 40. In pancreatic 
cancer, mutations in regulatory components of either Hedgehog signalling (e.g. 
mutations in the transmembrane receptors patched (Ptc) or smoothened (Smo, 
see paragraph 1.4.1) or the Wnt-signalling pathway (e.g. mutations in 
adenomatous polyposis coli (APC) or β-catenin, see paragraph 3.6.3, 4.3.1 and 
4.5.2) are typically absent. However, Hedgehog ligands are aberrantly expressed 
in the majority of PDACs (~75%), with enhanced expression in PanIN lesions 
and a further increase with disease progression41; cytoplasmic and nuclear 
accumulation of β-catenin is more heterogeneous with an increased expression in 
10-65% of PanIN lesions and PDAC42, 43. Recent studies have suggested that 
Hedgehog signalling is activated, particularly, in the tumour microenvironment 
and is an important stimulus of the desmoplastic reaction seen in pancreatic 
cancer44, 45; this aspect will be discussed in paragraph 1.4.1. I have studied the 
role of Wnt/β-catenin signalling in pancreatic cancer, which will be discussed in 
Chapter III and IV.  
 
1.2.3. Pancreatic cancer stroma 
Pancreatic cancer characteristically is surrounded by an intense fibrous or 
desmoplastic stroma that can account for a large proportion of the tumour mass 
(Figure 1.2)9. This surrounding tumour microenvironment is composed of 
extracellular matrix (ECM), and several cell types, including fibroblasts, 
pancreatic stellate cells, smooth muscle cells, immune and inflammatory cells, 
lipocytes and endothelial cells. Of particular interest is that, through reciprocal 
interactions between tumour and stromal cells, this desmoplastic stroma 
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increasingly is believed to participate actively in tumour progression46. Collagen 
type I and fibronectin are the main components of the connective tissue, with an 
observed threefold higher mean collagen content in pancreatic cancer and 
tumour-associated chronic pancreatitis compared to normal pancreatic tissue47, 
48. Although it has been shown that pancreatic cancer cells can produce collagen 
types I, III and IV, laminin, fibronectin and vitronectin49, evidence has now 
accumulated that the major sources of ECM production are myofibroblast-like 
cells, confirmed as pancreatic stellate cells50. In the normal exocrine pancreas, 
fibroblasts and pancreatic stellate cells have a low proliferative index and only 
secrete factors needed to maintain normal tissue homeostasis46. In the early 
stages of tumour progression, when the basement membrane is disrupted, the 
stromal response is similar to a response seen during wound healing and consists 
mainly of increased proliferation of stromal cells and collagen deposition. 
However, during tumour progression this stromal reaction does not revert back to 
a quiescent state, as is seen during wound repair51. The proliferation of stromal 
cells with an altered ECM is called desmoplasia, or the desmoplastic reaction, 
and has been studied extensively in different tumours, especially in breast52, 53 
and prostate cancer54, and more recently in pancreatic cancer38, 55. 
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Figure 1.2 Histology of pancreatic cancer. 
Haematoxylin and eosin (H&E) staining of pancreatic cancer tissue (A) and its 
schematic representation (B), demonstrating the extensive desmoplastic stroma in 
pancreatic cancer. Images provided by Mr Hemant M Kocher. 
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1.3. Clinical management of pancreatic cancer 
1.3.1. Diagnosis 
Due to the nonspecific symptoms, such as malaise, abdominal pain, nausea, or 
weight loss, in early stages of the disease, particularly in the absence of biliary 
tract obstruction, pancreatic cancer most commonly presents late with advanced 
disease. Tumours in the head of the pancreas often obstruct the common bile 
duct, resulting in symptoms of obstructive jaundice such as pale stool, dark urine, 
and/or pruritus. Tumours in the body and tail tend to present later and more often 
with pain, usually epigastric with radiation to the back; jaundice in these patients 
is usually caused by hepatic or hilar metastases. Extensive pancreatic infiltration 
or obstruction of the major pancreatic ducts will also cause exocrine dysfunction, 
resulting in malabsorption and steatorrhea or an unexplained episode of 
pancreatitis. In contrast, endocrine dysfunction, resulting in new-onset diabetes, 
occurs in small tumours in approximately 40% of patients, possibly due to 
tumour-secreted soluble factors affecting β-cell function, and has been associated 
with early disease56, 57.  
 
Routine blood tests are generally non-specific and, among many potential 
biomarkers, only carbohydrate antigen 19-9 (CA19-9) has clinical usefulness, in 
particular for monitoring response to treatment and in identifying recurrence in 
treated patients with known pancreatic cancer58. However, with a reported 
sensitivity of 70% to 90% and a specificity of 90%, CA19-9 lacks the desired 
sensitivity and specificity for early detection and diagnosis9.  
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Since treatment and prognosis depend on the extent of the disease, the evaluation 
of a patient with suspected pancreatic cancer is focussed on establishing a 
diagnosis and accurate staging of the disease. Transabdominal ultrasound may 
detect tumours > 2 cm in size and possibly extra-pancreatic spread (mainly liver 
metastases) or dilatation of the common bile duct, with a reported sensitivity of 
80% to 95%10. However, since a normal abdominal ultrasound does not exclude 
pancreatic cancer, the imaging modality of choice in all patients with a suspicion 
of pancreatic cancer is dynamic-phase helical or spiral computed tomography 
(CT), according to a specific pancreas protocol (i.e., triphasic cross-sectional 
imaging and thin slices and in specific aspect of venous phase of intravenous 
contrast). This has been shown to achieve diagnostic rates of 97% for pancreatic 
cancer, with accurate prediction of resectability in 80% to 90% of patients9, 59.  
 
There is no uniform consensus regarding the use of additional staging 
technologies. In patients with an equivocal CT and with a clinical suspicion of 
pancreatic cancer, endoscopic retrograde cholangiopancreatography (ERCP) 
and/or magnetic resonance cholangiopancreatography (MRCP) can provide 
detailed information of the pancreatic and bile-duct anatomy. Additionally, 
ERCP has the advantage that it provides an opportunity to sample for cytology or 
histology and that a stent can be placed to palliate biliary obstruction when 
surgery is not elected or must be delayed. Occasionally MR-angiography (MRA) 
is indicated to demonstrate the vascular anatomy. Endoscopic ultrasound (EUS) 
is highly sensitive in detecting small tumours (as small as 2 to 3 mm) and is 
particularly indicated in patients whose CT scans show no lesion or who have 
questionable vascular or lymph node involvement60, 61. Laparoscopy, including 
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laparoscopic ultrasound (LUS) and peritoneal washes, can detect occult 
metastatic lesions in the liver and peritoneal cavity that are below the detection 
threshold of the currently available imaging techniques, and can prevent 
unnecessary laparotomy in up to 30% of patients, as I have shown in a meta-
analysis62. Depending on a centre’s expertise, laparoscopic staging may be 
appropriate in some patients, especially in those with lesions in the body or tail, 
or in patients with a higher risk of disseminated disease (borderline resectable, 
large primary tumour or a high CA19-9)63, 64. For patients eligible for surgical 
resection, a tissue diagnosis is not required before surgical treatment. However, 
in patients with advanced, unresectable disease selected for palliative therapy, 
biopsy confirmation is necessary for determining the appropriate treatment 
strategy.  
 
Pancreatic cancer is staged according to the American Joint Committee on 
Cancer (AJCC) tumour–node–metastasis (TNM) classification (Table 1.2)65, 66. 
Based on this classification system local disease can be distinguished in 
potentially resectable disease (T1-T3) and unresectable, locally advanced disease 
(T4). However, there are no universally accepted criteria for resection and 
decisions should be made by a multidisciplinary team.  
 
Given the multistep progression from non-invasive precursor lesions to invasive 
pancreatic cancer, early detection of the disease will give the best chances of 
long-term cure. However, this will require screening of asymptomatic people, 
which due to the lack of sensitive and specific marker(s) of early pancreatic 
cancer currently is not recommended21, 67. Multiple studies are ongoing and 
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high-risk patients should be screened as part of a clinical trial in specialist 
centres. In Europe a large screening study for individuals at a high risk of 
pancreatic cancer is coordinated by The European Registry of Hereditary 
Pancreatitis and Familial Pancreatic Cancer (EUROPAC), which combines 
imaging and blood testing, with the option of molecular analysis of pancreatic 
juice. In the USA, the Cancer of the Pancreas Screening 2 (CAPS2) project has 
recently demonstrated a possible role for endoscopic ultrasound in screening for 
pancreatic cancer, but many challenges, such as the applicability in the general 
population and the cost/benefit ratio, remain68.  
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American Joint Committee on Cancer (AJCC) TNM staging of pancreatic cancer 
 Primary tumour (T) 
Regional lymph 
nodes (N) 
Distant 
metastasis (M) Characteristics 
Median survival 
(months) 
Stage 0 Tis N0 M0 Carcinoma in situ. Resectable  
Stage IA T1 N0 M0 Tumour limited to the pancreas and < 2 cm, no lymph node or distant metastasis. Resectable 24.1 
Stage IB T2 N0 M0 Tumour limited to the pancreas and > 2 cm, no lymph node or distant metastasis. Resectable 20.6 
Stage IIA T3 N0 M0 Tumour has extended beyond the pancreas but does not involve the celiac axis or superior mesenteric artery, no lymph node or distant metastasis. Resectable 15.4 
Stage IIB T1, T2 or T3 N1 M0 Regional lymph node metastasis. Resectable 12.7 
Stage III T4 N0 or N1 M0 Tumour has extended beyond the pancreas and involves the celiac axis or the superior mesenteric artery. Unresectable 10.6 
Stage IV T1, T2, T3 or T4 N0 or N1 M1 Metastatic disease. Unresectable 4.5 
 
Table 1.2 Staging of pancreatic cancer. 
American Joint Committee on Cancer (AJCC) staging of pancreatic cancer. T, tumour; N, node; M, metastasis. Survival rates are from Bilimoria et al.65. 
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1.3.2. Current treatment options 
Treatment is based on the extent of the disease, and the only potentially curative 
treatment is surgical resection. Alternative treatments, for more extensive 
disease, include palliative surgery to relieve symptoms, and endoscopic or 
percutaneous biliary stenting to relieve jaundice and/or gastric outlet obstruction. 
Chemotherapy and radiation therapy may be used as palliative treatment as well 
as in the adjuvant setting with surgery61.  
 
Fit patients with resectable pancreatic cancer, about 10% of all patients, should 
be referred to a high-volume specialist centre for surgical resection to increase 
resection rates and decrease hospital morbidity and mortality16. The type and 
extent of the surgery depend on the location and site of the tumour. The most 
widely used procedures are the proximal pancreaticoduodenectomy with 
antrectomy (Kausch-Whipple procedure) or the pylorus-preserving 
pancreaticoduodenectomy (Traverso-Longmire procedure) for tumours in the 
head of the pancreas, which may lead to similar quality of life and survival69. 
Left pancreatectomy (with splenectomy) is appropriate for localised tumours in 
the body or tail of the pancreas, but these tumours rarely present at an early, 
localised stage70.  
 
Neoadjuvant therapy (treatment given prior to surgery to reduce the size or 
extent of the tumour, in order to enhance chances of successful surgical removal 
of all tumour tissue) remains under investigation in pancreatic cancer; 
prospective randomised controlled trials testing different neoadjuvant regimens, 
such as gemcitabine-based chemotherapy or chemoradiation, are ongoing. 
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Fluorouracil-based neoadjuvant chemoradiation therapy may be considered in 
patients with borderline resectable disease; however, in patients with resectable 
disease it is only recommended in the setting of a clinical trial61. Adjuvant 
fluorouracil- or gemcitabine-based chemotherapy in patients with resected 
pancreatic cancer has been shown to increase the median and 5-year survival, 
compared with surgery alone71, 72. Based on consensus, when chemotherapy 
alone is given as adjuvant therapy, gemcitabine is preferred over fluorouracil, 
despite the fact that the results of a large prospective randomised controlled trial 
of bolus fluorouracil and folinic acid (leucovorin) versus gemcitabine (ESPAC-
3) did not reveal a significant difference in survival between the two drugs73. 
Adjuvant chemoradiation remains controversial. Data from ESPAC-1 and meta-
analysis suggested that chemoradiation therapy seems to prolong survival only in 
incompletely excised (R1 or R2 resection) cancers74.  
 
The initial treatment option for patients presenting with locally advanced 
pancreatic cancer (about 30%) is endoscopic stent insertion into the bile duct, 
and sometimes bypass surgery, if endoscopic stenting fails or if patients are 
found to be unresectable at the time of operation (but deemed resectable on 
preoperative imaging)75, followed by chemotherapy with gemcitabine or 
fluorouracil (or capecitabine) or chemoradiation therapy to control the tumour. 
 
Two treatment options with similar outcome are gemcitabine-based 
chemotherapy or chemoradiation with fluorouracil; these have both been shown 
to increase overall survival and quality of life in patients with locally advanced 
unresectable disease, compared with best supportive care or radiation therapy 
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alone76. Patients with good performance status appear to benefit from 
gemcitabine-based chemotherapy, with either a platinum analogue (oxaliplatin or 
cisplatin) or a fluoropyrimidine (fluorouracil or capecitabine)77-79. Folinic acid 
(leucovorin) enhances the effect of fluorouracil and is, therefore, commonly 
administered with this drug.  
 
In patients with metastatic disease (50% to 55%) the main objective is palliation. 
These patients have a limited survival (3 to 6 months) that is dependent on 
tumour burden and performance status at presentation16. As in locally advanced 
disease, biliary obstruction and, sometimes, gastric obstruction is relieved by 
endoscopic stent insertion or by surgical bypass of bile duct and gastric outlet 
obstruction. Monotherapy with gemcitabine is the palliative treatment of choice; 
patients with a good performance may benefit from combination therapy of 
gemcitabine and either a platinum analog (oxaliplatin or cisplatin), a 
fluoropyrimidine (fluorouracil or capecitabine) or an epidermal growth factor 
receptor (EGFR) inhibitor (erlotinib), which has been shown to give a modest 
improvement in survival compared with gemcitabine alone77-80. 
 
1.3.3. Potential novel therapies 
Despite increasing research in the field of pancreatic cancer, the only 
improvement that resulted in a significant change in clinical practice was made 
in 1997, when a phase III clinical trial demonstrated a modest survival advantage 
of gemcitabine over fluorouracil, with improved alleviation of some disease-
related symptoms such as pain reduction and weight loss, in patients with 
advanced disease (median survival 5.65 months versus 4.41 months)81. Since 
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then gemcitabine is the standard chemotherapeutic drug for patients with 
advanced pancreatic cancer. Owing to the poor prognosis, clinical trials are an 
appropriate setting for treatment of patients with any stage of disease and should 
be considered before selecting palliative approaches. Although new conventional 
cytotoxic agents, or other combinations with gemcitabine, may improve the 
survival for pancreatic cancer, these improvements most likely will be modest 
(as is the case in all different combination therapies discussed above). Research 
has significantly increased our understanding of the molecular nature of 
pancreatic cancer and agents designed to target specific pathways are of great 
interest and an important focus of clinical trials.  
 
The first, and only, targeted therapy approved by the U.S. Food and Drug 
Administration (FDA) for treatment of pancreatic cancer is erlotinib, an orally 
active small molecule that binds to the ATP binding site on the intracellular 
kinase domain of the epidermal growth factor receptor (EGFR) and, therefore, 
inhibits EGFR mediated signalling; the combination of gemcitabine and erlotinib 
in patients with advanced pancreatic cancer resulted in a significantly better 
overall survival as compared with gemcitabine alone (median survival 6.24 
months v 5.91 months)80. However, since the improvement was rather modest 
and also accompanied by more toxicity its clinical relevance has been criticised.  
Other targeted therapies that have been tested in phase III clinical trials for 
pancreatic cancer include monoclonal antibodies to EGFR (cetuximab), to 
vascular endothelial growth factor (VEGF; bevacizumab), inhibitors of RAS 
signalling (tipifarnib, blocks/inhibits the posttranslational modification of RAS), 
matrix metalloproteinase (MMP) inhibitors and inhibitors of the gastrin and 
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cholecystokinin receptor pathway. However, despite promising results in in vitro 
(most commonly two-dimensional biochemical assays with cell-based 
proliferation and cytotoxicity screens) and in vivo (most often tumours 
xenografted into immunocompromised mice) studies, the outcomes of these 
clinical trials were disappointing in their ability to improve the poor survival of 
patients with pancreatic cancer82. One possible reason for this failure is that the 
used preclinical experimental models did not accurately reflect the complexity of 
a human tumour, especially with respect to the tumour microenvironment38.  
 
1.4. Tumour-stroma interactions 
1.4.1. Tumour-associated fibroblasts 
As early as 1889 Stephen Paget hypothesised that predilection of certain organs 
to harbour metastasis depends on a cross-talk between cancer cells (“the seeds”) 
and specific organ microenvironments (“the soil”)83. And indeed, now 120 years 
later it is well appreciated that the “soil”, or the tumour-microenvironment is not 
a bystander but actively participates in tumour progression, even in the primary 
tumour84-86. Genetic changes in epithelial cells initiate cytokine and growth 
factor signalling pathways that alter the behaviour of stromal fibroblasts and 
stimulate both stromal and tumour cells. As a result of these genetic changes, 
tumour cells secrete growth factors including transforming growth factor-β 
(TGFβ), basic fibroblast growth factor (bFGF), platelet-derived growth factor 
(PDGF), hepatocyte growth factor (HGF), vascular endothelial growth factor 
(VEGF) as well as ECM-modifying matrix metalloproteinases (MMPs), inducing 
the activation of stromal cells and the formation of a “tumour-supportive” 
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stroma. Activated fibroblasts, called “tumour-associated fibroblasts” or 
“myofibroblasts”, in turn secrete a range of growth factors, such as epidermal 
growth factor (EGF), HGF, TGFβ, VEGF, amongst others, and proteases and 
MMPs, that all act in an autocrine and paracrine manner to stimulate tumour cell 
proliferation, migration, invasion, angiogenesis and matrix remodelling, resulting 
in a “vicious cycle” supporting tumour growth and invasive behaviour46, 86, 87.  
 
The TGFβ signalling pathway is involved in many aspects of cellular function, 
including cellular proliferation, differentiation, migration, apoptosis, adhesion, 
angiogenesis, immune surveillance and survival. Although most of the growth 
factors secreted by fibroblasts stimulate the proliferation of epithelial cells, the 
role of TGFβ is paradoxical as it acts tumour suppressive to normal epithelial 
cells but becomes tumour supportive during later stages of many cancers37, 46, 87. 
Initially TGFβ inhibits growth of epithelial cells by inducing cell-cycle arrest and 
apoptosis. When TGFβ receptor expression is decreased, or availability of TGFβ 
receptors at the cell surface is impaired e.g. due to a mutation in SMAD4, cells 
can escape the growth inhibitory function of TGFβ. The resistance of tumour 
cells to growth inhibition is usually accompanied by an increased expression of 
TGFβ by the tumour cells. In addition to this overexpression by tumour cells, 
high levels of TGFβ can also be produced by stromal cells, initiating the 
production of large amounts of ECM components. This overexpression of TGFβ 
by tumour and stromal cells has a wide tumour supportive effect, including 
altered expression of ECM components, stimulation of angiogenesis, 
immunosuppression as well as an increase in the production of other mitogenic 
growth signals, including PDGF and FGF46, 88.  
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Another signalling pathway shown to be important in the desmoplastic reaction 
and pancreatic tumour progression is the Hedgehog signalling pathway. 
Hedgehog signalling plays an important role during embryonic development and 
in adult tissues in the maintenance of stem or progenitor cells and regeneration. 
In the absence of ligands, a 12‑pass transmembrane receptor, Patched (Ptc), 
inhibits the activity of Smoothened (Smo), a 7‑pass transmembrane receptor. 
Three secreted ligands that bind to Ptc, have been identified: Sonic hedgehog 
(Shh; the best studied ligand), Indian hedgehog (Ihh) and Desert hedgehog 
(Dhh). Upon ligand binding, the inhibitory effect of Ptc on Smo is inactivated, 
allowing signal transduction through the pathway resulting in activation and 
nuclear translocation of Gli family of zinc finger transcription factors. Hedgehog 
signalling affects many cellular functions, including proliferation, apoptosis and 
differentiation89. Although Hedgehog signalling was initially thought to be 
activated in pancreatic cancer cells in an autocrine manner, it now increasingly is 
believed that Hedgehog ligands, secreted by the tumour, function in a paracrine 
manner resulting in pathway activation in stromal cells, including cancer 
associated fibroblasts, pancreatic stellate cells and endothelial cells44, 45, 90-92. In 
contrast to pancreatic epithelial cells, stromal cells adjacent to the tumour cell 
compartment demonstrated active Hedgehog signalling in a xenograft mouse 
model of pancreatic cancer, which could be inhibited by a Smo inhibitor45. 
Although the exact mechanisms of paracrine Hedgehog signalling and its tumour 
supportive role remain unclear, Shh has been shown to enhance the production of 
extracellular matrix proteins such as collagen and fibronectin, increase the 
proliferation, migration and invasion of pancreatic stellate cells and 
myofibroblasts44 and to affect the tumour vasculature91, 92.  
 43 
A pancreatic cancer specific study investigated the invasiveness of pancreatic 
cancer cells co-cultured with MRC5 fibroblasts and primary pancreatic 
fibroblasts that were non-irradiated, irradiated at 5 Gy, or irradiated at 10 Gy93. 
A small number of cancer cells invaded through Matrigel when they were 
cultured alone, whereas co-culture with MRC5 fibroblasts or primary pancreatic 
fibroblasts increased the invasive ability of the cancer cells Suit2 and Capan1, 
possibly via an increased expression of HGF and c-Met. Although this study 
supports the hypothesis that fibroblasts stimulate the invasive behaviour of 
cancer cells, for pancreatic cancer it has become increasingly clear that 
pancreatic stellate cells are the key cells responsible for the strong desmoplastic 
reaction seen in this tumour94.  
 
1.4.2. Pancreatic stellate cells 
Vitamin A storing cells with lipid droplets were first identified in mouse and 
human pancreas in 1982 and 1990, respectively, by electron and fluorescence 
microscopy, using the characteristic, rapidly fading, blue-green fluorescence that 
is emitted by vitamin A when exposed to ultraviolet light at 328 nm95, 96. 
However, significant progress was made when these cells were successfully 
isolated and characterised in 1998 by Apte et al97 and Bachem et al98, who 
named them, based on their similarities with hepatic stellate cells (HSCs), 
pancreatic stellate cells (PSCs). Stellate shaped cells, with rounded cell bodies 
and long cytoplasmic processes, were observed in the periacinar and interlobular 
space of the normal pancreas, accounting for 4% of all pancreatic cells. As with 
their hepatic counterparts, PSCs characteristically contain lipid droplets with 
positive vitamin A autofluorescence and express the cytoskeletal proteins 
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desmin, GFAP (glial fibrillary acidic protein), nestin and vimentin94, 97, 98. Using 
gene-expression microarray analyses, a recent study showed that of the 20,000 
genes studied, only 29 genes were differently expressed in PSCs compared to 
HSCs, suggesting a common stellate cell precursor and minor organ-specific 
differences99. Additionally, stellate cells are now thought to be part of a diffuse 
stellate cell system, since immunohistochemical analyses of stellate cell markers 
demonstrated the presence of stellate cells not only in liver and pancreas, but also 
in kidney, lung, colon and heart100. In primary culture or when activated during 
pancreatic injury, PSCs change from a quiescent fat-storing phenotype to a 
myofibroblast-like cell secreting ECM proteins such as collagen type I and III, 
fibronectin and laminin94, 98. This activation process is accompanied by the 
expression of alpha-smooth muscle actin (αSMA) and loss of the retinol 
containing fat droplets.  
 
Since this first isolation of PSCs, both in vitro studies (two-dimensional co-
cultures of pancreatic cancer cells and stellate cells) and in vivo studies (using 
human pancreatic samples, subcutaneous xenografts of pancreatic cancer cells 
and PSCs in nude mice or orthotopic mouse models)101-104, have supported the 
hypothesis that PSCs play a central role in pancreatic fibrogenesis, showing 
remarkable similarities between pancreatic cancer and alcohol-induced chronic 
pancreatitis105. A positive staining for desmin, GFAP and αSMA in the stroma of 
pancreatic cancer has demonstrated the presence of activated PSCs in the tumour 
desmoplasia and a co-localisation of αSMA with mRNA encoding procollagen 
α1 (I) suggested that these activated PSCs are the major source of ECM in the 
desmoplastic reaction in pancreatic cancer106.  Bachem et al showed that the 
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proliferation of PSCs cultured with cancer cell supernatants increased in a dose 
dependent manner, in which PDGF was proposed as a putative mediator for the 
cancer cell-stimulated PSC proliferation. They also demonstrated that cancer 
cells stimulated PSCs to produce fibronectin and collagen type I and III via 
FGF2 and TGFβ1. To confirm these results in vivo, they injected pancreatic 
carcinoma cell lines (MiaPaCa2, Panc1 and SW850) alone or in combination 
with PSCs into nude mice. Interestingly, tumour growth was increased in the 
presence of PSCs with an intense cytokeratin staining of the cancer cells, 
suggesting a higher proliferation of cancer cells in the presence of stellate 
cells101.  
 
Later, two similar studies by the Apte laboratory103 and by Hwang and co-
workers102, confirmed these findings in an orthotopic mouse model. PSCs were 
shown to increase the proliferation and invasion of cancer cells in vitro and in 
vivo, possibly through an increase in PDGF secretion by activated stellate 
cells103 and/or by increased activation of ERK1/ERK2 or AKT signalling in 
cancer cells leading to enhanced proliferation and survival, respectively102. 
Interestingly, a higher proportion of PSCs compared to cancer cells significantly 
enhanced tumour incidence, growth and metastasis, as shown by the intra-
pancreatic injection of different ratios of cancer cells and PSCs. This effect was 
even more pronounced when the number of cancer cells was lower (0.5x106 
instead of 1.0x106), in which case tumours developed only in the presence of 
stellate cells (in either a 1:1 or 1:5 cancer cell:PSC ratio) and not upon injection 
of cancer cells alone102. An important observation in the Apte study was the 
presence of αSMA and human nuclear antigen positive cells in metastatic liver 
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nodules of mice injected with human pancreatic cancer cells and stellate cells103. 
The question of whether these stellate cells indeed had accompanied cancer cells 
to metastatic sites has been addressed elegantly in a subsequent study by means 
of a gender mismatch approach. After co-injection of female AsPc1 cancer cells 
and male PSCs in a (female) orthotopic mouse model of pancreatic cancer, male 
PSCs could be identified in metastatic lesions in mediastinum, liver, diaphragm, 
and mesentery104. Although cancer cells stimulated the invasion of stellate cells 
through an endothelial monolayer in vitro, more studies will be needed to 
determine whether stellate cells and cancer cells invaded collectively as small 
clusters or if PSCs invaded first, to create a tumour-cell permissive 
microenvironment at a metastatic site, or maybe a combination of these. 
Nevertheless, this study highlights the important role for stellate cells in 
stimulating the metastatic process in vivo.  
 
Currently, PDGF is considered as the most effective mitogen for PSCs107. 
Additionally it increases the migratory capacity of PSCs and the expression of 
MMPs108, 109. As with tumour-associated fibroblasts, TGFβ stimulates ECM 
synthesis and is involved in many other processes occurring in PSC activation 
and desmoplasia via several direct and indirect mechanisms. Activin A, a 
member of the TGFβ family that has been found to be highly expressed in the 
wounded skin, stimulates PSC activation, increases collagen secretion and 
TGFβ1 expression and secretion in an autocrine manner110. Other activators of 
PSCs include FGF2, tumour necrosis factor-α (TNFα), the cytokines interleukin-
1 (IL1), IL6 and IL8, angiotensin II, ethanol and its metabolites and oxidative 
stress94, 107. Several studies have investigated diverse intracellular signalling 
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pathways following PSC activation, among which are the mitogen-activated 
protein kinase (MAPK), the phosphoinositide-3-kinase (PI3K), the Rho-Rho 
kinase (ROCK) and the TGFβ/SMAD pathways111. 
 
Similar to activated fibroblasts, the activated PSC, in turn, secrete autocrine and 
paracrine factors that can further increase their activated phenotype, stimulate the 
proliferation and invasion of cancer cells as well as increase angiogenesis102, 104, 
107, 112-114. One protein shown to be exclusively expressed by PSCs, and to be 
upregulated in pancreatic cancer, predominantly at the invasive front, is 
periostin; a secreted protein initially isolated in relation to osteoblast recruitment, 
attachment, and spreading112, 113, 115. Erkan and colleagues demonstrated that 
supernatant of pancreatic cancer cells (Panc1 and SU86.86) increased the 
periostin expression of PSCs which, in an autocrine loop, maintained and further 
enhanced PSC activation resulting in its own secretion along with collagen type 
I, fibronectin and TGFβ. In turn, recombinant periostin stimulated pancreatic 
cancer cell growth in hypoxic or serum-starved conditions and enhanced 
pancreatic cancer cell invasion (only at 100 ng/ml; inhibition was seen at 1 
µg/ml, possibly due to the activation of different intracellular pathways). 
Moreover, they demonstrated that supernatant of irradiated PSCs increased the 
invasion of cancer cells, an observation confirming the findings of irradiated 
MRC5 fibroblasts93, 112. Additionally, Baril and associates propose that the 
tumour supportive effects of periostin are mediated via its cell surface receptor 
integrin α6β4, in which binding of periostin to α6β4 results in the activation of 
focal adhesion kinase (FAK) and AKT, through activation of the PI3K pathway, 
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thereby promoting tumour cell invasion, migration and survival in hypoxic 
conditions115.  
 
Given the expression of cytoskeletal proteins that are known to be characteristic 
of several cell types (desmin expression in myocytes, GFAP in astrocytes, nestin 
in neuroepithelial stem cells and vimentin in mesenchymal cells) and the many 
similarities between hepatic and pancreatic stellate cells, the origin of stellate 
cells has been an area of debate. Upon hepatic or pancreatic injury, bone 
marrow-derived progenitor cells have been shown to be recruited to the liver116 
or pancreas117, respectively, suggesting the bone marrow as a source for stellate 
cells. In a model of chronic pancreatitis approximately 5% of stellate cells were 
derived from the bone marrow, reflecting a heterogeneous stellate cell population 
with possible different activities117. Indeed, a recent study using in vitro and in 
vivo xenograft co-culture approaches, revealed that, compared to CD10 negative 
PSCs, CD10 positive PSCs promoted tumour growth and invasion of Suit2 and 
Panc1 cancer cells more intensely and that cancer cells in turn increased the 
percentage of CD10 positive PSCs118.  One might also speculate that this 
heterogenenous PSC population reflects the presence of mesenchymal stem cells. 
Nestin-positive, as well as nestin-negative, pancreatic precursor cells isolated 
from mouse pancreas, formed clonal colonies in vitro, expressing the neural and 
pancreatic precursor markers nestin and Pdx1, which were able to differentiate 
into pancreatic endocrine and exocrine cells as well as pancreatic stellate cells 
and multiple neural lineages. However, the self-renewing capacity of these 
primary pancreas-derived multipotent precursors was very limited; less than 1% 
generated small secondary colonies, suggesting that these cells may represent a 
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restricted progenitor, rather than a true, stem cell population119. The role of 
resident stem cells in normal pancreas is further questioned because of the 
limited ability of the pancreas to hypertrophy after resection (unlike the liver) as 
well as the low level of de novo proliferation in normal pancreas (unlike for 
example skin, small or large bowel epithelium). 
 
Despite the steady increase in pancreatic stellate cell research since 1998, many 
questions still remain with respect to their origin, the function of PSCs in the 
quiescent state, the regulation of activation/deactivation and their cross-talk with 
neighbouring cells. An increased understanding of the PSCs and their role in 
pancreatic cancer progression will help to identify new therapeutic strategies that 
target PSCs.  
 
1.5. Three-dimensional (3D) in vitro models for other cancers 
The traditional method of studying cancer cell behaviour in vitro has been two-
dimensional (2D) monolayer culture. Although this has resulted in an enormous 
amount of information regarding genetic, biochemical and cell-biological 
processes involved in tumour formation, cells grown on flat 2D tissue culture 
substrates differ considerably in their morphology, differentiation as well as their 
cell-cell and cell-matrix interactions compared to cells in vivo120-122. In order to 
study transformed cell behaviour, and interactions with other cell types as well as 
with the acellular stroma, in a model that is still relatively easily amenable for 
experimental manipulation, more physiologically relevant 3D tissue culture 
models can provide a solution and bridge the gap between traditional 2D 
monolayer culture and the more complex animal models. 
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1.5.1. Different types of 3D in vitro models 
Since there is limited information, thus far, on 3D tissue culture models of 
pancreatic cancer, I will infer from models used for other organ systems. 
Different types of 3D in vitro models are currently being used, each of them with 
their own advantages and disadvantages. One commonly used approach is the 
use of organ cultures in which fragments of tissues are harvested in vivo, 
explanted and subsequently cultured in vitro. For example, rings from mouse 
aortae cultured between two thin layers of growth factor-reduced Matrigel have 
provided insight into mechanisms of pathological angiogenesis123, “organotypic” 
brain slices have been used extensively as models for brain cancer, where they 
have provided insights into, for instance, the effects of drugs or radiotherapy124, 
125 or isolated bladder tissues, on top of which cancer cells are cultured, have 
been used to study the invasive behaviour of bladder cancer126. These 
approaches are particularly useful for relatively short-term cultures, but the slices 
must be thin enough to provide adequate oxygenation and nutrition of the tissue. 
Moreover, the availability of tissue can be a limiting obstacle. 
 
Other 3D in vitro models have been established with isolated cells or cell-lines. 
One frequently used method is to implant cells in a 3D matrix scaffold generated 
from either purified molecules, such as collagen type I, or synthetic materials, 
such as cross-linked glycosaminoglycan composites or nanofibres and peptide 
scaffolds121, 127. Another class of 3D matrices is those generated by cells in vitro, 
in which fibroblasts are stimulated with ascorbic acid to increase their collagen 
production followed by extraction of fibroblasts120, 128, 129. The advantage of 
these “cell-derived matrices” is the use of the naturally deposited matrix as well 
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as the ability to visualise cells using live-cell imaging; however, these matrices 
often have lower amounts of collagen, larger internal spaces and less depth, 
making them less suitable for the study of invasion121, 130.  
 
Pioneering work in modelling glandular epithelial cells has been done for breast 
cancer where mammary epithelial cells were cultured in, or on, a reconstituted 
basement membrane derived from Engelbreth-Holm-Swarm (EHS) mouse 
sarcoma (commercially available as Matrigel)131, 132. After 15 days in this 3D 
culture normal breast epithelial cells developed into acinar structures (also called 
“spheroids”), characterised by a central hollow lumen with apico-basal polarity; 
hence structures recapitulating essential characteristics of breast glandular 
epithelium in vivo. This lumen formation requires clearance of cells, which has 
been shown to be due to, in part, apoptosis upon matrix detachment (anoikis) 
mediated by BIM, a pro-apoptotic BH3-only BCL family protein133, 134. This 
model underlines the differences in the response of cells when they are cultured 
in 3D versus 2D, as well as the importance of the composition and stiffness of 
the extracellular matrix (ECM) since normal breast epithelial cells did not 
develop into polarised structures when embedded into matrices composed of 
collagen type I alone122. 
 
Given the increased recognition of the importance of a 3D environment for cell 
behaviour and signalling, the field of bioengineering of 3D tissues is expanding 
rapidly, with currently a plethora of materials that can be used as 3D matrix 
scaffolds in vitro commercially available. Although collagen and Matrigel are 
commonly used ECM components, these matrices have a high lot-to-lot 
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variability (Matrigel in particular) and matrix stiffness can only be controlled by 
altering the concentration of sites bound by integrin adhesion receptors (for 
example by increasing the concentration of collagen; the importance of which 
will be discussed in more detail in the next paragraph). Therefore, many efforts 
are made to develop well-defined biomaterials, improve the diffusion of oxygen, 
other nutrients and growth factors or develop a more comprehensive mixture of 
ECM proteins that comprise the microenvironment. For example, a human 
equivalent to Matrigel, various collagen or chemically defined sponges with a 
highly oriented pore structure to improve nutrient delivery, or synthetic polymers 
that self-assemble, among many others, are now commercially available and the 
empirical testing of these synthetic or reconstituted matrix molecules will 
provide more details about cell behaviour, drug response or stem cell 
differentiation in 3D.  
 
Since tissues contain more than one cell type (with an important cross-talk 
between epithelial cells and stromal cells, which include mesenchymal cells (a 
heterogeneous population of fibroblasts and stellate cells), vascular cells 
(endothelial cells and pericytes), inflammatory or immune cells (lymphocytes, 
dendritic cells, neutrophils, macrophages, mast cells, and eosinophils) and organ 
specific adipose or nervous tissue55), 3D co-cultures that use multiple cell types 
will more likely mimic the in vivo situation. These “organotypic cultures” were 
first described for human skin cancer by the Fusenig laboratory135, 136, where 
they have been used extensively to study invasion137, 138. Organotypic cultures 
have been exploited recently to investigate different tumour types, such as 
ovarian139, breast140, 141, prostate142 or oesophageal cancer143-145, where they 
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have provided important insights into the cross-talk between stromal cells and 
cancer cells, the activation of fibroblasts in a tumour microenvironment, 
proliferation and morphological changes of cancer cells, cancer cell invasion and 
the molecular pathogenesis of a disease. For example in oesophageal cancer, 
organotypic models have been used to study the role of frequently altered genes 
(overexpression of EGFR, or expression of the catalytic subunit of human 
telomerase (hTERT) and mutated TP53R175H) in the pathogenesis of this cancer 
and in the mechanisms of tumour invasion144, 145. However, for pancreatic 
cancer, a tumour characterised by such a prominent stromal component, the use 
of 3D in vitro models has been limited.  
 
1.5.2. Matrix composition in 3D in vitro models and cell-matrix 
interactions 
Epithelial cells are characterised by an apico-basal polarity with microvilli-rich 
apical membranes facing a lumen, specialised cell-cell contact and basal surfaces 
contacting the basement membrane. Attachment to the basement membrane is 
mediated via integrins, heterodimeric transmembrane receptors that sense 
mechanical cues from the extracellular matrix (ECM) and transduce these signals 
to the epithelial cells. Cells within tissue are exposed to force, these forces can be 
macroforces occurring at tissue level, or microforces due to the reaction with 
other cells or with the ECM and depend on the spatial arrangement of the cell 
within a tissue and the state of the tissue in which the cell resides146. In fibrotic 
tumours, such as pancreatic cancer, the increase in ECM stiffness exerts elevated 
force on transformed epithelial cells147. These enhanced mechanical forces are 
sensed by so called “mechanoreceptors”, of which the best studied are the 
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integrins, mediating a cellular response that results in an increase in tumour cell 
growth, survival, motility and invasion and a decrease in their response to 
therapy148. On the other hand, when tumour cells invade the stroma they 
generate a change in the mechanical force within the ECM, that will respond by 
exerting a reciprocal force, which in an homeostatic situation is proportional to 
the magnitude of the tumour-derived force. However, due to the desmoplastic 
reaction the matrix is stiffer and less compliant and will exert larger forces 
against the expanding tumour mass. The combination of these reciprocal 
tensional forces and the activation of soluble growth factors (such as TGFβ, FGF 
or VEGF) together will stimulate tumour progression149.  
 
A variety of distinct adhesions are formed between the cells and the extracellular 
matrix, including focal complexes, focal adhesions, fibrillar adhesions and 3D 
matrix adhesions. The types of the cell-matrix adhesions organised by integrins 
and the signals they transduce are significantly affected by the surrounding 
matrix148, hence these adhesions are significantly different in rigid 2D tissue 
culture dishes compared to the 3D in vivo situation. Culturing cells in 3D tissue 
culture models has provided insight into some of these differences150. Focal 
adhesions are dynamic complexes of signalling, adaptor and structural proteins 
(characteristically containing αvβ3 and plaque proteins as paxillin, vinculin and 
focal adhesion kinase (FAK)) that mediate strong cell-substrate adhesion and 
transmit information in a bidirectional manner between ECM molecules and the 
cellular cytoskeleton151.  
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Interestingly, force appears to play a role in the development of focal adhesions, 
in which mechanical tension is necessary for the maturation of the focal 
adhesions152, 153. FAK has been shown to be an important regulator of 
mechanotransduction and acts to translate extracellular forces sensed by integrins 
into proliferative cellular signals via the activation of downstream signalling 
pathways, such as the mitogen-activated protein kinase ERK and subsequent 
progression of cells through the G1 phase of the cell-cycle147, 151. This can be 
one of the mechanisms whereby a stiff, fibrotic microenvironment with an 
increased mechanical force can induce a proliferative response in transformed 
tumour cells.  
 
Once focal adhesions are stable, they serve as an anchoring point from which 
activated α5β1 integrins translocate towards the cell body and drive the formation 
of fibrillar adhesions. Fibrillar adhesions function in generating extracellular 
fibrils of fibronectin. As this network of fibronectin accumulates, cells adapt a 
3D matrix adhesion that has a distinct molecular composition and 
phosphorylation pattern, strongly dependent on α5β1 integrin, the main 
fibronectin receptor120, 150.  
 
All these results together demonstrate that the composition of the ECM provides 
essential cues for the behaviour of tumour cells as well as stromal cells. This is 
also reflected in 3D tissue culture models, where the composition and stiffness of 
a chosen matrix can affect the behaviour of tumour cells as well as stromal cells. 
For example collagen gels are stiff compared to gels made from Matrigel, which 
is rich in laminin, collagen type IV and heparan sulphate proteoglycans, which 
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can be reflected in the behaviour of mammary epithelial cells (MECs). MECs 
develop into growth arrested, polarised acini when embedded in Matrigel, 
however increasing the matrix stiffness disturbs this morphogenesis and 
enhances proliferation via increased ERK and Rho activity147.  
 
1.5.3. Cell migration and invasion 
Cell migration is essential for physiological processes such as embryonic 
development and wound healing but is also a hallmark of tumour progression. A 
combination of 2D, 3D and in vivo models together with increased advances in 
optical imaging techniques have led to the current knowledge that there are 
different mechanisms by which cells can move through the extracellular matrix 
(ECM). The best understood is the mesenchymal cell motility, where cells move 
according to a “five-step migration cycle”154, 155: a narrow leading edge of a cell 
protrudes (this actin-rich protrusion is called a lamellipod if it is flat, a 
pseudopod if it is cylindrical or rounded, or a filopod if it is spike-shaped); this 
protrusion attaches to the ECM via integrin-dependent focal contacts, followed 
by breakdown of the ECM several micrometers rearward of the leading edge; 
when focal contacts develop into mature focal adhesions the actomyosin 
contractile force results in a forward movement of the cell body following the 
leading edge and retraction of the lagging cell tail leaving a small microtrack 
behind154. Mesenchymal cell migration is relatively slow, with velocities of 0.1-2 
µm/min, in comparison to immune cells, which can migrate 10-40 times 
faster156. Immune cells, as well as some cancer cells, use a less adhesive, 
amoeboid type of migration, which is characterised by a rapid remodelling of the 
cell cortex and the ability of cells to squeeze in between gaps in the ECM. 
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Movement is generated by cortical actin contraction, driven by Rho – ROCK 
signalling and requires ezrin, whereas mature focal contacts and proteolytic 
activity are lacking157, 158. Some tumour cells can switch between different 
mechanisms of motility, which enables them to continue moving when one type 
of motility is blocked due to changes in protein expression or mutations in the 
natural course of tumour progression or when one mode is blocked by 
pharmacological means159. This plasticity is, at least in part, dictated by the way 
a cell interacts with and responds to the surrounding ECM. It has been shown 
that β1 integrins promote rapid/random cell movement (amoeboid migration) via 
RhoA – ROCK signalling, whereas β3 integrins promote mesenchymal 
migration via activation of Rac160. 
 
A third form of motility is collective migration or invasion, involving the 
movement of sheets or clusters of (cancer) cells. Mechanistically, this is similar 
to collective mesenchymal motility where cells at the front demonstrate an 
increased expression of matrix metalloproteinases (MMPs) generating a “path” 
for the following cells. In contrast to single cell movements, which require loss 
of adherens junctions, maintenance of adherens junctions is an important 
requisite for collective motility161. It has been shown that collective cancer cell 
invasion is preceded by individual proteolytic mesenchymal invasion, where a 
small microtrack generated by a “forerunner cell” is sequentially filled by 
“following cells” maintaining cell-cell contact, resulting in a strand like 
collective invasion. These preceding cells could be cancer cells (with upregulated 
mesenchymal markers)162 or fibroblasts137.   
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1.5.4. Possible interventions in 3D in vitro models 
The big advantage of organotypic culture models is that they provide a system, 
which can be easily manipulated and specific questions can be addressed. Any 
cell type in the system can be genetically manipulated, the matrix composition 
can be modulated and exogenous therapies such as antibodies or small molecule 
inhibitors can be tested. In the organotypic skin cancer model the addition of 
several inhibitors (Met-kinase inhibitor or COX-2 inhibitor) has been used to 
assess their effect on cancer cell invasion163, 164, or cancer cells have been pre-
treated with RNA interference (e.g. small interfering RNA against Eps8, HAX1 
or β6 integrin) or membrane-permeable peptides (to block HAX1 binding)165, 
166. For many cancers, including pancreatic cancer, knowledge about important 
oncogenic mutations and pathways is increasing, which has lead to the 
development of novel therapeutic agents designed to target these specific 
pathways. However, although initial experimental results of targeted therapies in 
the laboratory were promising, until now clinical trials have been 
disappointing82. Organotypic culture models offer an elegant system to test drugs 
or novel therapeutic agents in a more physiologically relevant system. Recently, 
for example, in an organotypic model of melanoma, pharmacological AKT and 
MAPK pathway inhibitors (a PI3K inhibitor or an mTOR inhibitor) co-
administered with the chemotherapeutic reagents cisplatin or temozolomide have 
been shown to decrease the invasion of melanoma cells significantly more 
compared to treatment with any of the four therapeutics alone167. Or, in an 
oesophageal cancer organotypic model, bortezomib (a proteasome inhibitor) has 
been shown to increase the level of apoptosis in cancer cells as well as decrease 
angiogenesis168.  
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1.6. Modelling pancreatic cancer 
1.6.1. Two-dimensional (2D) in vitro models of pancreatic cancer 
As discussed in paragraph 1.4.2, the interaction between cancer cells and stellate 
cells has been studied extensively in 2D in vitro models. The effects of 
conditioned medium from pancreatic cancer cells on proliferation, matrix 
synthesis or motility of pancreatic stellate cells has been studied using well 
established 2D in vitro assays such as the “scratch-assay” (scratch-wounding of a 
monolayer culture followed by imaging of the wound closure) or a Transwell 
migration assay (migration of cells through pores of a microporous membrane) to 
study migration103, 106, 169. Pre-incubating conditioned medium with neutralising 
antibodies has for example revealed that, for pancreatic stellate cells, PDGF is 
the most effective mitogen and that FGF2 and TGFβ stimulate the synthesis of 
collagen type I and fibronectin101. Conversely, indirect invasion (Transwell 
invasion assay in which membranes are coated with Matrigel or other ECM 
component) and migration assays have demonstrated that PSCs promote tumour 
cell motility via secreted factors102, 103. Furthermore a 2D direct co-culture 
model of PSCs and cancer cells demonstrated enhanced proliferation of both cell 
types as well as an increase in matrix synthesis from PSCs compared to 
monoculture or indirect co-culture170.  
 
In addition to the interactions between cancer cells and PSCs, the cross-talk with 
endothelial cells also has been investigated in different 2D in vitro assays, such 
as the tube formation assay or a transendothelial migration assay104, 114. 
Conditioned medium from PSCs has been shown to increase tube formation of 
endothelial cells cultured on a Matrigel-coated tissue culture plate, which could 
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be blocked by pre-incubating the conditioned medium with VEGF neutralising 
antibody104, 114. The role of cancer cells in this stimulatory effect has been 
studied in a transendothelial migration assay, in which PSCs were cultured alone, 
or with cancer cells, on top of a Transwell membrane that was pre-coated with a 
monolayer of endothelial cells. It was shown that the migration of stellate cells 
through this endothelial monolayer increased significantly when PSCs were 
either co-cultured with AsPc1 cells or were exposed to AsPc1 supernatant; 
PDGF neutralising antibody in the supernatant could inhibit this effect104.  
 
1.6.2. In vivo models of pancreatic cancer 
These findings in traditional in vitro assays were strengthened in xenograft 
models, where pancreatic cancer cell lines were injected alone or with pancreatic 
stellate cells in immunodeficient mice, either subcutaneously101 or, 
physiologically more relevant, orthotopically102, 103. Although these in vivo 
models are giving us valuable insights, models most closely mimicking the 
pathophysiological and molecular features of human cancer are genetically 
engineered mouse models171.  
 
The gastrointestinal organs, including the pancreas, develop from the endoderm 
during gastrulation. Several key embryological signalling pathways are involved, 
with the same pathway having a different function at different stages of 
differentiation172. Retinoic acid (RA) appears to play a central role in 
specification of differentiation of the foregut endoderm towards pancreas173, 174. 
In addition to RA, inhibition of Hedgehog signalling determines the pancreatic 
lineage of epithelium that becomes the dorsal pancreatic bud (in contrast, 
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Hedgehog expression at this early stage of organogenesis (approximately 
embryonic day 9 (E9) in mice) leads to hepatic differentiation from the foregut 
endoderm)41, 175. Other essential regulators of pancreatic cell growth and 
differentiation are Notch and, more recently identified, Wnt signalling172, 176. 
Ultimately, cell differentiation and pancreas organogenesis is achieved by a 
subtle balanced and well-orchestrated pattern of gene-expression, a process 
controlled by transcription factors. 
 
The homeodomain transcription factor Pdx1 (pancreas duodenum homeobox 1) 
is one of the earliest transcription factors and is essential for pancreatic 
organogenesis; homozygous deletion of Pdx1 leads to pancreatic agenesis177, and 
Pdx1 is required for both endocrine and exocrine differentiation178. P48 is the 
pancreas-specific subunit of the heteromeric basic helix-loop-helix protein 
complex called Ptf1. Initially this transcription factor was considered as an 
exocrine transcription factor, however more recent evidence suggests it also 
plays an important role in early pancreatic development where it gives rise to all 
three pancreatic cell lineages179. The mechanisms of final lineage differentiation 
are not fully understood, especially the differentiation of exocrine and ductal 
lineage180. Cells expressing Pdx1 at E8.5, E12.5 or later give rise to acinar and 
endocrine cells but not to ductal cells. On the other hand, expression of Ptf1/p48 
(also known as Pft1a) becomes restricted to exocrine cells only by E13.5180.  All 
these cell lineage studies and genetically engineered mouse models have been 
facilitated by the Cre-lox technology where a target gene or gene segment is 
flanked by a pair of inverted repeat DNA elements, or loxP sites (“floxed”), and 
expression of Cre-recombinase (a site specific recombinase that recognises loxP) 
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under the control of a site specific promoter leads to excision of the floxed gene 
or gene segment181.  
 
In 2003 an excellent animal model of pancreatic cancer was created using 
transgenic mice that expressed the oncogenic KRASG12D allele from its 
endogenous promoter (and thus at physiological levels), controlled by Cre-
mediated recombination driven by the pancreatic specific promoters Pdx1 or 
Ptf1/p48. Pancreata of all these mutant mice developed tumours, which 
mimicked human pancreatic intra-epithelial neoplasia (PanIN). When these mice 
became older, higher-grade PanIN lesions were observed and, interestingly, in 
many mice the acinar parenchyma was largely replaced by an intense stromal 
reaction with inflammatory cells, fibroblasts and collagen deposition; resembling 
the desmoplastic reaction seen in human pancreatic cancer. Upon study of 29 
mice, two mice demonstrated invasive and metastatic pancreatic cancer (at the 
age of 6.25 and 8.25 months), with similar sites of metastasis as is seen in human 
pancreatic cancer182. These KRASG12D mice were subsequently crossed with 
either conditional INK4A/ARF null mice, which have a conditional deletion of 
exons 2 and 3 of the INK4A/ARF locus that eliminates both p16INK4A and p19ARF 
proteins183, or with mice harbouring a G-to-A substitution at nucleotide 515 of 
the endogenous TP53, corresponding to the TP53R172H mutation in human 
cancers184. The addition of these mutations/deletions resulted in invasive and 
highly metastatic tumours (Table 1.3)183, 184, demonstrating a multistep 
progression from pre-invasive to invasive disease, which is in keeping with the 
tumour progression model described for human pancreatic cancer27. To further 
investigate the specific contribution of INK4A and ARF, and the interaction 
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between p19ARF and p53 function, to the progression of pancreatic cancer, Pdx-
Cre;KRASG12D mice were crossed with different combinations of null mutations 
(homozygous or heterozygous) in INK4A, ARF or TP53, which revealed that 
both, INK4A and ARF contributed to PDAC progression and that the 
combination of inactivated tumour suppressors in the presence of mutated KRAS 
determined the differentiation phenotype of the tumours. Conditional deletion of 
INK4A resulted in more poorly differentiated tumours, including tumours with a 
sarcomatoid and anaplastic histology, whereas with loss of TP53 there was a 
higher prevalence of well- or moderately differentiated adenocarcinomas (Table 
1.3)185.  
 
Additionally, two studies exploring the role of disrupted TGFβ signalling in the 
progression of early pancreatic cancer in the context of mutated KRASG12D, 
demonstrated that TGFβ signalling also influences tumour histology186, 187. Mice 
with oncogenic KRAS signalling and a loss of SMAD4 developed cystic 
neoplasms resembling either human IPMNs186 or MCNs187, which progressed to 
invasive pancreatic cancers, although with a lower propensity compared to mice 
expressing mutated KRAS and TP53 (Table 1.3)187. Moreover, loss of both 
INK4A/ARF and SMAD4 (in the presence of mutated KRAS) resulted in enhanced 
progression to invasive cancer and interestingly also in an increased expression 
of epithelial markers. Consistent with the role of TGFβ in promoting epithelial-
to-mesenchymal transition (EMT), mice harbouring mutated KRAS and loss of 
INK4A/ARF, but wild type SMAD4, demonstrated a high proportion of poorly 
differentiated tumours, with increased proliferation, invasion and EMT; 
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characteristics that were lost when SMAD4 was deleted, resulting in well- to 
moderately differentiated tumours186.  
 
In summary, the loss of different tumour suppressor genes in combination with 
activated, oncogenic KRAS activity can alter the type of precursor lesion and 
direct the ultimate differentiation state and behaviour of the tumour. An 
important note is that in the absence of oncogenic KRAS, the loss of any tumour 
suppressor gene (TP53, INK4A/ARF or SMAD4) did not result in the 
development of invasive PDAC, suggesting that mutation of KRAS is the 
initiating genetic alteration with subsequent mutations accelerating the progress 
to invasive PDAC as well as determining its differentiation182, 183, 185-187. 
Moreover, these endogenous genetically engineered mice can also be used to 
study other signalling pathways known to be deregulated in pancreatic cancer, 
including various developmental signalling pathways such as Hedgehog, Notch 
and Wnt signalling; the latter (Wnt/β-catenin signalling) will be discussed in 
greater detail in paragraph 4.5.  
 
In addition to the discussed mouse models, which are all based on conditional 
expression under the control of the transcription factors Pdx1 or Ptf1/p48, more 
genetically engineered mouse models have been described using different 
promoters to drive mutagenic expression. Of interest is that, although in the Pdx-
Cre;KRASG12D models all three different cell lineages (endocrine, acinar and 
ductal) express the oncogenic KRAS allele, the only neoplastic phenotype that 
develops is PanIN lesions with PDAC; endocrine and acinar tumours are not 
observed. Although this may suggest a ductal origin of pancreatic cancer, 
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expression of mutant KRAS only in mature duct cells, under control of the 
cytokeratin 19 (CK19) promoter, failed to develop PDAC or faithfully 
recapitulate the stepwise progression of precursor lesions188. Subsequent studies 
exploring the pancreatic lineage responsible for PDAC expressed oncogenic 
KRAS in cells of acinar lineage by using the Elastase or Mist1 promoter (Table 
1.2)189-191. The first functional evidence that PDAC can arise from non-ductal 
cells was shown in an elegant study by Guerra et al, who used an inducible 
Elastase-Cre-system (Tet-off) to control temporally the expression of KRASG12V.  
Untreated mice, with oncogenic KRAS expression in acinar and possibly centro-
acinar cells, developed acinar-ductal metaplasia, which progressed to PanIN 
lesions and PDAC, a process that was accelerated by the addition of mutant 
TP53.  However, oncogenic KRAS signalling in adult mice did not produce any 
histological alterations, unless there was the coexistence of exocrine injury 
induced by caerulein, which resulted in multiple PanIN lesions and PDAC190. 
Further support for transdifferentiation from acinar into a ductal precursor 
phenotype, was established with two tamoxifen inducible Cre-lines controlled by 
Elastase or Mist1 (a transcription factor required for acinar organisation and with 
selective acinar expression in the adult pancreas). In this study mutant KRASG12D 
was sufficient to reprogram acini into the PanIN lineage, with no requirement of 
tissue damage, albeit invasive PDAC was not (yet) observed191.   
 
Altogether, these mouse models can provide excellent insight into the different 
pathogenetic changes that lead to the development of invasive pancreatic cancer. 
However, the long latency periods involved make these models costly and non-
amenable to rapid experimental manipulation. For many of the problems needed 
 66 
to be investigated in pancreatic cancer, with a special attention to its large 
stromal component and the interaction between tumour and stromal cells, it is 
possible that three-dimensional, physiologically relevant organotypic models can 
provide a solution. 
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Table 1.3 Mouse models of pancreatic cancer 
Reference Promoter Model Background Tumours Other Organs 
Hingorani 
2003182 
Pdx1 or 
p48 
Pdx1-Cre;LSL-KRASG12D and 
p48-Cre;LSL-KRASG12D B6/129SvJae 
All 3 stages of PanIN, 7% progression to PDAC with local 
spread and metastasis to liver 
Pdx-Cre mice: 
mucocutaneous 
papillomas, intestinal 
metaplasia of the gastric 
epithelium, hyperplastic 
polyps of duodenum 
Aguirre 
2003183 
Pdx1 Pdx1-Cre;LSL-KRAS
G12D; 
INK4A/ARFfl/fl FVB/B6 
PanIN and 100% progression to PDAC with metastasis 
mainly to duodenum, stomach, spleen and occasionally liver  
Hingorani 
2005184 
Pdx1 Pdx1-Cre;LSL-KRAS
G12D; 
LSL-TP53R172H B6/129SvJae 
PanIN and progression to PDAC in 96.3% with metastasis 
mainly to liver and lung and a high degree of genomic 
instability 
Oesophageal papillomas 
and hyperplasia, 
papillomatosis of  
biliary tree 
Bardeesy 
2006185 
Pdx1 
Pdx1-Cre;LSL-KRASG12D;TP53fl/fl 
with either INK4A+/+ or INK4Afl/+ 
or INK4Afl/fl 
FVB/n 
Rapid progression to invasive cancer, independent of 
INK4A status (adenocarcinoma in 100%, 80% and 40%, 
INK4A status respectively) 
 Pdx1 
Pdx1-Cre;LSL-KRASG12D;TP53fl/+ 
with either INK4A+/+ or INK4Afl/+ 
or INK4Afl/fl 
FVB/n Progression to invasive adenocarcinoma but with longer latency period compared to homozygous deletion of TP53 
 Pdx1 Pdx1-Cre;LSL-KRAS
G12D; 
TP53+/+;INK4Afl/fl FVB/n 
Invasive sarcomatoid pancreatic tumours in 100%, with 
metastasis in 33% 
 
 
 
Lymphomas in mice with 
INK4A/ARFflox allele, 
independent of concurrent 
expression of Pdx-Cre or 
LSL-KRASG12D 
(hypomorphic activity of 
INK4A/ARFflox allele).  
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 Pdx1 Pdx1-Cre;LSL-KRAS
G12D; 
INK4A/ARFfl/fl FVB/n 
Invasive tumours in 100% of mice (48% adenocarcinoma, 
26% sarcomatoid, 26% anaplastic), with metastasis in 11% 
 Pdx1 Pdx1-Cre;LSL-KRAS
G12D; 
INK4A/ARFfl/+ FVB/n 
Invasive tumours but with a longer latency period compared 
to INK4A/ARFfl/fl or TP53fl/+;INK4Afl/fl 
Or cutaneous papillomas 
(extra-pancreatic 
expression of Pdx1) 
Bardeesy 
2006186 
Pdx1 or 
p48 
Pdx1 or p48-Cre; 
LSL-KRASG12D;SMAD4fl/fl FVB/n 
IPMN and invasive PDAC with increased proliferation of 
stromal and epithelial cells 
  
Pdx1 or p48-Cre; 
LSL-KRASG12D;SMAD4fl/fl; 
INK4A/ARFfl/+ or INK4A/ARFfl/fl 
FVB/n 
IPMN and increased progression to PDAC; retained 
epithelial differentiation as compared to tumours with 
SMAD4 expression 
Gastric tumours in  
Pdx1-Cre mice 
Izeradjene 
2007187 
Pdx1 Pdx1-Cre;LSL-KRAS
G12D; 
SMAD4fl/+ 
BISwiss/129/ 
SvJae/C57BI/6 
Pre-invasive PanIN lesions and MCNs in body and tail of 
pancreas Large gastric tumours 
 p48 p48-Cre;LSL-KRAS
G12D; 
SMAD4fl/+ or SMAD4fl/fl 
BISwiss/129/ 
SvJae/C57BI/6 
Pre-invasive PanIN lesions and MCNs in body and tail of 
pancreas, lower % metastasis compared to Pdx-Cre;LSL-
KRASG12D;LSL-TP53R172H 
 
 
Brembeck 
2003*188 
CK19 CK19-KRASG12V B6/SJL Periductal lymphocytic infiltration, occasionally ductal hyperplasia 
Mucous neck cell 
hyperplasia (precursor to 
gastric adenocarcinoma) 
Grippo 
2003*189 
Rat 
elastase Ela-KRAS
G12D FVB/n 
Acinar-ductal metaplasia, cystic acinar neoplasm and 
lesions resembling preinvasive intraductal papillary 
mucinous neoplasms, no progression to PDAC 
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Guerra 
2007190 
Rat 
elastase 
Elas-tTA/tetO-Cre; 
LSL-KRASG12Vgeo B6/129SvJ/FVB 
KRASG12V expression during late embryonic development: 
At 1-3 months: acinar-ductal metaplasia, with progression 
to PanIN lesions in older animals. At 12 months: high grade 
PanIN lesions in 80% of mice, in 50% progression to PDAC 
 
 Rat elastase 
Elas-tTA/tetO-Cre; 
LSL-KRASG12Vgeo;TP53fl/+ B6/129SvJ/FVB 
All mice (n=17) developed invasive PDAC with lymph 
node and perineural invasion and metastasis to liver, lung, 
diaphragm and spleen; 50% of mice died before 6 months, 
no mice survived 12 months 
 
 Rat elastase 
Elas-tTA/tetO-Cre; 
LSL-KRASG12Vgeo B6/129SvJ/FVB 
KRASG12V expression in adult mice: no histological 
alterations or difference in proliferation  
 Rat elastase 
Elas-tTA/tetO-Cre; 
LSL-KRASG12Vgeo B6/129SvJ/FVB 
KRASG12V expression in adult mice with caerulein-induced 
pancreatitis: increased atrophic acini and at 8 months 
acinar-ductal metaplasia, with high grade PanIN in all mice 
and invasive PDAC in 30% 
 
Habbe 
2008191 
Rat 
elastase or 
Mist1 
Elas-Cre-ERT2Tg/+; 
LSL-KRASG12D or  
Mist1-CreERT2/+;LSL-KRASG12D 
B6/129SvJae 
PanIn lesions grade I-III, surrounded by acinar-ductal 
metaplasia, independent of exocrine injury; no progression 
to invasive PDAC 
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Heiser 
2006192 
Pdx1 Pdx1-Creearly;CTNNB1exon3 fl/+ Mixed Pancreatic hypoplasia  
 Pdx1 Pdx1-Crelate;CTNNB1exon3 fl/+ Mixed Increased pancreas mass, with increased proliferation of acinar cells, no tumour formation  
Strom 
2007193 
Pdx1 Pdx1-Crelate;APCfl/fl Mixed Increased pancreas mass, with increased proliferation of acinar cells, no tumour formation  
Heiser 
2008176 
p48 p48-Cre;CTNNB1exon3 fl/+ Mixed Ductal associated lesions and large, well-encapsulated pancreatic tumours (resembling SPN), no metastasis  
 p48 p48-Cre;CTNNB1
exon3 fl/+; 
LSL-KRASG12D Mixed 
Acinar-ductal metaplasia, few PanIN lesions, extensive 
desmoplastic reaction and cribriform and ductal tumours  
Morris IV 
2010194 
p48 p48-Cre;CTNBB1
fl/fl or 
CTNBB1fl/+ Mixed Reduced acinar regeneration post-caerulein treatment  
 Rat elastase 
Elas-Cre-ERT2Tg/+; 
LSL-KRASG12D;CTNBB1exon3 fl/+ Mixed 
In contrast to Elas-Cre-ERT2Tg/+;LSL-KRASG12D animals, no 
PanIN lesions developed  
 
Table 1.3 Mouse models of pancreatic cancer. 
LSL, Lox-Stop-Lox, Pdx, pancreas duodenum homeobox 1; Ela, elastase; Mist1, muscle intestine and stomach 1; PanIN, pancreatic intraepithelial neoplasia; 
MCN, mucinous cystic neoplasm; IPMN, intraductal papillary mucinous neoplasm; PDAC pancreatic ductal adenocarcinoma; APC, adenomatous polyposis 
coli; CTNNB1, gene encoding β-catenin. *, Models in which oncogenic KRAS was not expressed under control of the endogenous promoter, possible resulting 
in hyperphysiological KRAS levels, or activation of KRAS in inappropriate/non-targeted cell type or developmental stage. 
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1.6.3. Three-dimensional (3D) in vitro models of pancreatic cancer 
Pancreatic endocrine tissue has been cultured as organotypic slices from peri-
natal mouse embryos195. However, in pancreatic cancer research only a few 
studies using one of the discussed 3D models have been reported. Culture of 
pancreatic cancer cells on type I collagen-glycosaminoglycan scaffolds has 
demonstrated that pancreatic cancer cells adhere to these 3D collagen scaffolds, 
and subsequently proliferate, in an α2β1 integrin specific manner mediated by the 
balance of divalent cations Mg2+ and Ca2+196, 197. Additionally, normal 
pancreatic epithelial cells and pancreatic cancer cells have been embedded in 
collagen type I and Matrigel198, 199. Normal pancreatic duct epithelial cells 
(HPDE-E6E7) differentiated into spheroids, whereas cancer cells formed more 
disorganised colonies when embedded in Matrigel198. Another study by 
Deramaudt and colleagues embedded pancreatic ductal cells that were isolated, 
and characterised, from the previously discussed K19-KRASG12V mice188 and 
their age-matched wilde-type littermates in collagen type I. In order to 
investigate how oncogenic KRAS and inactivated TP53 cooperate in pancreatic 
tumourigenesis, ductal cells from the K19-KRASG12V mice were transduced with 
dominant-negative TP53V143A.  Embedding of wild-type, KRASG12D or TP53V143A 
pancreatic ductal cells in collagen type I resulted in the formation of well-
organised, polarised spheroids. In contrast, cells with mutated KRAS and loss of 
p53 function (KRASG12V/TP53V143A-ductal cells) developed into spheroids with a 
disrupted cellular architecture and loss of apico-basal polarity199.   
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1.7. Aims 
Although the described 3D models of pancreatic cancer study pancreatic cancer 
cell behaviour in 3D cell culture systems, with intact cell-cell and cell-matrix 
interactions and the formation of polarised spheroids, the cross-talk between 
cancer cells and stromal cells has not been investigated. Given the importance of 
the paracrine (and autocrine) signalling loops between pancreatic cancer cells 
and PSCs in the formation of a tumour supportive microenvironment and 
pancreatic cancer progression50, 94, 3D models incorporating these elements 
(pancreatic cancer cells, PSCs and the desmoplastic stroma) could prove 
invaluable for studying the tumour-stroma interactions in a physiologically 
relevant system. Therefore, the first aim of my project was to develop a 
physiologically relevant 3D organotypic culture model of pancreatic cancer and 
use this model to study the tumour-stroma interactions.  
 
In the second part, I used the organotypic culture model to test the hypothesis if 
targeting pancreatic stellate cells with all-trans retinoic acid (ATRA) could 
provide a novel therapeutic strategy in pancreatic cancer. 
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2.CHAPTER II  MATERIALS AND METHODS 
 
2.1. Cell culture 
2.1.1. Cell lines, media and culture reagents 
2.1.1.1. Pancreatic cancer cells 
The human pancreatic cancer cell lines used were Capan1, a well differentiated 
cell line sourced from a liver metastasis, with mutations in KRAS, TP53, INK4A, 
SMAD4 and BRCA2200-202; AsPc1, which is moderately differentiated, obtained 
from ascites and carries mutations in KRAS, TP53 and INK4A202, 203; PaCa3, a 
poorly differentiated cell line from a primary tumour with methylation of the 5’ 
CpG island of INK4A204; HPAF, a moderately differentiated cell line derived 
from ascites with mutations in KRAS, TP53 and INK4A202, 205; CFPAC1, a cell 
line derived from liver metastasis from a patient with pancreatic cancer and 
cystic fibrosis, carrying mutations in KRAS, TP53, SMAD4 and methylated 
INK4A, along with the most common mutation in CFTR (CFTRΔF508)206; 
Panc1, a poorly differentiated cell line derived from a primary tumour with 
mutated KRAS, TP53 and INK4A202, 207 and PaTu8988S, which was isolated, 
together with a second cell line called PaTu8988T, from liver metastasis of a 
primary pancreatic adenocarcinoma from a 64-year old woman, carrying 
mutations in KRAS and TP53 with methylation of the 5’ CpG island of INK4A208, 
209.  
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2.1.1.2. Stromal cells 
Non-tumourigenic, hTERT immortalised, MRC5 fibroblasts and human 
pancreatic stellate cells were used. MRC5 fibroblasts are derived from human 
foetal lung and have previously been shown to produce similar results as primary 
human pancreatic stellate cells93, 112. Using the outgrowth method98, pancreatic 
stellate cells were isolated from an unused, normal, adult male human pancreas 
(donation for transplantation) donated by the UK Human Tissue Bank (Ethics 
approval; Trent MREC (05/MRE04/82)). The resulting cell strain, designated 
FS1, was verified as being of stellate cell origin based on the expression of 
characteristic stellate cell markers (presence of lipid droplets in the cytoplasm 
and expression of cytoskeletal proteins GFAP, Desmin, Vimentin and αSMA), 
as published previously97, 98. MRC5 fibroblasts and FS1 stellate cells were 
immortalised, using ectopic human telomerase reverse transcriptase (hTERT) 
expression, by Dr Fiona Li and Ms Jennifer Sandle in our laboratory, as 
described previously210. Cells were labelled as MRC5hTERT and FS1hTERT (or 
PS1) cells, respectively, after confirmation of immortalised cell telomerase 
activity by TRAP assay and continuous passage without loss of phenotypic 
characteristics over the last five years. 
 
2.1.1.3. Culture conditions and routine cell culture 
Pancreatic cancer cells were cultured as adherent monolayers in sterile tissue 
culture flasks in an humidified atmosphere at 370C, 8% CO2 in either RPMI 
(PAA Laboratories, #E15-842; Capan1, AsPc1, PaCa3 and CFPAC1) or 
Dulbecco's Modified Eagle's Medium (DMEM, PAA Laboratories, #E15-843; 
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HPAF, Panc1, PaTu8988S and PaTu8988T) medium, supplemented with 10% 
foetal bovine serum (FBS, Biosera). MRC5 fibroblasts and PS1 stellate cells, 
after hTERT immortalisation, were grown, at the same humidified culture 
conditions as pancreatic cancer cells, in RPMI and DMEM:F12 (Invitrogen, 
#11320-074) medium, respectively, supplemented with 10% FBS and 1µg/ml 
puromycin (Sigma, #P9620) as a selection agent. 
 
When cells reached 80-90% confluency, medium was aspirated off and cells 
were washed with Phosphate Buffered Saline (PBS, CR-UK Media Services) 
before trypsin-EDTA (PAA Laboratories, #L11-003) was added for 2 – 5 
minutes at 370C to detach cells from the surface. Once cells were detached, 
trypsin was inactivated with medium containing FBS and cell suspensions were 
centrifuged for 3 minutes at 1200 revolutions per minute (rpm), followed by 
removal of supernatant and resuspension of the cell pellet in standard medium. If 
counting of cells was required, 20 µl cell suspension was pipetted either into a 
chamber of a haemocytometer, and cells were counted manually under a light 
microscope, or 20 µl cell suspension was pipetted into 9.98 ml of “CASYton”, an 
isotonic solution for automatic counting with a Casy counter (Scharfe) via 
electrical signals that are generated when cells pass through a measuring 
capillary. Cells were subcultured at a ratio varying from 1:2 to 1:10, depending 
on their growth rate.  
 
For storage of cells, cell pellets were resuspended at a concentration of 1 - 2x106 
cells/ml in a mixture of 90% FBS with 10% dimethyl sulphoxide (DMSO), 
which acts as a cryoprotectant. One ml of cell suspension was pipetted into a 
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cryovial and cells were gradually frozen, thereby reducing the risk of ice crystal 
formation and cell damage, and stored in liquid nitrogen.  
 
When recovering cells from the liquid nitrogen stock, cells were thawed as 
quickly as possible to remove the cryopreservative and prevent formation of ice 
crystals and cell death. Cryovials were placed in a waterbath (370C) and, once 
completely thawed, cell suspensions were transferred to a 15 ml falcon tube 
containing prewarmed standard medium. The DMSO was removed by 
centrifuging cells for 3 minutes at 1200 rpm, supernatant was aspirated and cells 
were resuspended in standard medium and plated in a tissue culture flask.  
 
2.1.2. Generation of spheroids 
Three-dimensional multicellular spheroids of Capan1 and PaCa3 cells were 
grown by suspending 50,000 cells in standard medium per well in 6-well plates 
that were coated overnight with poly(2-hydroxyethylmethacrylate) (polyHEMA 
at 6mg/ml ethanol; Sigma Aldrich), preventing cells from attaching to the 
surface211. Established spheroids were harvested after 2 weeks. Capan1 
spheroids usually consisted of about 15-20 cells while PaCa3 spheroids generally 
were smaller, composed of about 10 cells. 
 
2.1.3. Collection of supernatant 
Three different methods of conditioned medium harvest were used. For 
conditioned medium to be used in Western blot analysis and invasion assays, 
cells were cultured for 8 hours in serum free medium supplemented with 
respective ATRA or vehicle treatment (stellate cells appeared stressed if serum 
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starved for longer durations of time), after which the medium was collected and 
centrifuged for 5 minutes at 1200 rpm to collect cell debris. For Western blot 
analysis the supernatants were concentrated by vacuum drying at 45°C at 7.5 bar 
for 4 hours (after addition of protease inhibitors, with NaF and Na3VO4). The 
obtained pellets were dissolved in sample buffer and boiled at 1000C for Western 
blotting (see paragraph 2.7). For invasion assays the supernatants were either 
used immediately (preferred) or stored at -200C or for long term storage at -800C.  
 
Due to their hydrophobic character, Wnt proteins tend to precipitate in the 
absence of serum. Hence, the conditioned medium used for the pTOPFlash and 
pFOPFlash dual luciferase reporter assays was collected after 24 hours of culture 
in RPMI, containing 10% FBS, supplemented with either ATRA or vehicle 
control. Supernatants were centrifuged for 5 minutes at 1200 rpm and stored at 
40C.  
 
Supernatant was also collected for proteomic analysis, which will be discussed 
separately in paragraph 2.10. 
 
2.2. Reagents 
2.2.1. Antibodies 
All antibodies used are summarised in Table 2.1. 
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Primary antibody Species raised in 
Supplier  
(catalogue number) 
Dilution for 
IF or IHC 
Dilution for 
WB 
HSC70 Mouse Santa Cruz (#sc-7298) N.A. 1:5000 
αSMA Mouse Dako  (Clone 1A4, #M0851) 1:300 1:100 
Vimentin Mouse Dako (Clone V9, #M0725) cs 1:2000 FFPE 1:50 1:250 
GFAP Mouse Sigma-Aldrich  (Clone G-A-5, #G3893) 1:500 1:250 
Desmin Mouse Sigma-Aldrich  (Clone DE-U-10, #D1033) 1:100 1:250 
Ki67 Rabbit Novocastra (#NCL-Ki67p) 1:200 N.A. 
Cleaved caspase-3 Mouse R&D Systems (#AF835) 1:100 N.A. 
E-cadherin Mouse Abcam  (Clone HECD-1, #ab1416) 1:1000 1:200 
β-catenin Mouse BD Biosciences  (Clone 14,#610154) 1:200 N.A. 
Ezrin Mouse BD Biosciences  (Clone 18, #610603) 1:200 N.A. 
P-ERM Rabbit Cell Signalling (#3141S) 1:100 N.A. 
Cytokeratin WSS Rabbit Dako (#Z0622) 1:500 N.A. 
sFRP4 Rabbit Santa Cruz (#sc-30152) 1:50 1:200 
Anti-mouse HRP Goat Abcam (#ab5879) N.A. 1:1000 
Anti-rabbit HRP Goat Abcam (#ab98485) N.A. 1:2000 
Biotinylated anti-rabbit Swine Dako (#E0353) 1:500 N.A. 
Anti-mouse-Alexa-488 Goat Invitrogen (#A11029) 1:500 N.A. 
Anti-mouse-Alexa-488 Rabbit Invitrogen (#A11059) 1:500 N.A. 
Anti-rabbit-Alexa-488 Goat Invitrogen (#A11034) 1:500 N.A. 
Anti-mouse-Alexa-546 Goat Invitrogen (#A11003 ) 1:500 N.A. 
 
Table 2.1 Antibodies used for the experiments. 
HSC70, heat shock 70kDa protein 8; αSMA, α-smooth muscle actin; P-ERM, Phospho-
Ezrin (Thr567)/Radixin (Thr564)/Moesin (Thr558); Cytokeratin WSS, wide spectrum 
screening, recognising a broad spectrum of human cytokeratins; sFRP4, secreted 
frizzled-related protein 4; HRP, horseradish peroxidase; cs, coverslips; FFPE, formalin 
fixed paraffin embedded; IF, immunofluorescence, IHC, immunohistochemistry; WB, 
Western blot; N.A. not applicable. 
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2.2.2. Retinoic acid 
All-trans retinoic acid (ATRA) (Sigma Aldrich, #R2625) was dissolved in 100% 
ethanol, filter purified and used at 1 µM concentration freshly diluted before use 
in culture medium. Medium was changed every 24 hours and cells incubated 
with culture medium, supplemented with an equivalent amount of vehicle (0.1% 
ethanol), served as controls. Due to its characteristic, electron rich polyene chain 
(Figure 2.1), exposure of ATRA to daylight, heat or oxygen results in rapid 
isomerisation and oxidative degradation212, 213. Therefore, all experiments were 
carried out in subdued light and 1 mM stock solutions were stored at -800C 
protected from direct light. 
 
 
 
 
 
 
Figure 2.1 All-trans retinoic acid (ATRA). 
 
 
2.2.3. Plasmids 
A β-catenin/TCF reporter with 10 TCF responsive elements and a minimal 
TATA box inserted into the pGL4.10 luciferase reporter construct with the Luc2 
gene (Promega), called pTOPFlash for “TCF optimal binding sites”, was used. 
The pTOPFlash luciferase activity was compared to the pFOPFlash luciferase 
activity, which carries 10 mutated TCF binding sites (pFOPFlash, far from 
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optimal binding sites)214. The sequence of pTOPFlash and pFOPFlash is 
provided in Table 2.2. As an internal control reporter, a Renilla plasmid was 
used, containing RLuc cDNA (encoding Renilla luciferase) downstream of a 
SV40 early promoter region, which drives a strong, constitutive expression of 
Renilla luciferase. All three plasmids were a kind gift from Dr Marc van de 
Wetering (Hubrecht Institute, Utrecht, The Netherlands).  
 
In order to amplify obtained plasmids, Subcloning Efficiency™ DH5α™ 
competent Escherichia coli cells (Invitrogen #18265-017) were chemically 
transformed with plasmid DNA according to manufacturer’s instructions. 
Briefly, competent cells were mixed on ice with the DNA, followed by a short 
heat shock. Then, cells were incubated in lysogeny broth (LB) medium for 60 
minutes at 370C, and allowed to express the antibiotic resistance gene before 
plating on ampicillin containing agar plates for selection overnight. Next day a 
single colony was picked and bacteria were amplified in LB medium with 
ampicillin, on a shaker at 370C, for 14-16 hours. Plasmid was purified with a 
PureLink™ HiPure Plasmid Maxiprep Kit (Invitrogen, #K2100-07) and quantity 
and purity of DNA was measured with a NanoDrop spectrophotometer (OD 
260/280 ratio > 1.80).  
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 TCF responsive elements and minimal TATA box in pGL4.10 (Promega) 
TOP10 
CATTTCTCTGGCCTAACTGGCCGGTACCTGAGCTCGCTAGCCTCGAGGAT
GGACCCCCCCTTTGATCTTACCCCCTTTGATCTTACCCCCTTTGATCTTACC
CCCTTTGATCTTACCCCCTTTGATCTGTCGACCCCCTTTGATCTTACCCCCT
TTGATCTTACCCCCTTTGATCTTACCCCCTTTGATCTTACCCCCTTTGATCT
TGGGCTGCAGGTCAGCTCTAGAGGGTATATAATTGGATCCAGATCTGGCC
TCGGCGGCCAAGCTTGGCAATCCGGTACTGTTGGTAAAGCCACCATGGAA
GATGCCAAAAACATTAAGAAGGG 
FOP10 
CATTTCTCTGGCCTAACTGGCCGGTACCTGAGCTCGCTAGCCTCGAGGAT
GGCCGCCCCCTTTGGCCTTACCCCCTTTGGCCTTACCCCCTTTGGCCTTAC
CCCCTTTGGCCTTACCCCCTTTGGCCTGTCCACCCCCTTTGGCCTTACCCC
CTTTGGCCTTACCCCCTTTGGCCTTACCCCCTTTGGGCTTACCCCCTTTGGC
CTTGGGGCTGCAGGTCAGCTCTAGAGGGTATATAATTGGATCCAGATCTG
GCCTCGGCGGCCAAGCTTGGCAATCCGGTACTGTTGGTAAAGCCACCATG
GAAGATGCCAAAAACATTAAGAAGGG 
 
Table 2.2 Sequence of pTOP-Flash and pFOP-Flash reporter constructs. 
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2.2.4. Small interfering RNA (siRNA) oligos 
Cells were transfected with a pool of siRNA oligos (Dharmacon), whose 
sequences are listed in Table 2.3.  
 
On-target plus siRNA sFRP4 (J-011388-05) Sequence 
sFRP4 siRNA #1 GGAGAGAUCAGCUUAGUAA 
sFRP4 siRNA #2 CAACGGUGGUGGAUGUAAA 
sFRP4 siRNA #3 GGAGGAUGUUAAGUGGAUA 
sFRP4 siRNA #4 GAGCUAACUAGUUUCCAAA 
  
Non-targeting siRNA Pool #2 (D-001206-14) Sequence 
Non-targeting siRNA #2 UAAGGCUAUGAAGAGAUAC 
Non-targeting siRNA #3 AUGUAUUGGCCUGUAUUAG 
Non-targeting siRNA #4 AUGAACGUGAAUUGCUCAA 
Non-targeting siRNA #5 UGGUUUACAUGUCGACUAA 
 
Table 2.3 Sequence of siRNA oligos. 
Sequence of targeted small interfering RNAs (siRNAs) against secreted frizzled-related 
protein 4 (sFRP4) and sequence of non-targeting siRNAs that were used as control. 
 
 
2.2.5. Primers 
Primers used for semi-quantitative reverse transcription PCR were ordered from 
Invitrogen and are summarised in Table 2.4. Primers used for quantitative real-
time PCR were from Applied Biosystems and are summarised in Table 2.5. 
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Gene Forward primer Reverse primer Tm Size 
WNT1 CTGCCTCTCTTCTTCCCCTT TCACAGCTGTTCAATGGCTC 55 251 
WNT2 GCGGCCTTACAATAAGCAGA GGCAGAAGCCAACCACTATT 55 291 
WNT2b GTGTCCTGGCTGGTTCCTTA GAAGCTGGTGCAAAGGAAAG 55 188 
WNT3 CGCCTCGGAGATGGTAGTAG AAAGTTGGGGAGTTCTCGT 55 129 
WNT3a CTCCCACACCGTCAGGTACT ACGGGACGAGAGGCTTCTAT 55 181 
WNT4 GCCAGCGTTCTTCCTTTCAA CCCTTGACACATGGCGATTA 55 212 
WNT5a GCACATGCTTTTATCCGTGA TGCAGCACTGTCCAGATTTC 55 272 
WNT5b CCGCCTCTGCAACAAGACCT AACTTGCAGTGGCAGCGCTG 55 111 
WNT7b CCAAGTCCCAGAACACACCT TCTCCGGTACCCAGTGTAGG 55 134 
     
FZ1 TTCAGCAGCACATTCTGAGG CCTGCACACATTTTCCCTTT 55 154 
FZ2 TCACGGTCTACATGATCAAA GCAACCTAAAAGTGAAATGG 55 266 
FZ3 GGATGATCAAAGAAGCAAAG TTGAGCCGATGAGAACTACT 55 186 
FZ4 GACTTTGGAAGGAACCTTTT TGAAACCCCGTCTCTACTAA 55 238 
FZ5 GGTTTGGTGCAGGTGAATTT CTACAGCATGGGATAGGCACT 55 125 
FZ6 TTCGGCAGCTCACTAGGATT CATCAGAAAATCTTGCCCAA 55 190 
FZ7 CTGGAGTTCTTTGAAATGTGCT AAGGTTAGCTCCCATGATTCTC 55 133 
FZ8 CGGTTTGGGTATTCTTAATG ACAGGGGTAAGCCTCTAAAC 55 215 
FZ9 AACACAGAGAAGCTGGAGAA ACCACCAGTGACATGAAAAT 55 251 
FZ10 AGAAACCCTTCAGTGCTACA AAAGTGTCTCTGCCAACCTA 55 205 
LRP5 GTGTGTGACAGCGACTACAG CTATTTACAGGGGCACAGAG 55 253 
LRP6 ATGTGTGGCTTCTGACTTTT GGTACAGGCTTTATGAGACG 55 211 
     
TCF1 GGTCACAAGCACAAAGCTCA CTCCCCAATTTGCCTGATAA 55 233 
TCF3 CTATTTCTGCTGCTGTTCCT ACTTTCCACATGACAAAACC 55 209 
TCF4 TGATCTGTGTCCAAAAGTGA CTTCAAGTCCCATGAGAAAG 55 222 
AXIN2 TACCGGAGGATGCTGAAGGC CCACTGGCCGATTCTTCCTT 55 345 
     
SFRP1 TCTTCCTCTGCTCGCTCTTC GCTGGCACAGAGATGTTCAA 60 284 
SFRP3 TATACCAGCTCTGGCTGCCT TTCGAGTTCCTGCCAGACTT 60 245 
SFRP4 AGCCAGTCCCAAGAAGAACA TCTGTACCAAAGGGCAAACC 60 285 
SFRP5 GTCTTCCTGTGCTCGCTCTT TGTGCTCCATCTCACACTGG 60 250 
     
GAPDH CCATGGAGAAGGCTGGGG CAAAGTTGTCATGGATGACC 60 195 
HPRT GACCAGTCAACAGGGGACAT CCTGACCAAGGAAAGCAAAG 60 132 
 
Table 2.4 Primers used for reverse transcription PCR (RT-PCR). 
Tm, annealing temperature (0C); Size, product length in base pair; FZ, Frizzled receptor; 
LRP, low density lipoprotein receptor-related protein; TCF, T-cell factor; SFRP, 
secreted frizzled-related protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
HPRT, hypoxanthine phosphoribosyl transferase. 
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Gene Assay ID (Applied Biosystems) 
RARβ Hs00977140_m1 
FGF9 Hs00181829_m1 
ITGA1 Hs00235030_m1 
DKK1 Hs00183740_m1 
SFRP4 Hs00180066_m1 
18s X03205 
 
Table 2.5 Primers used for quantitative real-time PCR. 
RARβ, retinoic acid receptor β; FGF9, fibroblast growth factor 9; ITGA1, integrin α1; 
DKK1, Dickkopf 1; SFRP4, secreted frizzled-related protein 4; 18s, human 18s 
ribosomal RNA.  
 
 
2.3. Cell transfection 
2.3.1. Introduction of plasmid DNA into pancreatic cancer cells 
Pancreatic cancer cells were seeded in a 24-well plate at a confluency of 70-80% 
(between 5.0 and 6.5x104 cells per well) in standard culture medium containing 
FBS. The next day, cells were transfected with 100 ng pTOPFlash or pFOPFlash 
reporter plasmids, together with 10 ng Renilla, using FuGENE6 (Roche, 
#11814443001) following manufacturer’s instructions. Briefly, a DNA (µg): 
Fugene (µl) ratio of 1:3 was prepared in OptiMEM (Invitrogen, #51985), 
incubated for 15 minutes at room temperature and 25 µl transfection mixture was 
added to each well containing cells in 500 µl standard medium (with FBS). The 
next day, medium was changed to either standard medium or to conditioned 
medium (see paragraph 2.1.3.); luciferase and Renilla activity were read at 48 
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and 72 hours post transfection, using a Dual Luciferase Assay System (Promega, 
#E1910, see paragraph 2.4.4 for more details). 
 
2.3.2. Introduction of siRNA into pancreatic stellate cells 
Pancreatic stellate cells (PS1) were plated in a 6-well plate at a confluency of 30-
40% (2.0x104 cells per well) in standard medium containing FBS but without 
puromycin. The following day PS1 cells were transfected with a pool of 4 
siRNAs targeting sFRP4 at a final concentration of 100 nM, or with a pool of 
non-targeting siRNA at the same concentration of 100 nM (Dharmacon, 
sequences listed in Table 2.3), using Oligofectamine (Invitrogen, #12252-011) as 
transfection reagent. Transfection complexes were prepared in OptiMEM, 
incubated for 20 minutes at room temperature, and 200 µl of transfection mixture 
was added to PS1 cells, which were grown in 800 µl OptiMEM. Cells were 
incubated with transfection mixture for 4 hours at 370C, before 500 µl of 
standard medium, supplemented with serum and ATRA or ethanol, was added 
(to get the correct concentration in the final 1500 µl, serum and ATRA/ethanol 
were added in a 3x concentration in the 500 µl DMEM:F12 medium). Cells were 
treated every 24 hours with 1 µM ATRA or with 0.1% ethanol and knock-down 
of sFRP4 expression was confirmed 2, 3, 5, 6 and 7 days post transfection by 
quantitative real-time PCR. 
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2.4. Functional assays 
2.4.1. Cell viability assay 
Cells in the supernatant of organotypic gels were collected by centrifugation (5 
minutes, 1500 rpm), washed in PBS and resuspended in 1 ml PBS. Cell viability 
was confirmed by a negative Trypan Blue stain. In a separate tube, 10 µl cell 
suspension was mixed with 10 µl 0.4% Trypan Blue (Sigma Aldrich) and loaded 
into a chamber of a haemocytometer. Cells were viewed under a light 
microscope at x100 magnification and the percentage of dead cells was 
determined by dividing the number of blue cells by the total number of cells, 
multiplied by 100. If the Trypan Blue positive cells were < 10%, the remaining 
cell suspension was lysed for Western blot analysis. 
 
2.4.2. Cell proliferation assay 
PS1 cells were plated (3,000 cells per well) in a 96-well plate coated with diluted 
collagen type I (BD Bioscience, #354236), fibronectin (Sigma Aldrich, #F0895) 
or Matrigel (BD Bioscience, #354234). All dilutions were 1:100 in PBS and, as a 
control, cells were plated on uncoated tissue culture plastic. Cell proliferation 
was analysed at day 1, 2, 4 and 6 with Cell Proliferation Reagent WST-1 (Roche, 
#5015944) added 3 hours before spectrophotometric reading, according to the 
manufacturer’s protocol. 
 
2.4.3. Transwell invasion assay 
Cancer cells were cultured in serum free medium on top of an 8 µm Transwell 
membrane (Corning, #3422) coated with Matrigel. After 72 hours, cells invaded 
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through the membrane were fixed by placing the inserts for 15 minutes in 500 µl 
formaldehyde/PBS solution (3.7%); inserts were washed in PBS, cells on top of 
the membrane were removed with a cotton tip, and invaded cells were stained 
with Crystal Violet (5 mg/ml in 2% Ethanol; inserts were placed in 500 µl in 24-
well plate) overnight. The following day, inserts were washed extensively in 
water so that only cells that had invaded through the membrane demonstrated a 
positive staining, Crystal Violet was dissolved in 1% SDS (200 µl in 24-well 
plate) for 1 hour and invasion was quantified using absorbance at 560 nm. 
 
2.4.4. Dual luciferase reporter assay 
Cells transfected with pTOPFlash or pFOPFlash and Renilla reporter constructs 
were washed with PBS and incubated with passive lysis buffer (PLB) for 15 
minutes on a rocking platform at room temperature. Cell lysates were distributed 
in 96-well plates (Thermo Scientific, 950288) and, using a plate-reading 
luminometer (PerkinElmer, VICTOR, 1420-050), firefly luciferase reporter 
activity was measured first by adding Luciferase Assay Reagent II (LAR II) 
followed by quenching of the firefly luminescence and initiation of the Renilla 
luciferase reaction by adding Stop&Glo® Reagent. Firefly luciferase activity was 
normalised to the internal Renilla control. 
 
2.5. Organotypic culture 
2.5.1. Submerged organotypic culture model 
Figure 2.2 shows the different types of 3D tissue culture models used. In all 
systems, the extracellular matrix (ECM), composed of 75% collagen type I and 
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25% Matrigel after preliminary experiments with different ratios had suggested 
this was the best combination, was prepared as described previously for an 
organotypic skin cancer model138. One ml of a mixture of 5.25 volumes of 
Collagen type I, 1.75 volumes of Matrigel, 1 volume of 10 x RPMI, 1 volume of 
filtered FBS and 1 volume of either 5x105 cancer cells, spheroids (Figure 2.2A, 
F) or stromal cell suspension (5x105 MRC5 or PS1 cells) (Figure 2.2B, C, D, G) 
were plated into wells of a 24-well plate coated with diluted collagen type I 
(1:100 in PBS).  
 
In the submerged organotypic model (Figure 2.2C, G), 5x105 cancer cells 
(Capan1 or PaCa3) or their spheroids (collected by gravity sedimentation on ice), 
suspended in 1 ml of RPMI medium were added on top of the gels. Experiments 
were in triplicate and cancer cells or their spheroids were cultured on the surface 
of gels prepared with or without fibroblasts or stellate cells as a control. Medium 
was changed on alternate days and gels were harvested at different time points (7 
and 14 days), fixed in 10% formal saline, bisected and embedded in paraffin or 
snap-frozen. 
 
2.5.2. Air-liquid organotypic culture model 
To study the invasion of cancer cells in a 3D organotypic model, the described 
submerged model was slightly modified by lifting the submerged gels onto a 
metal grid which was covered by a nylon sheet pre-coated with 7 volumes of 
collagen type I, 1 volume of 10 x RPMI, 1 volume RPMI and 1 volume FBS 
(Figure 2.2D, E)138; 250 µl collagen mixture was pipetted onto the nylon sheets, 
allowed to polymerise for 15 minutes at 370C, cross-linked with 1% 
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glutaraldehyde/PBS and left at 40C for 1 hour. In order to remove the toxic 
glutaraldehyde, membranes were washed in PBS (3x) and medium (1x) and, 
covered in medium, left at 40C overnight. The following day, the submerged 
organotypics were lifted onto metal grids covered by the coated nylon sheets and 
fed from below.   
 
Cancer cells (5x105 Capan1, HPAF or PaCa3) were grown on top of gels 
containing 5x105 PS1 cells (Figure 2.2D) or Capan1 and PS1 cells were mixed in 
different ratios (total cell number was kept constant at 5x105 cells, Table 2.6) on 
top of gels that were prepared without cells (Figure 2.2E). Gels were harvested at 
day 10 and processed as above. 
 
 
Capan1:PS1 Capan1 (x105) PS1 (x105) 
1:0 5.00 0.00 
10:1 4.55 0.45 
5:1 4.17 0.83 
2:1 3.30 1.70 
1:1 2.50 2.50 
1:2 1.70 3.30 
1:5 0.83 4.17 
1:10 0.45 4.55 
0:1 0.00 5.00 
 
Table 2.6 Different ratios of cancer cells and stellate cells in organotypic 
culture. 
Capan1 cancer cells and PS1 stellate cells were cultured in different ratios on top of 
organotypic gels, raised to an air-liquid interface (Figure 2.2E). The total number of 
cells was kept constant at 5.0x105. 
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Figure 2.2 Schematic representation of different types of organotypic 
culture models used.  
(A) Cancer cells were embedded in an extracellular matrix (ECM) gel, composed of 
collagen type I and/or Matrigel (different ratios have been used). (B) Cancer cells and 
pancreatic stellate cells were co-cultured within an ECM gel, composed of 75% collagen 
type I and 25% Matrigel. (C) Submerged organotypic culture model, in which cancer 
cells were grown on top of an ECM gel, composed of 75% collagen type I and 25% 
Matrigel embedded with stromal cells, and were fed from the top. (D) and (E) Raised 
air-liquid organotypic culture model, in which the submerged gels were lifted onto a 
metal grid (which was covered by a nylon sheet coated with a mixture of collagen type I, 
foetal bovine serum and culture medium) and were fed from below. PS1 stellate cells 
were either embedded in the ECM gel (D) or admixed with cancer cells and cultured on 
top of ECM gels (E). In addition to cancer cells in (A) and (C), pre-established spheroids 
were cultured in ECM gels composed of different ratios of collagen type I and Matrigel 
(F) or in the submerged organotypic culture model on top of gels containing stromal 
cells (G).  
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2.6. Polymerase Chain Reaction (PCR) 
2.6.1. Isolation of RNA and cDNA synthesis 
For reverse transcription PCR, cells were lysed with TRIzol® Reagent 
(Invitrogen, #15596-018). After addition of chloroform, the aqueous phase 
containing the RNA was transferred to an RNase free eppendorf tube and the 
RNA was recovered by precipitation with isopropanol, washed with 75% ethanol 
after which RNA pellets were left to air-dry and dissolved in RNase free water. 
Quantity and purity of RNA was measured with a NanoDrop spectrophotometer 
(OD 260/280 ratio > 1.80) as well as with an agarose gel to control for 
contamination with genomic DNA. In case of genomic DNA contamination, 
RNA was treated with DNase before reverse transcription for cDNA synthesis. 
cDNA was synthesised from extracted RNA, using Superscript III First Strand 
Synthesis kit using random hexamers, according to manufacturer’s instructions 
(Invitrogen, #18080-051). 
 
For quantitative real-time PCR, cells were lysed with the TaqMan® Gene 
Expression Cells-to-CT™ Kit (Applied Biosystems, # 4399002) according to the 
manufacturer’s protocol. Briefly, cells were trypsinised, centrifuged, washed in 
cold PBS, with 50 µl PBS containing ≤ 105 cells, mixed with lysis solution 
(which included DNase I) and incubated for 5 minutes at room temperature. 
Next, in order to inactivate the lysis reagents and prevent inhibition of reverse-
transcription or PCR, a stop solution was added to the lysates and cDNA was 
synthesised using a reverse transcription enzyme mix and buffer, for 1 hour at 
370C.  
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2.6.2. Reverse transcription PCR 
cDNA was amplified in a reaction mix with the forward and reverse primer 
(Table 2.4) at a final concentration 5x10-4 nmol/µl and MegaMix Blue 
(Microzone Ltd), containing Taq polymerase, dNTPs, buffer and a blue agarose 
loading dye. Cycle numbers of denaturing at 950C, annealing at 550C or 600C, 
and DNA extension at 720C, were optimised to collect data from samples in the 
exponential phase of amplification. The PCR product was subsequently loaded 
on a 1% agarose gel, stained with ethidium bromide to visualise the DNA bands 
under UV light, and DNA was separated by electrophoresis. Gene expression 
was analysed, relative to the expression of a housekeeping gene, such as GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) or HPRT (hypoxanthine-guanine 
phosphoribosyltransferase).   
 
2.6.3. Quantitative real-time PCR 
cDNA was amplified and quantified using TaqMan® Gene Expression Assays 
(Applied Biosystems, Table 2.5), which include a primer set (spanning at least 
one exon junction) and a TaqMan® probe with a fluorescent reporter dye 
attached to the 5' end and a non-fluorescent quencher at the 3’ end of the probe. 
Only probes that are hybridised to the complementary target are cleaved by the 
5’- nuclease activity of DNA polymerase, resulting in the separation of the 
reporter dye from the quencher and an increase in fluorescence at each PCR 
cycle proportional to the amount of probe cleavage.  For each gene, the first 
cycle when exponential amplification could be detected (CT) was normalised to 
the endogenous expression of the housekeeping gene 18s.  
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2.7. Western blotting 
2.7.1. Isolation of protein 
At a confluency of approximately 70%, cells were washed in PBS and lysed for 
10 minutes on ice using RIPA lysis buffer (Upstate) with freshly added 1 mM 
NaF, 50 mM Na3VO4 and a 1:100 dilution of protease inhibitor cocktail 
(Calbiochem). Cell debris was collected by centrifuging the lysates at 15,000 
rpm for 10 minutes at 40C and protein concentration in the supernatant was 
determined with Bio-Rad's DC Protein Assay (Bio-Rad Laboratories), according 
to the manufacturer’s instructions. 
 
2.7.2. Western blot analysis 
An equal amount of cellular protein, varying between 5 and 20 µg depending on 
the experiment, was mixed with sample buffer and boiled for 5 minutes at 1000C. 
Denatured proteins were separated on 8–10% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred to 
nitrocellulose membranes. Non-specific binding sites were blocked with 5% 
skimmed milk in 0.1% Tween20-PBS, followed by incubation with primary 
antibody at 40C overnight (Table 2.1). Membranes were washed in 0.1% 
Tween20-PBS and subsequently incubated with appropriate secondary HRP-
conjugated antibody for one hour at room temperature. Specific bands were 
visualised using Amersham ECL (or ECL Advanced if low protein 
concentrations) Western Blotting Detection Kit (GE Healthcare).  
 
Concentrated supernatant samples, which were collected from the same number 
of cells plated for different treatments (in order to allow comparison of the 
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amount of secreted protein in the medium from differently treated cells in the 
absence of a protein loading control), were dissolved in sample buffer, boiled at 
1000C, separated on 10% SDS-PAGE gels and transferred to nitrocellulose 
membranes. Transfer and protein loading were confirmed by staining the 
membranes with Ponceau S (Sigma, #P7170), which binds to the positively 
charged amino groups of the protein, followed by blocking of non-specific 
binding sites (after removal of the Ponceau stain by rinsing the membranes in 
distilled water) and immunodetection as described above.  
 
2.7.3. Densitometry and analysis 
For Western blotting, densitometric analysis of specific bands was done using 
Image J software (Image J 1.39u). To obtain a semi-quantitative measurement of 
the level of total protein, band densities were normalised to the HSC70 loading 
control detected on the same membrane.  
 
2.8. Immunohistochemistry 
2.8.1. Organotypic cultures 
For immunohistochemistry of paraffin embedded gels, 4 µm sections were de-
waxed and rehydrated. Antigen retrieval was by boiling sections in 10 mM 
citrate buffer (pH 6.0) for 20 minutes; endogenous peroxidase was blocked with 
a 0.45% solution of H2O2 in methanol. Proliferation and apoptosis were assessed 
by staining with antibodies to Ki67 and cleaved caspase-3, respectively, followed 
by incubation with biotinylated secondary antibody. Peroxidase-labelled 
streptavidin (Dako, #P0397) was added and visualised using 3,3-
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diaminobenzidine tetrahydrochloride (DAB, Sigma Aldrich, #D5637) before 
counterstaining with Mayer’s haematoxylin. 
 
2.8.2. Patient samples 
Archived patient samples were obtained with prior Research Ethics Committee 
approval (East London & the City REC3 07/H0705/87). Staining procedures 
were similar to immunohistochemistry of paraffin embedded gels with quenching 
of endogenous peroxide (0.45% H2O2 in methanol) followed by blocking with 
normal serum and incubation with anti-E-cadherin (1:200, after antigen retrieval 
in 5% Urea), anti-β-catenin (1:200), anti-sFRP4 (1:50) or matched IgG (control) 
for 1 hour at room temperature. Subsequently, sections were incubated with HRP 
conjugated anti-mouse or anti-rabbit secondary antibody followed by the 
avidin:biotinylated enzyme complex (ABC) using a Vectastain ABC kit (Vector 
Laboratories), DAB and counter stained with haematoxylin. 
  
2.8.3. Oil Red O staining 
For Oil Red O staining, fixed PS1 cells were incubated with a saturated solution 
of Oil Red O (Sigma Aldrich, #O-0625) in isopropanol for 10 minutes at room 
temperature, followed by extensive washing in distilled water; visualisation was 
by light microscopy. Vitamin A storage in lipid droplets was examined using 
fluorescence microscopy at an excitation wavelength of 320-380 nm 
demonstrating the characteristic, rapidly fading blue-green fluorescence of 
vitamin A215. 
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2.8.4. Light microscopy 
When cells or spheroids were embedded into extracellular matrix gels (Figure 
2.2A, F), live cell images were taken with a time-lapse microscope (Zeiss 
Axiophot) at x200 magnification and processed with Simple PCI image editing 
software (version 5.3.1.081004). Bright field images of H&E, Ki67 and cleaved 
caspase-3 stained sections were taken (x630 or x200 magnification) with a light 
microscope (Zeiss Axiophot) using a digital camera (Nikon DXM1200) and 
image editing software (Nikon ACT-1, version 2.20). 
 
2.9. Immunofluorescence 
2.9.1. Cells cultured on coverslips 
Cells were seeded on coverslips in a 24-well plate as monoculture, or co-culture 
of cancer cells and PS1 stellate cells in a 2:1 ratio (cancer cells:PS1 cells) at a 
density dependent on the time of fixation. For fixation the following day, 1x105 
cells were plated, whereas 1x104 cells were plated for a one-week treatment with 
all-trans retinoic acid (ATRA).  
 
For immunofluorescence, cells were fixed with 3.7% formaldehyde, 
permeabilised with 0.1% Triton-X100 (except for staining for sFRP4), blocked 
with 0.1% BSA and incubated for 1 hour at room temperature with primary 
antibody (Table 1) followed by appropriate Alexa488-labelled secondary 
antibody. F-actin was stained with Phalloidin-TRITC and nuclei were visualised 
with 4',6-diamidino-2-phenylindole (DAPI). Negative controls were with 
isotype-specific immunoglobulins at matching concentration. 
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2.9.2. Organotypic cultures 
For immunofluorescent staining of paraffin embedded gels, sections were 
dewaxed, and rehydrated. Antigens were retrieved by boiling sections in 10 mM 
citrate buffer, at pH 6.0, except for a dual-staining with rabbit cytokeratin and 
mouse vimentin or αSMA where pH was 7.5. Sections were permeabilised in 
0.2% Triton-X100 (except for staining for sFRP4), blocked with 2% Bovine 
Serum Albumin (BSA) + 0.02% Fish Skin Gelatin + 10% foetal bovine serum 
(FBS) and incubated with primary antibodies (Table 1) overnight at 40C, 
followed by 1 hour incubation at room temperature with the appropriate 
secondary antibody (1:500) and DAPI. Controls (uniformly negative) were with 
appropriate isotype-specific immunoglobulins at matching dilution. 
 
2.9.3. Confocal microscopy 
Immunofluorescent stained cells and gels were visualised (x630 or x400 
magnification) with a Confocal laser scanning microscope (Zeiss LSM 510, Carl 
Zeiss Inc.), using Immersol 518 TF oil (Zeiss) as an imaging medium. Z-stacks 
were rendered into three-dimensional images with Volocity software (version 4, 
Improvision) and organised in Adobe Photoshop. For generation of movies, z-
stacks of respective sections were played at 1 frame per second. 
 
2.10. Proteomic analysis 
In collaboration with Dr Mark Weeks (Veterinary Laboratories Agency 
Weybridge, Addlestone) full cell lysates and supernatant of stellate cells treated 
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for 7 days with 1 µM ATRA or vehicle control were subjected to tandem mass 
spectrometry (MS/MS). 
 
PS1 cells were seeded in 10 cm2 dishes (1.0x105 cells per dish) and treated with 
1 µM ATRA or vehicle control for 7 days. After 7 days, cells were incubated in 
serum free medium, supplemented with ATRA or vehicle control, for 8 hours 
and supernatant was collected. In order to allow cells to recover from the serum 
starvation, cells were incubated for 12 more hours in complete medium (with 
ATRA or ethanol) before being lysed with RIPA lysis buffer (Upstate) with 
freshly added 1 mM NaF, 50 mM Na3VO4 and a 1:200 dilution of EDTA free 
protease inhibitor cocktail (Calbiochem, #539134), as described in paragraph 2.7.  
 
EDTA free protease inhibitors were added to the supernatants (1:200 dilution) 
and samples were concentrated using Amicon Ultra centrifugal filter units with a 
≥ 3kDa molecular weight cutoff (MWCO) membrane (Millipore, #UFC900324). 
To remove any traces of glycerine, membranes were pre-rinsed with distilled 
water before supernatant samples were added to the filter units and were 
centrifuged for 30 minutes at 4000 g-force at 40C. The concentrated supernatant 
samples were recovered from the bottom of the filter (3-5 ml per sample) and 
desalted with ZebaTM desalt spin columns (Pierce Protein Research Products, 
Thermo Fisher Scientific, #89894), according to manufacturer’s instructions.  
 
Protein assays of full cell lysates and supernatant samples and all subsequent 
experiments, including Tandem Mass Tags (TMT) labelling (TMTsixplex 
Isobaric Mass Tagging Kit, Pierce Protein Research Products, Thermo Fisher 
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Scientific, #90064) and tandem mass spectrometry were carried out by Dr Mark 
Weeks.  
 
2.11. Statistical analysis 
2.11.1. Organotypic cultures 
For all experiments with organotypic cultures at least 3 gels from 3 separate 
experiments were analysed at 4-6 random areas by two independent observers. 
For total cell count, proliferation, apoptosis and invasion of cancer cells, cells 
were counted in six random fields per gel at x200 magnification. For ezrin 
stained sections, cellular processes and cells within the matrix (defined as below 
the line of the epithelial cell mass) were counted per field at x630 magnification. 
For β-catenin, the percentage of cells with intense membranous or cytoplasmic 
stain (subjectively assessed on a +, ++ or +++ range) and the number of cells 
with a nuclear stain was recorded per field at x630 magnification. E-cadherin 
expression was quantified with the morphometric analysis software from NIS-
Elements (Nikon, NIS-Elements AR 3.0, SP3, Hotfix 4 (Build 472)). In each 
image, taken at x630 magnification, the area of green E-cadherin stain within the 
region of interest was determined. Initial thresholds were set for pixel intensity 
and area to ensure only the truly positive staining was measured; these settings 
were kept constant to enable comparison.  
 
Data were analysed and groups were compared using the Mann-Whitney U-test 
(SPSS for Windows, version 14.0.0, or in Prism 5). All comparisons were two-
tailed and significance was defined as p<0.05.  
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2.11.2. Patient samples 
Patient samples were scored for the percentage of positive cells (0-10%, 10-40%, 
40-70% or > 70%) and the intensity (+, ++, +++) and localisation (membranous, 
nuclear of cytoplasm) of positive staining. Correlation of E-cadherin and β-
catenin expression with survival was analysed using the log-rank test (Mantel–
Cox); significance was defined as p<0.05. 
 
2.11.3. Western blot, PCR and functional assays 
For normally distributed data, groups were compared using a two-tailed 
Student’s t-test; significance was defined as p<0.05.  
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3.CHAPTER III  RESULTS – PART I 
A physiologically relevant three-dimensional organotypic culture model of 
pancreatic cancer 
 
3.1. Introduction 
The isolation and immortalisation of a normal human pancreatic stellate cell line, 
and the expertise in organotypic culture modelling for other cancers in our 
laboratory138, 216, has given me the opportunity to develop an organotypic culture 
model for pancreatic cancer. Organotypic culture models can be set up in a 
number of ways, depending on what question one is aiming to answer. The 
different culture model systems used in this project are summarised in Figure 2.2 
and will be discussed in this chapter.  
 
3.2. Characterisation of isolated pancreatic stellate cells 
The hTERT immortalised normal human pancreatic stellate cells (PS1) expressed 
the characteristic stellate cell markers desmin, glial fibrillary acidic protein 
(GFAP), vimentin and α-smooth muscle actin (αSMA), as determined by 
immunofluorescence, even after nearly five years of continuous tissue culture 
(Figure 3.1A). Vitamin A storing lipid droplets could also be identified in their 
cytoplasm, especially when cells were treated with all-trans retinoic acid, which 
is known to render stellate cells quiescent (Chapter IV)217, 218, (Figure 3.1B). 
These markers together, which were evident in > 95% of PS1 cells, are 
considered the defining criteria of pancreatic stellate cells97, 98. Assays for the 
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immortalised PS1 cells cultured on various diluted substrates revealed no 
differences in proliferation or expression profiles (Figure 3.1Ca and b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Expression of stellate cell markers by immortalised PS1 cells and 
their proliferation on different substrates. 
(A) Isolated and immortalised PS1 cells express the stellate cell markers desmin, glial 
fibrillary acidic protein (GFAP), α-smooth muscle actin (αSMA) and vimentin (a-d). 
Insert in (a) shows a negative immunofluorescent staining for the isotype-specific 
immunoglobulins (IgG), which were used, at matching concentration, as negative 
control. Scale bar, 20 µm. (B) Oil Red O visualised fat storing vesicles (arrowheads) in 
the cytoplasm of immortalised PS1 cells (a), which store vitamin A as detected by 
autofluorescent particles (b, arrows). Scale bar, 5 µm. ((C)a) Proliferation of PS1 cells is 
unaffected by culture on various substrates, including diluted collagen type I (C), 
fibronectin (FN), Matrigel (M) or PBS alone (P). Mean ± SEM. ((C)b) Western blot of 
the stellate cell marker, αSMA, after culture on various substrates, alongside cell lysates 
from pancreatic cancer cells (HPAF, PaCa3) and human pancreatic fibroblasts (HPF). 
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3.3. Cancer cells cultured within the matrix 
In order to investigate the behaviour of cancer cells that already have invaded 
into the stroma, cancer cells and their spheroids were embedded within the ECM 
(Figure 2.2A, F). To understand the influence of pancreatic stellate cells on 
invaded cancer cells, these cell types were co-cultured within an ECM gel 
(Figure 2.2B). This first part of my project was initiated by Dr Tariq Mirza, 
whose preliminary data I could use to further optimise the organotypic culture 
models of pancreatic cancer.  
 
Preliminary experiments investigating the growth of different cancer cells 
(Capan1, PaCa3, HPAF, PaTu8988S) and their spheroids (Capan1, PaCa3) 
embedded in pure collagen type I (collagen) or in a mixture of 50:50 
collagen:Matrigel, demonstrated varying growth patterns according to specific 
cell line in either matrix. For Capan1 cells, PaTu8988S cells, Capan1 spheroids 
or PaCa3 spheroids there was no significant difference when cells were 
embedded in pure collagen or in a mixture of collagen:Matrigel (Figure 3.2A, Bb 
and 3.3B). Remarkably, Capan1 spheroids lost their spherical shape in both types 
of matrices but PaCa3 spheroids maintained their shape till the end of day 7 
(Figure 3.2Ab, Bb). However, PaCa3 cells differentiated into multicellular 
spheroids when cultured in collagen but not when cultured in collagen:Matrigel 
gels (Figure 3.2Ba), suggesting an important role for the stiffness of the matrix 
which can be overcome when pre-established spheroids are used. HPAF and 
PaTu8988S cells differentiated into multicellular spheroids after 14 days of 
culture in either matrix, although HPAF cells appeared less cohesive when 
grown in collagen:Matrigel compared to collagen gels (Figure 3.3A, B).  
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Moreover, when stellate cells were co-cultured with cancer cells in ECM gels 
composed of 75% collagen and 25% Matrigel, cancer cells developed into 
multicellular spheroids after 7 days, and more obvious after 14 days, of co-
culture (Figure 3.4).  
 
In summary, similar to the observations made for the breast cancer model131, 133, 
cells cultured within an ECM gel differentiated into multicellular spheroids or 
colonies. The morphology (e.g. well-organised spheroids or more disorganised 
multicellular colonies) differs according to cell line, composition of the matrix or 
presence of additional stromal cells, but overall cells grown within these 3D 
culture systems recapitulate important features of glandular epithelial cells in 
vivo. Based on these experiments, combined with preliminary experiments at an 
earlier stage of this project by Dr Tariq Mirza (data not shown), it was concluded 
that most representative and consistent results were obtained with extracellular 
matrix gels composed of 75% collagen and 25% Matrigel. Hence, all subsequent 
experiments were done with this matrix composition.  
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Figure 3.2 Capan1 and PaCa3 cells or spheroids embedded in extracellular 
matrix gels.  
Phase-contrast images, taken with a time-lapse microscope at x200 magnification and 
processed with Simple PCI image editing software, demonstrate that Capan1 cells have 
similar growth patterns in collagen type 1 (collagen) or in a mixture of 50% collagen 
and 50% Matrigel (C:M) (A)a, whereas PaCa3 cells differentiate into spheroids when 
cultured in collagen, but not when cultured in collagen:Matrigel ((B)a). (A)b Capan1 
spheroids lose their shape when embedded in either matrix, while PaCa3 spheroids 
maintain their multicellular structure ((B)b). Scale bar, 50 µm. 
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Figure 3.3 HPAF and PaTu8988S cells embedded in extracellular matrix 
gels.  
Phase contrast and bright field images of haematoxylin and eosin (H&E) stained 
sections show that HPAF cells develop into multicellular spheroids when cultured in 
collagen gels but demonstrate a more disorganised and disrupted morphology when 
cultured in collagen:Matrigel (C:M) gels (A). PaTu8988S cells differentiate into 
spheroids when cultured in either matrix, collagen or a mixture of collagen and Matrigel 
(B). Scale bar, 100 µm. 
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Figure 3.4 Cancer cells and stellate cells co-cultured in extracellular matrix 
gels. 
Bright field images of H&E stained sections demonstrate that, in the presence of stellate 
cells, cancer cells differentiate into multicellular spheroids, which is most pronounced 
for Capan1 and HPAF cells after 14 days of co-culture. PaCa3 cells form more 
multicellular colonies rather than organised spheroids. Scale bar, 50 µm. 
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3.4. Role of pancreatic stellate cells in modulating tumour cell 
behaviour in a submerged organotypic model 
In vivo ductal epithelial cells are characterised by an apical membrane facing a 
lumen, and basal surfaces contacting the basement membrane and extracellular 
matrix. The submerged organotypic culture model, where cancer cells were 
grown on top of ECM gels in which pancreatic stellate cells were embedded, was 
designed to mimic this situation (Figure 2.2C, G). The first submerged 
organotypic culture models were done by Dr Tariq Mirza, whose work I 
continued to develop this model further. This submerged model has been 
optimised to study, in particular, the early events in tumour progression 
 
3.4.1. Morphological and proliferative responses of tumour cells  
Preliminary experiments with gels harvested at different time points (day 4, 7, 10 
and 14) suggested that the most reproducible experiments occurred after 7 days 
of culture on 75:25 collagen:Matrigel gels (experiments terminated at day 4 and 
10 were done at early stages of this project by Dr Tariq Mirza; gels harvested 
after 14 days of tissue culture did not have many cells on top, as these may have 
peeled off during harvesting). When cultured on top of extracellular matrix gels, 
the well-differentiated Capan1 cells developed into structures with well-defined 
“lumens” (Figure 3.5A), while the poorly-differentiated PaCa3 cells formed 
multicellular epithelial layers, clusters and occasional lumens (Figure 3.5B). 
Staining for the proliferative marker Ki67 revealed that the proliferating cells 
were confined to the peripheral rims of these clusters whereas a positive cleaved 
caspase-3 staining, indicative of apoptosis, was more pronounced within the 
central luminal region (Figure 3.5A, Bd,e).  
 109 
Since multicellular spheroids are thought to provide a good three-dimensional 
(3D) model representing polarised, epithelial morphology133, I additionally 
cultured pre-established Capan1 and PaCa3 spheroids on top of organotypic gels. 
However, similar to when embedded into the gel, Capan1 spheroids rapidly lost 
their spherical structure upon plating onto organotypic gels and the cells grew as 
an epithelial palisade monolayer; PaCa3 spheroids maintained their shape 
(Figure 3.6A). All these reproducible morphological changes occurred 
irrespective of whether the gels contained MRC5 fibroblasts or PS1 stellate cells.  
 
For both Capan1 and PaCa3 cell lines, the total number of cancer cells reduced 
significantly when single cell suspensions were plated and cultured for 7 days 
onto gels containing MRC5 fibroblasts (Capan1 p<0.05; PaCa3 p<0.001, Mann-
Whitney U test) or onto gels containing PS1 cells (Capan1 p<0.005; PaCa3 
p<0.001, Mann-Whitney U test) (Table 3.1A and Figure 3.5C). These differences 
in cell numbers could not be explained solely by differences in proliferation or 
apoptosis (Table 3.1A).  
 
Pre-established Capan1 spheroids seemed to be unaffected by the presence of 
stromal cells (Table 3.1B, Figure 3.6B-D). In contrast, some changes in total cell 
numbers, proliferation and apoptosis were observed when PaCa3 spheroids were 
cultured on top of gels with or without stromal cells. When PaCa3 spheroids 
were cultured with MRC5 fibroblasts, there were fewer cells on top of the gels 
(p<0.001, Mann-Whitney U test); there was no difference in proliferation and the 
percentage of cells undergoing apoptosis was significantly higher in the 
spheroid-initiated cultures with MRC5 fibroblasts (p<0.001, Mann-Whitney U 
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test) (Table 3.1B). With PS1 cells embedded in the matrix the total number of 
cells did not change significantly, nor did the rate of apoptosis. However, PaCa3 
spheroids with PS1 cells showed less proliferation as compared to controls 
(p<0.001, Mann-Whitney U test) (Table 3.1B). 
 
In all organotypic cultures the incidence of apoptosis (range 0-20.2%) was very 
low as compared to proliferation (range 5.7-84.9%).  
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Figure 3.5 Morphological and proliferative responses of cancer cells grown in a submerged organotypic culture model. 
(A) and (B) H&E stain demonstrates differences observed in morphology after culturing Capan1 (A) and PaCa3 (B) cells for 7 days on gels with no stromal 
cells (a), MRC5 fibroblasts (b) or PS1 stellate cells (c). Images d and e demonstrate the different zones of proliferating (Ki67 immunostain, arrows, d) and 
apoptotic (cleaved caspase-3 immunostain, arrowheads, e) cells, which leads to lumen formation. Scale bar, 20 µm. (C). Total counts per high power field for 
Capan1 cell gels (a) and PaCa3 cell gels (b) at day 7 (median, inter-quartile range). Mann-Whitney U test; *, p<0.05. 
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Table 3.1 Cell counts in submerged organotypic culture model 
A Cells 
 Capan1 PaCa3 
 MRC5 Neg Pos Mann-Whitney U Test Neg Pos Mann-Whitney U Test 
 Total 158.00  (136.50-203.25) 
144.00  
(119.25-156.00) 0.046 93.50 (83.75-116.00) 67.00 (62.50-71.00) <0.001 
 % Ki67 + 29.59 (26.24-34.04) 27.66 (22.60-33.15) 0.591 10.60 (8.82-11.56) 50.34 (41.21-59.55) <0.001 
 % Caspase-3 + 10.68 (7.80-12.44) 10.19 (9.53-12.54) 0.591 4.43 (3.23-6.91) 2.82 (1.49-4.03) 0.008 
        
 PS1 Neg Pos Mann-Whitney U Test Neg Pos Mann-Whitney U Test 
 Total 83.50 (72.00-101.75) 67.00 (62.50-76.50) 0.004 74.00 (60.50-90.00) 52.50 (46.75-62.00) <0.001 
 % Ki67 + 10.84 (9.27-13.48) 12.35 (10.41-15.57) 0.113 17.16 (12.82-21.10) 17.03 (12.85-30.00) 0.476 
 % Caspase-3 + 2.80 (1.50-4.24) 2.74 (1.53-3.39) 0.458 1.72 (1.19-3.31) 1.87 (0.00-3.13) 0.723 
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B Spheroids 
 Capan1 PaCa3 
 MRC5 Neg Pos Mann-Whitney U Test Neg Pos Mann-Whitney U Test 
 Total 31.00 (25.00-35.75) 29.50 (22.50-34.00) 0.669 92.00 (72.75-101.75) 40.50 (24.75-46.00) <0.001 
 % Ki67 + 60.65 (57.60-68.34) 55.72 (49.73-60.42) 0.031 52.71 (46.44-57.14) 56.26 (44.89-63.94) 0.658 
 % Caspase-3 + 5.05 (0.81-8.17) 5.07 (3.85-7.55) 0.874 2.76 (1.56-3.11) 7.19 (5.07-9.42) <0.001 
        
 PS1       
 Total 66.00 (41.00-91.00) 57.00 (52.25-80.25) 0.843 101.50 (81.25-108.50) 95.00 (78.00-119.00) 0.777 
 % Ki67 + 19.67 (17.07-25.64) 21.56 (17.30-27.51) 0.504 30.77 (25.89-34.95) 13.64 (10.34-26.79) 0.001 
 % Caspase-3 + 1.04 (0.00-2.44) 1.10 (0.00-1.25) 0.227 1.83 (0.00-2.83) 1.09 (0.00-1.77) 0.394 
 
Table 3.1 Cell counts in submerged organotypic culture model.  
Total cell count, % Ki67 positive (+) and % active caspase-3 positive (+) cells per field as median with (inter-quartile range), in organotypic cultures with 
Capan1 or PaCa3 cells (A) or their spheroids (B) on top of gels with (pos) or without (neg) MRC5 fibroblasts or PS1 stellate cells. N = 35 to 44 fields across 6 
gels with or without PS1 cells and n = 18 fields across 3 gels with or without MRC5 fibroblasts.  
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Figure 3.6 Capan1 and PaCa3 spheroids on top of organotypic gels.  
(A) Demonstrates the morphology of Capan1 (a) and PaCa3 (b) spheroids after 7 days of 
culture on the surface of organotypic gels. Scale bar, 20 µm. 
Total counts (B), % Ki67 positive cells (C) and % Caspase-3 positive cells (D) per high 
power field for Capan1 spheroid gels (a) and PaCa3 spheroid gels (b) at day 7 (median, 
inter-quartile range).  
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Because of the somewhat surprising differences in cell numbers, I hypothesised 
that the changes observed could result from alterations in cell-cell and cell-
matrix adhesions and I sought to evaluate this further. 
 
3.4.2. Expression of adhesion molecules on tumour cells on organotypic 
gels 
Breast cancer cells have been shown to regain their characteristic apico-basal 
polarity when grown in three-dimensional culture models133, 150 and the 
differentiation from single cell suspensions into multicellular luminal structures, 
upon plating on top of organotypic gels, suggested this also was true in our 
model. Accordingly, I immunostained organotypic cultures for E-cadherin 
(epithelial cadherin, mediating adherens junctions) and phosphorylated ezrin, 
radixin, moesin (p-ERM) proteins (reorganisation of the cytoskeleton and 
internal membranes which is necessary for polarisation)121, 131, 219. In both 
Capan1 and PaCa3 cultures the cell-cell junctions were positive for E-cadherin 
whereas no expression was evident in the absence of cell-cell contact, such as at 
the cell-matrix interface (Figure 3.7A). These findings mimicked the breast-
cancer model133, 150. A 3D-reconstructed, cross-sectional image of a layer of 
Capan1 cells, which had established the typical lumen-containing structure, 
clearly demonstrates that cells in the peripheral rim of the lumen expressed E-
cadherin at the plasma membrane, whereas there was no positive staining when 
the cells were in contact with the medium or with the matrix (arrowheads, insert, 
Figure 3.7A).  When these luminal structures were stained for p-ERM proteins, 
the most positive cells (of the peripheral rim) generally were located at the 
junction with the lumen, or at the interface with the medium (Figure 3.7B).  
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There also was prominent p-ERM staining where the cells were lining newly 
developing small lumens (sL) and where cells were in contact with the 
underlying matrix (arrowhead, insert). PaCa3, which formed less obvious 
luminal structures, also expressed E-cadherin at cell-cell junctions, which was 
lost at the cell-matrix interface (Figure 3.7A) where p-ERM was expressed 
(Figure 3.7B).  
 
3.4.3. Modification of E-cadherin and β-catenin expression in tumour cells 
due to presence of stromal cells 
In the presence of either of the two stromal cell types, E-cadherin expression 
became focally patchy amongst the mass of cancer cells (Figure 3.8A, B), with a 
reduction in the total area of the E-cadherin stain in both cancer cell lines (Figure 
3.8C). Western blot analyses of the lysates of supernatant cells (before lysis 
viability of these cells was confirmed by a negative Trypan Blue stain), 
confirmed that E-cadherin expression was down-regulated in the presence of PS1 
stellate cells (Figure 3.8D). This effect occurred across the full thickness of the 
transformed cancer cell, as can best be appreciated in the animation of the z-
stack of these cells shown in Supplementary Movie 1 (attached on CD). 
 
Since a decrease in E-cadherin has been associated with the transition of an 
epithelial cell to a mesenchymal cell (the epithelial-mesenchymal transition 
(EMT)) and subsequent individual or mesenchymal cell migration, I also 
investigated the possibility of changes in other markers for EMT such as 
cytokeratin and vimentin220. The transformed epithelial cells expressed 
consistently less cytokeratin in the presence of either stromal cell type (Figure 
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3.9A, B). However, vimentin was not expressed in the cancer cells, even in the 
presence of stromal cells, which uniformly expressed this marker (Figure 3.9C, 
D). 
 
In contrast to the observed decrease in E-cadherin expression, β-catenin, which 
binds to the cytoplasmic domain of E-cadherin, showed a more pronounced 
expression in cancer cells in the presence of stromal cells, relative to when 
stromal cells were absent (Figure 3.10A, B). This increased expression was 
observed both at the cell membrane and in the cytoplasm; nuclear β-catenin 
expression was rarely seen. Moreover, β-catenin positivity also occurred in the 
cellular processes seen within the extracellular matrix gel, which were previously 
shown to be driven by a change in the subcellular distribution of ezrin, a 
membrane-cytoskeleton linker protein221.  
 
3.4.4. Ezrin expression in cancer cells in response to stromal cells 
In keeping with previous observations221, following 7 days of culturing cancer 
cells on top of gels containing MRC5 fibroblasts or PS1 stellate cells, ezrin 
staining was observed in the basal aspect of cells, compared to a more apical 
expression when there were no stromal cells embedded into the gels. 
Interestingly, in the presence of stromal cells, there was an increase in ezrin-
positive cellular processes invading into the matrix as well as an increase in the 
number of invading cells, as compared to gels without stromal cells (in which 
there were no cellular processes or invading cells into the matrix, Figure 3.11). 
The depth of this invasion is best represented in Supplementary Movie 2 
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(attached on CD), which shows the animation of z-stacks across one-cell 
thickness. 
 
 
 
Figure 3.7 E-cadherin and p-ERM expression. 
(A) and (B) show 3D reconstruction and rendering of a z-stack of immunofluorescent 
images of Capan1 (a) and PaCa3 (b) cells for E-cadherin (A) and phosphorylated ezrin 
radixin moesin (p-ERM) (B). E-cadherin is seen primarily at points of cell-cell contact 
while loss of E-cadherin expression is seen where cells either are in contact with the 
extracellular matrix (Mx, arrow heads) or with the medium. Inserts show E-cadherin and 
p-ERM expression in an invagination of cells into the extracellular matrix. Note that E-
cadherin expression is lost while p-ERM is expressed at the cell-matrix junction both in 
Capan1 and PaCa3 cells (arrow heads). P-ERM also is expressed at the margins of 
newly forming micro-lumens (sL=micro-lumens, L=large lumen). Scale bar, 100 µm. 
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Figure 3.8 E-cadherin expression in organotypic cultures. 
(A) Capan1 and (B) PaCa3 organotypic gels with no stromal cells (a), MRC5 (b) and 
PS1 (c) cells, respectively, with immunofluorescent E-cadherin stain rendered grey. 
Scale bar, 20 µm. (C) Quantification of E-cadherin staining demonstrating the 
percentage of E-cadherin stain, determined by the area of positive E-cadherin stain 
divided by the region of interest, as median and inter-quartile ranges for Capan1 (a) and 
PaCa3 (b) cells. Mann-Whitney U test; *, p<0.05. (D). Western blot analysis of 
Capan1(a) and PaCa3 (b) cells isolated from the supernatant of organotypic gels shows 
loss of E-cadherin expression in the presence of PS1 stellate cells. Quantification of 
replicates is shown in respective graphs. Mean ± SEM, Student’s t-test; *, p<0.05. 
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Figure 3.9 Cytokeratin and vimentin expression in organotypic cultures. 
(A) Capan1 and (B) PaCa3 organotypic gels with no stromal cells (a, b), MRC5 (c, d) 
and PS1 (e, f) cells, respectively, with DAPI stain for nuclei (a, c, e) and 
immunofluorescent cytokeratin (CK) stain (b, d, f), both rendered grey. There is a 
reduction in cytokeratin expression in the presence of stromal cells as compared to when 
no stromal cells are present. Scale bar, 15 µm.  
(C) Capan1 and (D) PaCa3 organotypic gels with no stromal cells (a, b), MRC5 (c, d) 
and PS1 (e, f) cells, respectively, with DAPI stain for nuclei (a, c, e) and 
immunofluorescent vimentin stain (b, d, f), both rendered grey. The stromal cells 
embedded in the matrix express vimentin, whereas the cancer cells do not show a 
positive staining for vimentin. Scale bar, 15 µm. 
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Figure 3.10 β-Catenin expression in organotypic cultures.  
(A) Capan1 and (B) PaCa3 organotypic gels with no stromal cells (a), MRC5 (b) and 
PS1 (c) cells, respectively, showing β-catenin expression by immunofluorescent stain 
rendered as a grey image. Quantification of number of cells with β-catenin expression 
(median and inter-quartile ranges) in the membrane and cytoplasm is shown in (d) and 
(e), respectively. Mann-Whitney U test; *, p<0.005. Scale bar, 20µm. 
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Figure 3.11 Ezrin expression in organotypic cultures.  
(A) Capan1 and (B) PaCa3 organotypic gels with no stromal cells (a), MRC5 (b) and 
PS1 (c) cells, respectively, with immunofluorescent ezrin stain, rendered as a grey 
image. Arrowheads point to invading cells and processes. Quantification of number of 
ezrin positive cellular processes (d) (median and inter-quartile ranges) as well as whole 
cells (e) shows a significant increase of these in response to the presence of stromal 
cells, which did not express ezrin. Mann-Whitney U test; *, p<0.005. Scale bar, 20µm. 
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3.4.5. E-cadherin and β-catenin expression in pancreatic cancer tissues 
E-cadherin and β-catenin staining in organotypic cultures seemed to mimic the 
situation observed in clinical specimens. Table 3.2 summarises the clinical 
details of 51 patients with pancreatic ductal adenocarcinoma (PDAC); the 
median age was 66.5 (range 45-81 years), male:female ratio was 31:20, median 
follow-up was 26 months and median survival was 18.6 months after surgery and 
adjuvant therapy.  
 
In small normal pancreatic ducts there was minimal β-catenin expression. In 
contrast, cancer cells demonstrated a strong increase in cytoplasmic β-catenin 
staining in 18 of the 51 patients studied (35.2%), with a minority of specimens 
exhibiting nuclear localisation (Table 3.3 and Figure 3.12A). Conversely, most 
normal pancreatic ducts demonstrated strong membranous E-cadherin 
expression, which was reduced in cancer tissue. Additionally, carcinoma cells 
exhibited a more cytoplasmic E-cadherin expression (Table 3.3 and Figure 
3.12B). The changes in both β-catenin and E-cadherin expression, were shown in 
all stages of pancreatic cancer progression: invasion into surrounding stroma, 
perineural invasion and lymph node metastasis (Figure 3.12), and were not 
related to any significant difference in survival (Table 3.3). 
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   Log-rank (Mantel-Cox)* 
T stage T1 8 0.259 
 T2 15  
 T3 28  
    
N stage N0 21 0.676 
 N1 30  
    
Differentiation Well 6 0.062 
 Moderate 26  
 Poor 19  
    
Nil 4 0.936 Venous and/or neural 
invasion Venous 15  
 Neural 13  
 Both 19  
    
Resection margin Negative 18 0.045 
 Positive 33  
    
Chemoradiotherapy None 11 0.807 
 Chemotherapy 22  
 Radiotherapy 8  
 Both 10  
 
Table 3.2 Clinical details related to patient samples stained for E-cadherin 
and β-catenin.  
*, Comparison of Kaplan-Meier survival curves across sub-groups for each variable 
known to affect survival of patients with pancreatic ductal adenocarcinoma. T, tumour 
stage and N, nodal involvement, both according to the AJCC staging for pancreatic 
cancer (Table 1.2).  
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Figure 3.12 β-Catenin and E-cadherin expression in patient samples. 
(A) Shows β-catenin expression in normal (a) and pancreatic cancer ducts (b, c, d). ((A)a) demonstrates no expression in small ducts of normal pancreas 
(arrowheads), with robust cell-cell junction expression in acinar cells (arrows). ((A)b, c, d) show heterogeneous expression of β-catenin at the cell-cell 
junctions, cytoplasm (arrowheads) and nucleus (arrows) when cells are invading the surrounding stroma (b), the perineural region (c, N=nerve) and lymph 
nodes (d, LN=lymph node). (B) Shows E-cadherin expression in normal (a) and pancreatic cancer ducts (b, c, d). ((B)a) demonstrates strong membranous 
expression in ducts of normal pancreas (arrowheads) and in acinar cells (arrow). ((B)b, c, d) show heterogeneous expression of E-cadherin with pancreatic 
cancer cells not expressing E-cadherin (arrowheads) or a more cytoplasmic expression (arrows) when invading the surrounding stroma (b), the perineural 
region (c, N=nerve) and lymph nodes (d, LN=lymph node). Scale bar, 20 µm.  
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   Normal (%) PDAC (%) 
Log-rank 
(Mantel-Cox) 
PDAC* 
β-catenin Total score Weak (0-4) 15 (83.3) 28 (44.9) 0.425 
  Strong (5-6) 3 (16.7) 23 (45.1)  
      
 Membranous Absent 13 (72.2) 34 (66.6) 0.597 
  Present 5 (27.8) 17 (33.3)  
      
 Cytoplasmic Absent 18 (100) 33 (74.8) 0.514 
  Present 0 (100) 18 (35.2)  
      
E-cadherin Total score Weak (0-4) 8 (44.4) 34 (66.6) 0.344 
  Strong (5-6) 10 (55.6) 17 (33.3)  
      
 Membranous Absent 5 (27.8) 28 (54.9) 0.630 
  Present 13 (72.2) 23 (45.1)  
      
 Cytoplasmic Absent 15 (83.3) 30 (58.8) 0.919 
  Present 3 (16.7) 21 (41.2)  
 
Table 3.3 β-Catenin and E-cadherin immunostaining of pancreatic ductal 
specimens. 
Normal, normal pancreatic tissue, score for small pancreatic ducts; PDAC, pancreatic 
ductal adenocarcinoma. *, Comparison of Kaplan-Meier survival curves for different 
staining patterns in patients with pancreatic ductal adenocarcinoma. 
 
 127 
3.5. Invasion of cancer cells when cultured in raised air-liquid 
organotypic model 
In order to, more specifically, study the invasion of pancreatic cancer cells in a 
3D organotypic model, the submerged model can be lifted onto a metal grid that 
is covered by a coated nylon sheet. This raised “air-liquid” model, which has 
been shown to be a reproducible model to study invasion in squamous cell 
carcinoma (SCC), is fed from below, creating a gradient that stimulates cancer 
cells to invade (Figure 2.2D, E)137, 138. Once harvested, sections can be 
immunostained with a pan-cytokeratin antibody to distinguish between cancer 
cells and pancreatic stellate cells or fibroblasts and tumour cell invasion can be 
quantified. 
 
3.5.1. Stromal cells embedded in matrix 
Surprisingly, when 5x105 Capan1, HPAF or PaCa3 cells were plated onto a gel 
containing 5x105 PS1 stellate cells, there was minimal to no invasion of cancer 
cells, even after 14 days of culture (Figure 3.13). It has been proposed that close 
proximity between cancer cells and fibroblasts (juxtacrine signalling) is essential 
for invasion137, 222. Additionally, pancreatic stellate cells (PSCs) and tumour 
cells injected in different ratios in an orthotopic nude mouse model, resulted in 
increased tumour formation and distant metastasis when there was an equal or 
greater amount of PSCs to tumour cells102. Thus, to investigate whether an 
increase in the relative number of PSCs would increase the invasion of cancer 
cells when cancer cells and PSCs were in direct contact, different ratios of PS1 
 128 
stellate cells and cancer cells were directly mixed on top of the extracellular 
matrix gels (Figure 2.2E, Table 2.6). 
 
3.5.2. Stromal cells and cancer cells in different ratios on top of gels  
When cancer cells and stellate cells were co-cultured on top of ECM gels, in 
different ratios but with the total cell number kept constant at 5x105 cells, 
invasion increased significantly from a 2:1 cancer cell:stellate cell ratio onwards 
(Figure 3.14, 3.15). More cancer cells invaded into the ECM gel when they were 
co-cultured with relatively more stellate cells, in which stellate cells appeared to 
precede invading cancer cells (Figure 3.15, 3.16). Interestingly, a dual staining 
for cytokeratin (green, for cancer cells) and αSMA (red, for stellate cells) 
demonstrated different modes of cancer cell invasion (single-cell invasion or 
collective invasion in strands or clusters of cells) within one organotypic gel, 
with most commonly clusters of cancer cells invading collectively into the ECM 
gel. Pancreatic stellate cells seemed to remodel the matrix and generate tracks 
wide enough for the cancer cells to follow (Figure 3.16, insets)137. Additionally, 
some cancer cells also demonstrated leading edge protrusions (Figure 3.16, 
arrows), possibly with a proteolytic tip-cell function remodelling the matrix and 
generating microtracks themselves162. When cancer cells or PS1 stellate cells 
were cultured alone on top of organotypic gels there was no invasion. In addition 
to the observed increase in invasion with an increased proportion of stellate cells, 
cancer cells on top of the gel also seemed to have a looser, more disrupted 
organisation when there were more stellate cells (Figure 3.14, 3.16).  
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Figure 3.13 Air-liquid organotypic culture model with stellate cells 
embedded in ECM gel. 
H&E staining of organotypic gels demonstrates that there is minimal to no invasion of 
either Capan1 (well differentiated) or HPAF (moderately differentiated) or PaCa3 cells 
(poorly differentiated) when PS1 cells are embedded into the matrix. Scale bar, 100 µm. 
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Figure 3.14 Capan1 and PS1 cells in different ratios on top of organotypic gels raised to grids.  
H&E staining of organotypic cultures demonstrates enhanced invasion with an increased number of stellate cells, starting from a cancer cell:stellate cell ratio 
of 2:1 onwards (quantification is shown in Figure 3.15), which is accompanied by a looser, more disrupted organisation of cancer cells on top of the 
organotypic gels. Scale bar, 100 µm. 
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Figure 3.15 Quantification of cancer cells invading into the ECM gel. 
Number of invading cells and cohorts of cancer cells (>2 cells) cultured in different 
ratios with PS1 cells on top of organotypic gels (Figure 3.14); cancer cells were 
identified by their characteristic morphology (rounded cells with hyperchromatic nuclei 
versus elongated stellate cells). Mean ± SD, n = 6 fields per ratio. 
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Figure 3.16 Cytokeratin and αSMA staining in organotypic cultures.  
Immunofluorescent staining for cytokeratin (green, Capan1 cancer cells) and αSMA (red, PS1 stellate cells) demonstrates that stellate cells invade first into 
the extracellular matrix (ECM) gels, followed by cancer cells. Insets in Capan1:PS1 ratios 1:2 (i) and 1:5 (ii) are enlarged on the right to show that PS1 cells 
are the leading cells, forming tracks in the ECM for the cancer cells. A minority of cells, which seemed not to be preceded by stellate cells, demonstrate 
leading edge protrusions (arrows), possibly enabling these cells to invade into the gels. Scale bar, 100 µm 
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3.6. Discussion 
3.6.1. Pancreatic stellate cell line isolated from normal human pancreas, 
PS1 
PSC have been identified as the key cells responsible for the stromal reaction in 
pancreatic cancer and chronic pancreatitis and a small proportion of these cells 
may have extra-pancreatic origin103, 117, 223. Recently, two other groups have 
developed immortalised human PSC lines102, 215. However these lines (both were 
tumour-derived) did not express key stellate cell proteins including desmin and 
GFAP. Moreover large T-cell antigen (SV40), which can induce phenotypic and 
genetic changes224, was used for immortalisation. The possibility must exist 
therefore that these lines are not truly representative of characteristic normal (not 
tumour-associated) stellate cells. The PSC line isolated in our laboratory, termed 
PS1, was sourced from normal human pancreas, immortalised with hTERT and 
exhibited all PSC characteristics such as lipid droplets and expression of key 
cytoskeletal proteins (Figure 3.1)97, 98.  
 
Additionally I have used non-tumourigenic MRC5 fibroblasts, derived from 
human foetal lung, which previously were validated as representative stromal 
cells in the absence of a pancreatic stromal cell line93, 112. The use of a relatively 
“normal” stellate cell line, as well as non-tumourigenic fibroblasts, might be 
advantageous to dissect out the early events in cancer-stroma cross-talk. Since it 
would be interesting to explore whether tumour-derived, as distinct from normal, 
stromal cells influence the cancer cells differently, I have tried to isolate 
pancreatic stellate cells from human pancreatic cancer tissue (after ethical 
 134 
permission was obtained), using the previously published outgrowth method98. 
Although initially some stellate cells grew out of the small (± 1 mm3) tissue 
blocks, they quickly became quiescent and did not expand. When more 
pancreatic cancer tissue will be available, new attempts to obtain primary, 
tumour-associated, pancreatic stellate cells will be made in our laboratory.  
 
3.6.2. Morphology of pancreatic cancer cells in organotypic culture 
The well-differentiated pancreatic carcinoma cells Capan1 and, to a lesser extent, 
PaCa3 cells developed into structures resembling ducts with a lumen when 
cultured on top of extracellular matrix gels (irrespective of the presence of 
stromal cells). The luminal space was occupied by loosely packed, apoptotic 
cells while the luminal wall consisted of a well-organised multicellular, 
proliferative layer. A positive staining for phosphorylated ERM (ezrin, radixin, 
moesin) proteins, which bind to the actin cytoskeleton and regulate the structure 
and function of specific domains of the cell cortex required for polarisation, 
indicated a distinct apico-basal polarity of epithelial cells forming the lumen.  
 
Ezrin, radixin and moesin are highly homologous proteins that originated from 
gene duplication in vertebrates. With a characteristic conserved lipid and 
membrane binding domain at the amino-terminal (N-terminal), called band four-
point-one ERM (FERM), they are, together with the closely related tumour-
suppressor merlin, members of the band FERM superfamily219. All proteins are 
widely expressed in vertebrates, with ezrin particularly located in microvilli on 
the apical side of polarised epithelial cells, radixin predominantly present in the 
liver and microvilli of bile canaliculi and moesin primarily expressed in 
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endothelial cells and leukocytes225. In the inactive state an intramolecular 
interaction between the FERM N-terminus and the carboxy-terminus (C-
terminus) masks important membrane and filamentous actin (F-actin) binding 
sites. For activation of ERM proteins, the required dissociation of this 
intramolecular binding has been shown to be mediated via the interaction of the 
FERM domain with the membrane lipid phosphatidylinositol 4,5-biphosphate 
(PI(4,5)P2), followed by phosphorylation of a conserved threonine residue at the 
C-terminal by kinases including Rho kinase and protein kinase Cα225, 226. 
Through binding of F-actin, via a large binding domain in the C-terminal, and by 
direct or indirect association of the FERM domain with cytoplasmic tails of 
transmembrane proteins, ERM proteins play an important role in the dynamic 
membrane-cytoskeleton interactions needed for maintenance of cell shape, cell 
adhesion, cell migration and division219, 225.  
 
Besides linking the actin cytoskeleton with the plasma membrane, the FERM 
domain has also been shown to bind signalling molecules, thereby interacting 
with different signalling pathways of which the best understood is the Rho-
signalling pathway. ERM proteins have been reported to function downstream, 
with Rho-activation resulting in redistribution of ERM proteins to the plasma 
membrane, as well as upstream of Rho, through interaction of the FERM domain 
with Rho guanine nucleotide dissociation inhibitor (RhoGDI), a negative 
regulator of Rho activity, thereby providing an autoregulatory feedback loop. 
Upon binding of RhoGDI, GDP-bound, inactive, Rho is released from the 
RhoGDI complex and activated by the exchange of GDP for GTP, resulting in 
reorganisation of actin filaments, partially through the ERM system219, 227, 228.  
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Recent studies suggest that ERM proteins are essential for the formation of a 
cavity during embryogenesis227. Ezrin has been shown to be the only ERM 
protein expressed in the developing intestinal epithelium in mice and a study in 
ezrin knockout mice has demonstrated that ezrin was required for the 
organisation of the underlying terminal web from which microvilli project and 
for the dissemination of polarity from cell to cell during secondary lumen 
expansion229. In the present organotypic cultures, phosphorylated-ERM (p-ERM) 
was found mainly in the cells lining the large luminal space. Interestingly, p-
ERM also was concentrated at the margins of newly forming micro-lumens, 
which, when observed in the three-dimensionally rendered images, suggests that 
p-ERM may be vital in maintaining the micro-lumen, akin to developmental 
processes227, 228.  
 
When studying the cell-biological processes involved in tumour formation in 
vitro, multicellular spheroids are thought to provide a good three-dimensional 
(3D) model representing the characteristic epithelial, polarised, morphology; the 
importance of which has already been recognised for nearly three decades121, 132, 
133, 230. Spheroids can be studied and generated in different ways, including the 
culture of cells on non-adherent surfaces such as agarose or polyHEMA, by 
using bioreactors or spinner flask culture in which fluid turbulence prevents 
attachment and stimulates aggregation, and by culture of cells in or on top of 
extracellular matrix gels. The multicellular aggregates generated in this manner 
have been shown to exhibit many similarities to solid tumours, including the 
discussed polarised morphology, with proliferating and apoptotic cells as well as 
well-oxygenated and hypoxic cells231, gene expression232 and drug response230, 
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233. A recent study in melanoma cells demonstrated a marked difference in gene 
expression in cells cultured as spheroids (generated on polyHEMA) versus cells 
in traditional 2D culture232. Additionally, since spheroids demonstrate a pattern 
of sensitivity to various treatment modalities (chemotherapy, radiotherapy, 
immunotherapy among others) that is similar to human tumours, they may prove 
valuable for (high-throughput) drug screening and development234.  
 
For pancreatic cancer cells it has been shown that some cancer cell lines, 
including Capan1 cells, develop well-defined spheroids with cell polarisation and 
lumen formation when cultured on agarose-coated plates235, in spinner culture236 
or in Matrigel198. Interestingly, Lehnert et al demonstrated that two subclones of 
the pancreatic cancer cell line A818, A818-1 and A818-6, developed into 
multicellular spheroids when cultured in suspension on agarose-coated plates, 
which was stimulated by co-culture of foreskin fibroblasts, possibly mediated by 
autocrine and paracrine epimorphin secretion235.  
 
In order to study the interactions between these physiologically relevant 
spheroids, that may influence cellular proliferation, survival, differentiation and 
secretion, and the extracellular matrix, I also cultured pre-established (on 
polyHEMA) Capan1 and PaCa3 spheroids in ECM gels and on top of 
organotypic gels with MRC5 fibroblasts and stellate cells. Although Capan1 cells 
developed spheroids in vitro in the presence of polyHEMA, flattening of 
spheroids occurred when they were cultured within or on top of extracellular 
matrix, irrespective of the presence or absence of matrix producing cells. This 
suggests that anoikis-induced lumen formation (on polyHEMA) may employ 
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different biological mechanisms from physiologically relevant systems (on 
ECM) where, upon contact with the ECM, the pre-established spheroids’ shape is 
disrupted. Given this, and that single cell suspensions differentiated into 
spherical 3D structures resembling neoplastic pancreatic ductal epithelium, I 
discontinued using pre-established spheroids.  
 
The morphological changes observed in the submerged organotypic culture 
model, i.e. the development of multicellular luminal structures with a 
proliferating rim and an apoptotic core, were maintained when organotypic 
cultures were lifted to an air-liquid interface (Figure 3.13 - 3.16 and in next 
chapter Figure 4.10 – 4.12). This reinforces the importance of cell-matrix 
interactions in the formation of polarised acinar structures231 and demonstrates 
that the raised air-liquid organotypic model is a valid model to study cancer cell 
invasion.  
 
3.6.3. Changes evoked by presence of stromal cells 
3.6.3.1. Proliferative indices, E-cadherin and β-catenin 
For both cancer cell lines, fewer tumour cells were observed when they were 
cultured in organotypic culture with MRC5 fibroblasts or stellate cells. This 
result was somewhat surprising, since activated stellate cells have been reported 
to stimulate tumour growth in vivo and in vitro101, 237. As I was unable to detect 
much impact of stromal cell presence on proliferative indices but showed 
significant changes in levels and distribution of various cell adhesion-related 
molecules, I speculated that a reduction in cell-cell or cell-matrix adhesion had 
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led to cancer cell loss. And indeed, there was a trend towards more cells in the 
supernatant of gels that included stromal cells, with these cells expressing 
significantly less E-cadherin (Figure 3.17 and 3.8). 
 
 
 
Figure 3.17 Cell counts in supernatants from organotypic cultures. 
Counts of Capan1 cells in the supernatant of gels with or without stromal cells at 
respective time-points. The last set of bars, include cells at the bottom of the well, after 
the gels had been harvested. Although there was a trend in an increase in the number of 
detached cells in the presence of stromal cells, this was not statistically significant (one-
way ANOVA, n=18, mean ± SEM). Similar counts were obtained for PaCa3 
organotypic cultures (data not shown).  
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Figure 3.18 Canonical Wnt/β-catenin signalling. 
Cytoplasmic β-catenin (β) exists in a cadherin bound form, where it links the 
cytoplasmic domain of E-cadherin, via α-catenin (α), to the actin cytoskeleton (F-actin, 
filamentous actin). Together with another catenin, p120, this stabilises the cadherin-
catenin complex and thus cadherin-mediated adherens junctions. β-Catenin is also the 
central player in the canonical Wnt/β-catenin pathway. When Wnt receptors (Frizzleds, 
which co-operate with LRP5 or 6) are not engaged (A), cytoplasmic β-catenin not bound 
to the cadherin complex is phosphorylated by the destruction complex, comprised of 
Axin, APC and GSK3β, and subsequently degraded by the proteasome. TCF 
transcription factors bind to their DNA recognition sequence, but transcription is 
inhibited by the recruitment of TLE1. Upon binding of Wnt (B), Dvl binds to the 
Frizzled receptor resulting in the phosphorylation of LRP via the recruitment of Axin 
and the kinases GSK3β and CK1.  As a consequence, β-catenin is not phosphorylated, 
accumulates in the cytoplasm and enters the nucleus, where it activates gene 
transcription via binding to TCF transcription factors and the recruitment of a diverse 
range of co-activators (of which only a few are illustrated). See text paragraph 4.3 for 
more details. LRP, low density lipoprotein receptor-related protein; APC, adenomatous 
polyposis coli; GSK3β, glycogen synthase kinase 3β; CK1, casein kinase 1; Dvl, 
Dishevelled; TCF, T-cell factor; TLE1, transducin-like enhancer of split 1, the vertebrate 
homologue of Groucho; CBP, CREB-binding protein, a protein with intrinsic histone 
acetyltransferase activity; Bcl9, B-cell CLL/lymphoma 9; Pygo, Pygopus; Brg1, also 
known as SMARCA4, SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4; TNIK, TRAF2 and NCK interacting kinase. 
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The decrease of E-cadherin expression at cell-cell junctions was accompanied by 
an increase in cytoplasmic β-catenin expression (Figure 3.10). Although there 
may be several mechanisms involved, one possibility is dysregulation of the 
Wnt/β-catenin pathway. 
 
Since β-catenin is essential in mediating cadherin-based cell adhesions as well as 
in the activation of canonical Wnt-signalling, there has been much interest in 
understanding how cell-cell adhesion and Wnt-signalling are coordinating the 
use of this common protein (Figure 3.18; detailed information on Wnt signalling 
is given in paragraph 4.3.1). Many developmental studies and cell-culture models 
of colon cancer have demonstrated that cadherin levels can affect nuclear β-
catenin signalling, based on the hypothesis that E-cadherin can antagonise Wnt-
signalling by sequestering β-catenin at the cell membrane in the cadherin-catenin 
complex or, vice versa, that a decrease in E-cadherin expression will increase the 
cytoplasmic pool of β-catenin and thereby increase Wnt-signalling238, 239. 
However, studies investigating the loss of E-cadherin in cell-lines with inactive 
Wnt-signalling, such as non-transformed keratinocytes or breast cancer cells, did 
not show evidence of an upregulation of β-catenin signalling238, 240. Moreover, a 
transgenic mouse model of pancreatic β-cell carcinogenesis (Rip1Tag2 mice) 
demonstrated that the loss of E-cadherin could induce the progression from 
adenoma to carcinoma241 but that this was not mediated via Wnt/β-catenin 
signalling; the increased levels of cytoplasmic β-catenin were phosphorylated by 
the adenomatous polyposis coli (APC)/Axin destruction complex and degraded 
by the proteasome242. Hence, E-cadherin is only able to antagonise Wnt-
signalling if there is already a certain degree of active Wnt signalling, as in 
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developmental processes or in colon cancer with mutations in APC or β-catenin 
and a compromised degradation of β-catenin. Additionally, the integrity of the 
cadherin/catenin complex and the signalling activity of β-catenin are tightly 
regulated by phosphorylation, which influences the extent to which β-catenin is 
used for cell-cell adhesion or for transcription243. Serine/threonine 
phosphorylation of E-cadherin or β-catenin increases the binding affinity 
between E-cadherin and β-catenin, whereas tyrosine phosphorylation of β-
catenin leads to dissociation of the cadherin/catenin complex. Several oncogenic 
kinases, such as the receptor tyrosine kinases Met (HGF receptor) and ErbB2 
(EGF receptor) or the cytoplasmic tyrosine kinase Src, have been reported to 
phosphorylate β-catenin, resulting in accumulation of cytoplasmic β-catenin with 
increased nuclear signalling243, 244.   
 
Moreover, at the transcription level, Wnt targeted transcription also regulates E-
cadherin expression. Activation of the Wnt/β-catenin pathway can lead to a 
repression of E-cadherin via binding of the TCF/β-catenin complex to the 
promoter of E-cadherin or via increased expression of the transcription factor 
Snail, a repressor of E-cadherin gene transcription245, 246. A recent study also 
reported an essential role for histone deacetylase 1 (HDAC1) and HDAC2 in 
silencing E-cadherin expression in highly metastatic pancreatic cancer cells, 
mediated by a HDAC1/HDAC2/Snail containing repressor complex which binds 
to the E-cadherin promoter247. Additionally, Brabletz and colleagues have 
suggested that, predominantly in colorectal cancers, epithelial-mesenchymal 
transition (EMT) is dominant at the invasive tumour edge248. This was 
stimulated by unknown microenvironmental factors resulting in an increase in β-
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catenin expression with concomitant decrease in E-cadherin expression. The role 
of the tumour microenvironment in modulating Wnt-signalling is corroborated 
by findings that suggested active Wnt signalling as a characteristic feature of 
cancer stem cells, with Wnt activity, and therefore cancer stemness, being 
regulated by myofibroblast secreted factors, specifically HGF249. 
 
The observations in organotypic cultures could be confirmed in human 
pancreatic cancer tissues, with absent membranous E-cadherin expression in 
55% and increased cytoplasmic β-catenin expression in 35% of pancreatic cancer 
tissues; proportions similar to previous reports43, 250. A reduction in E-cadherin 
has been demonstrated at tumour edges of pancreatic cancer, where it was 
associated with a poor prognosis251, as well as in pancreatic cancers with an 
undifferentiated phenotype252. A recent study analysing E-cadherin expression in 
329 pancreatic cancer tissues, demonstrated that many pancreatic cancers had a 
focal loss of E-cadherin expression (41%), possibly reflecting influences from 
the microenvironment250. Interestingly, I also observed upregulation of β-catenin 
at the cell membrane; this may be a consequence of a generalised upregulation of 
β-catenin rather than just translocation from cytoplasm to membrane. It has been 
shown that culture of pancreatic cancer cell lines on collagen type I resulted in 
disruption of the cadherin/catenin complex with a decrease in total E-cadherin 
and an increase in tyrosine phosphorylation of β-catenin, in this instance 
mediated by activation of focal adhesion kinase (FAK)253.  
 
It is plausible that ‘EMT’-like changes in pancreatic cancer are, at least in part, 
induced by stromal cells and that these need to be targeted to halt tumour 
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progression. Perhaps arguing against this concept of EMT as being a driving 
force in this organotypic model is the fact that I failed to detect positivity for 
vimentin expression in the transformed cells (Figure 3.9). While I have not 
addressed the mechanisms responsible for the changes in E-cadherin and β-
catenin expression directly, a convergence of E-cadherin, β-catenin and Wnt 
signalling via a central role of β-catenin may explain, in part, the observations in 
the organotypic cultures243.  
 
3.6.3.2. Ezrin expression in cancer cells 
Changes were observed in the subcellular localisation of ezrin, one of the closely 
related ERM proteins. Due to their important function in organising membrane-
cytoskeletal complexes and specialised membrane domains, ERM proteins 
regulate cellular activities that are also important in tumour development and 
progression. Of all ERM proteins, ezrin expression in particular has been linked 
with invasive behaviour of various tumours254-256 and has previously been shown 
to be associated with pancreatic tumour progression and disease-free survival221. 
Ezrin has been shown to bind cell membrane receptors previously associated 
with cancer, including the hyaluronate receptor CD44 and the receptor tyrosine 
kinase Met, and to interact with several tumour-associated signalling pathways, 
including the already mentioned Rho-signalling, the PI3K/AKT pathway and 
MAPK219, 255-258. The multiple interactions of ezrin suggest a central role of 
ezrin as an integrator of signals in metastatic progression. In keeping with these 
observations, the translocation of ezrin, from the apical to the basal compartment 
of cancer cells, and an increase in ezrin positive cells and invasive cellular 
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processes protruding into the underlying stroma, was instigated by the presence 
of stromal cells in the organotypic culture model (Figure 3.11).  
 
Interestingly, developmental studies in mouse, fly and C. elegans have revealed a 
reciprocal relationship between ezrin and E-cadherin259-261. In Drosophila 
embryos, which have only moesin of the three ERM proteins, moesin has been 
shown to organise actin filaments and stabilise E-cadherin by interacting with the 
synaptotagmin-like protein bitesize (btsz) whereas expression of mutant ezrin 
disrupted E-cadherin distribution and actin assembly at adherens junctions259. In 
early mouse embryos, phosphorylated ezrin has been shown to be required not 
only for the formation of microvilli at apical and basolateral membranes but also 
for the removal of ezrin and microvilli from the basolateral cortex, which is 
necessary for the assembly of E-cadherin mediated cell-cell interactions during 
compaction of the blastomeres at the 8-cell stage260. In C. elegans, control of 
intestinal tube formation and integrity is mediated by E-cadherin and ERM 
homologues; in this instance controlled by crumbs and Disc large261.  
 
Another member of the band FERM family that has a high degree of sequence 
homology with ERM proteins (but has not been investigated in this study), is the 
tumour suppressor gene neurofibromatosis 2 (NF2), encoding a protein named 
merlin, for moesin-, ezrin-, radixin-like protein262. Although it is clear that 
merlin and ERM have some overlapping functions and bind to identical or 
similar proteins of the plasma membrane, they also have distinct and possibly 
opposite functions (with merlin acting as a tumour suppressor and ezrin 
expression associated with cell motility and invasion)219, 221. Similar to ERM 
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proteins, merlin mediates the assembly of adherens junctions, but it also controls 
cell proliferation by regulating the availability of receptor tyrosine kinases at the 
cell surface. Merlin has been shown to mediate contact-dependent inhibition of 
cell proliferation by blocking the internalisation of ligand-bound EGFR (and 
therefore EGFR signalling), possibly though an interaction with CD44228. 
Moreover, merlin has been demonstrated to inhibit the activation of Ras and Rac, 
thereby blocking Ras-dependent proliferative signals263.  
 
3.6.4. Tumour cell invasion and matrix remodelling in the raised air-liquid 
organotypic culture model 
Direct cell contact as well as the ratio between cancer cells and stellate cells 
significantly modulated cancer cell invasion. When stellate cells were embedded 
in the extracellular matrix gel, cancer cells did not invade into the matrix, but 
there was marked invasion when stellate cells and cancer cell were admixed on 
top of ECM gels. Cancer cells invaded collectively, preceded by pancreatic 
stellate cells, with the extent of invasion dependent on the relative ratio of 
stellate cells to cancer cells. Although I haven’t investigated the matrix 
remodelling by stellate cells and/or cancer cells in more detail, the observation 
that cancer cells seem to invade the extracellular matrix via tracts created by 
preceding stellate cells, is consistent with a recently published model for 
squamous cell carcinoma137. Using reflectance imaging of the collagen matrix, 
Sahai and colleagues showed that in order to invade collectively, cancer cells 
require close proximity to fibroblasts, which create tracks via Rho-A and ROCK 
dependent actin-myosin activity with MMP mediated proteolysis. The 
observation that cancer cells did not invade when stellate cells were embedded in 
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the gel and there was no direct cell-cell contact, could suggest that similar 
mechanisms are also occurring in our system.  
 
Although the exact mechanisms of collective invasion are not yet completely 
understood, the presence of coordinated cell-cell junctions, distinct polarised 
morphology of especially the leader cell, force generation with actin-myosin 
activity and ECM remodelling with track formation, with important signalling 
cross-talk within the cell cluster as well as with the surrounding tissue, are all 
essential264. If cell cohesions are lost, cells will switch from collective to single 
cell invasion, which, although to a lesser extent, also could be seen in the 
organotypic gels. This plasticity of cells, and the mode of invasion, is partly 
mediated via cues from the stroma265. For example, it has been shown that active 
TGFβ signalling can switch breast cancer cells from collective to single cell 
migration266, and collective invasion of oral squamous cancer cells was 
stimulated by paracrine stromal-derived factor-1 (SDF1) and HGF, secreted by 
activated fibroblasts267. Also signalling pathways involved in collective 
migration during embryonic morphogenesis and known be deregulated in 
pancreatic cancer, such as FGF and Wnt/β-catenin signalling40, 268, may be 
involved in collective cancer cell migration. A recent study in zebrafish 
demonstrated that Wnt/β-catenin signalling was active only in the leader cells of 
the migrating primordium, which activated FGF signalling in the trailing cells 
and regulated migration via differential expression of two chemokine receptors 
CXCR4b and CXCR7b269.  
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Several matrix metalloproteinases (MMPs), a family of at least 25 zinc-
dependent extracellular endopeptidases that target a variety of ECM proteins, 
have been reported to be highly expressed in pancreatic cancer55. MMP-11 has 
been found to be overexpressed by proliferating fibroblasts within the 
juxtatumoural stroma, the stromal compartment adjacent to the neoplastic cells, 
of infiltrating PDAC but was only focally expressed by fibroblasts within chronic 
pancreatitis tissues270. PSCs have been shown to secrete MMP-2 and MMP-9, 
MMPs known to degrade basement membrane collagen, and MMP-13, known to 
degrade fibrillar collagen. MMP-2 secretion was increased by such PSC 
activating factors as TGFβ1, ethanol and acetaldehyde271. Additionally it has 
been shown that cancer cells stimulate MMP-2 secretion by PSCs via basigin 
(BSG), a transmembrane glycoprotein that has a metalloproteinase-inducing 
ability, indicating that cross-talk between tumour and stromal cells might further 
increase MMP-2 production237.  
 
Despite this high expression of MMPs in pancreatic cancer and their known role 
in cancer cell invasion, not all cancer cells are sensitive to matrix protease 
inhibitors and initial clinical trials with MMP inhibitors have been 
disappointing82, 158, 265. It increasingly is believed that cancer cells can migrate 
through the ECM in a proteolysis dependent (mesenchymal-type invasion of 
single cells or collective invasion) and in a proteolysis independent (amoeboid-
type invasion) manner, with different patterns of invasion within one tumour and 
an ability of cancer cells to switch between different modes of motility154, 157. 
Amoeboid-type invasion refers to the motility of rounded cells that don’t show 
obvious polarity or develop mature focal adhesions and are independent on 
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extracellular proteolysis. Instead, cells have been demonstrated to migrate 
through force generated by high levels of actomyosin contractility, driven by 
Rho-ROCK signalling, resulting in a propulsive, pushing migration mode in 
which cancer cells are able to squeeze through gaps in the ECM158, 272. 
Interestingly, ezrin, which is phosphorylated by ROCK219, has been shown to be 
required for amoeboid-type migration, in which its expression was localised in 
the direction of cell movement in 3D Matrigel matrices158, as well as for the 
formation of podosomes (small, 1 µm, adhesive actin-containing cell protrusions 
that recognise and sense the ECM and thereby modify cytoskeletal behaviour)221.  
 
3.7. Conclusion 
The many similarities between clinical specimens and organotypic cultures 
suggest that this organotypic culture model is a reproducible, biomimetic, three-
dimensional in vitro model, which allows examination of the interactions 
between stromal elements and pancreatic cancer cells. Stromal cells may be 
contributing to the malignant behaviour of cancer cells by modulating cell-cell 
adhesion and ezrin re-distribution, possibly through activation of the Wnt/β-
catenin pathway, which has been investigated further (discussed in the next 
chapter).  
 
Additionally, this model has the potential to test drugs targeting specific 
compartments of cancer and/or stroma in an easily amenable and controllable 
system as well as the potential to incorporate other matrix components, such as 
immune and endothelial cells, to further investigate epithelial-stromal 
interactions.  
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3.8. Future challenges 
Although the described organotypic models have been shown to be 
physiologically and clinically relevant, they are still a simplified representation 
of a human tumour. The knowledge and expertise gained with this organotypic 
model can be used to expand the stromal components with additional cell types. 
Some more complex models, including more than one stromal cell type, already 
are being developed for other diseases. For example, for oesophageal cancer it 
has been shown that the role of tumour-stroma interactions in pathological 
angiogenesis can be studied by adding a first layer of pure collagen on top of (2D 
monolayer) cultured endothelial cells, followed by a second overlay of collagen 
containing fibroblasts and cancer cells168. In preliminary experiments for an 
organotypic culture model with pancreatic stellate cells and endothelial cells, I 
tested the optimal culture medium for co-culture of PS1 stellate cells and Human 
Umbilical Vein Endothelial Cells (HUVECs). As demonstrated in Figure 3.19, 
for continuous proliferation HUVECs required medium supplemented with 
endothelial cell growth supplement (AbD serotec, #4110-5004), a purified 
endothelial mitogen from bovine hypothalamus273. Although PS1 cells were able 
to proliferate in this medium, studying any interactions between these cell types 
would be complicated. Aiming to avoid the need for additives such as endothelial 
mitogen, we obtained immortalised HUVECs (kind gift from Dr Anno, 
Hiroshima University, Japan) and Dr Raghu Kadaba is continuing this project in 
our laboratory.  
 
Besides the possibility of incorporating endothelial cells in organotypic cultures, 
adding immune cells could also be an interesting challenge since changes in 
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immune response and inflammation also have an important role in the 
desmoplastic reaction seen in pancreatic cancer and inflammation is thought to 
activate pancreatic stellate cells274. In addition to the influence of immune cells 
on pancreatic stellate cells (or vice versa), interactions between cancer cells and 
immune cells can be studied. Certainly, direct 2D co-culture of malignant B- 
cells with normal T-cells suppressed normal immunological synapse 
formation275. Organotypic cultures could allow a better analysis of the 
immunosuppressive effects of pancreatic cancer or stellate cells on co-implanted 
immune cells.  
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Figure 3.19 Proliferation of HUVEC and PS1 cells cultured in different 
growth media. 
Proliferation of HUVEC was significantly affected by the removal of endothelial cell 
growth supplement from either their standard medium (M199) or from stellate cell 
medium (DMEM:F12). The hTERT immortalised PS1 stellate cells proliferated well in 
their standard medium as well as in medium supplemented with endothelial cell growth 
supplement, M199 HUVEC medium however decreased the proliferation of PS1 cells 
from day 6 onwards. Graphs display the absorbance of formazan dye produced by 
metabolically active cells; mean ± SEM (WST-1 assay, Roche, #5015944).  
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4.CHAPTER IV   RESULTS – PART II 
Targeting the tumour stroma offers exciting opportunities for treatment of 
pancreatic cancer 
 
4.1. Introduction 
Although it is now well recognised that the tumour microenvironment actively 
participates in tumour progression46, the tumour stroma has not yet been targeted 
commonly for therapy. In pancreatic cancer, a tumour characterised by an intense 
desmoplastic stroma and by a poor response to the currently available 
chemotherapeutic drugs38, targeting the tumour stroma would be of particular 
interest and may offer a novel therapeutic strategy. The organotypic culture 
model enabled me to test this hypothesis, by targeting the tumour 
microenvironment and studying the effects on cancer cell behaviour, in a 
physiologically relevant system.  
 
4.2. Rendering stellate cells quiescent with retinoic acid and its impact 
on tumour cell behaviour 
4.2.1. Background 
The fat-soluble vitamin A is essential for normal organogenesis and later in life 
for appropriate function of many organ systems, including the promotion of good 
vision, a healthy immune system, regulating fertility and maintaining normal cell 
proliferation and differentiation276. Clinical vitamin A deficiency, which is still a 
major public health problem, is characterised by several ocular symptoms such 
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as night blindness, xerophthalmia (dry eyes) and/or keratomalacia (corneal 
necrosis/ulceration) and a generalised impaired resistance to infections277. On the 
other hand, excess dietary vitamin A can result in acute (excessive intake over a 
period of hours or a few days) or chronic (high amounts of vitamin A for months 
or years) toxicity, with signs of liver and central nervous system toxicity in acute 
toxicity and skin lesions, osteoporosis, blurred vision or more non-specific 
symptoms in chronic toxicity. Moreover, high concentrations of retinoids 
(analogues of retinol with or without biological activity as well as structurally 
unrelated compounds with retinoid activity) are teratogenic, resulting in severe 
embryonic malformations such as cranial-neural-crest, neural-tube, 
musculoskeletal or urogenital defects213, 278.  
 
Vitamin A exerts its functions through conversion into retinoic acid (RA), which 
is the most biologically active, naturally occurring member of the retinoids. In 
the intestinal lumen, dietary retinyl esters (together with β-carotene, the main 
source of dietary vitamin A) are enzymatically converted to retinol by pancreatic 
triglyceride lipase and the intestinal brush border enzyme phospholipase B. 
Retinol is taken up by enterocytes via a saturable carrier-mediated process, is 
subsequently re-esterified and incorporated into chylomicron esters before it is 
passed into the lymphatics and transported through the blood213. In vitamin A 
sufficiency, retinol accumulates in the liver where it is stored in the form of 
retinyl esters in lipid droplets, mainly, in hepatic stellate cells (~ 85%). Retinol 
recycles extensively between plasma, where it is bound to retinol-binding protein 
4 (RBP4) and has a concentration of about 1–2 µM, liver and extra-hepatic 
tissues213. In addition to retinol bound to retinol binding protein, some low 
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(nanomolar) concentrations of retinoids, including all-trans RA (ATRA) and 13-
cis RA, can also be found in plasma, bound to albumin; the biological function of 
these circulating retinoic acids is not known276.  
 
If cells require RA, retinol is taken up from the blood via the STRA6 receptor 
and oxidised first into retinaldehyde by retinol or alcohol dehydrogenases (RDHs 
or ADHs) and then into various forms of retinoic acid (RA) by retinaldehyde 
dehydrogenases (RALDHs). The most important, biologically active, isoforms of 
retinoic acid include all-trans RA (ATRA), 9-cis RA and a metabolite of ATRA, 
13-cis RA. Synthesised retinoic acid can then either enter the nucleus to activate 
gene transcription or, via unknown mechanisms, be secreted and function in a 
paracrine manner to target cells that lack the enzymes required for RA synthesis. 
There are several enzyme classes active in RA synthesis, of which the most 
important are RDH1, RDH10, ADH1, ADH3 and ADH4 for retinaldehyde 
synthesis and RALDH1, RALDH2 and RALDH3 for RA synthesis. RA is further 
metabolised by three cytochrome P450 (CYP) enzymes (CYP26A1, CYP26B1, 
CYP26C1), resulting in degradation of RA (Figure 4.1)279, 280.  
 
In the nucleus, RA binds to two ligand activated nuclear transcription factors, the 
RA receptors (RARα, RARβ and RARγ) and the retinoid X receptors (RXRα, 
RXRβ and RXRγ). RARs and RXRs act as heterodimers and bind to a DNA 
sequence known as the RA-response element (RARE) in the promoter region of 
target genes, thereby regulating gene expression (a more detailed description is 
given in Figure 4.2). Each RAR and RXR isoform has unique functions and 
various RAR/RXR heterodimers differentially transduce retinoid signals to 
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control the expression of numerous RA target genes281, 282. In addition to 
forming a heterodimer with RAR, RXR can also heterodimerise with other 
nuclear receptors, including the thyroid hormone receptor (TR), vitamin D 
receptor (VDR), peroxisome proliferator activated receptor (PPAR) and liver X 
receptor (LXR), as well as form homodimers with signalling capacity282, 283. 
RXR heterodimers can be “non-permissive”, in which the transcriptional activity 
of RXR is subordinated to ligand binding to its heterodimerisation partner, as is 
the case with RXR/RAR, RXR/TR or RXR/VDR heterodimers. But RXR can 
also more actively regulate gene transcription through “permissive 
heterodimers”, in which binding of a RXR ligand (9-cis retinoic acid or other 
ligands, termed rexinoids) can activate transcription, which has been shown for 
RXR/PPAR, RXR/LXR heterodimers and RXR homodimers281, 283, 284. These 
permissive heterodimers may integrate RA signalling with other signalling 
pathways, such as PPAR or LXR signalling, which are important regulators of 
lipid metabolism and glucose homeostasis, or cell-differentiation and apoptotic 
pathways283, 285.  
 
More than 500 genes have been reported to be inducible by RA expression, 
however in an extensive literature review only 27 genes were unambiguously 
shown to contain functional RAREs, including HOX genes (specify the anterior-
posterior axis during development), CD38, IL2RA (interleukin 2 receptor alpha) 
and components of the RA-signalling pathway such as CRABP2 (cellular retinoic 
acid binding protein 2) and all three RAR genes286. In most cases the regulation 
of target gene expression appeared to be indirect, through intermediate 
transcription factors or non-classical associations of receptors with other 
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proteins. Transcription factors known to be repressed by RA include activating 
protein 1 (AP1), a heterodimeric transcription factor composed of members of 
the Fos and Jun families of DNA binding proteins, or nuclear factor kappa-B 
(NFκB); transcription factors commonly involved in carcinogenesis through their 
role in many cellular processes such as cell proliferation, apoptosis, cell 
migration and inflammation276, 285, 287. Hence, in mutual interactions with other 
signalling pathways, RAR and RXR receptors regulate gene networks that are 
essential for organogenesis, for cell differentiation, proliferation, survival and 
death288-290.  
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Figure 4.1 Metabolism of retinoic acid.  
Dietary retinoids are converted in the intestinal cells to retinyl ester (RE) and transported 
to the liver in chylomicrons. Hepatocytes hydrolyse the retinyl esters to retinol (ROH), 
which is then either bound to retinol binding protein 4 (RBP4) for transport to target 
tissue, or (in vitamin A sufficiency) delivered to stellate cells for storage in lipid droplets 
in the form of retinyl esters. Some retinyl esters are stored in extra-hepatic stellate cells, 
including these in the pancreas, kidney, lung, colon and heart, which may be important 
for supply of retinol to tissues with a high demand. If cells require retinoic acid, retinol 
is secreted into the circulation bound RBP4 and taken up by cells via the cell surface 
receptor STRA6, which binds RBP4. Cytoplasmic retinol is oxidised first into 
retinaldehyde (RAL) by retinol or alcohol dehydrogenases (RDHs or ADHs) and then 
into various forms of retinoic acid by retinaldehyde dehydrogenases (RALDHs). 
Synthesised retinoic acid (RA) can then either bind to CRABP, which facilitates the 
transport of RA into the nucleus, or be secreted and function in a paracrine manner. RA 
is catabolised in the cytoplasm by the CYP26 class of P450 enzymes. In the nucleus, RA 
binds to the RA receptors (RARs) and Retinoid X receptors (RXRs); all-trans RA 
(ATRA) binds to RARs, whereas 9-cis-RA is thought to be a bifunctional ligand and can 
bind both RAR and RXRs. RAR and RXR heterodimerise and activate gene 
transcription via binding to RA-response elements (RARE). CRBP, cellular retinol 
binding protein, solubilises the fat-soluble retinol and protects it from degradation; 
LRAT lecithin:retinol acetyltransferase for esterification; REH, retinyl ester hydrolase; 
CRABP, cellular retinoic acid binding protein. 
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Figure 4.2 Regulation of transcription by RAR-RXR heterodimers. 
In the absence of RA signalling histone deacetylase (HDAC) containing complexes are 
bound to the RAR-RXR dimer indirectly via co-repressors (CoR, including the co-
repressor SIN3), resulting in chromatin condensation and gene silencing. Upon binding 
of RA the ligand binding domain, responsible for ligand binding and dimerisation, 
undergoes a conformational change, which destabilises the interface with the co-
repressors and allows binding with transcriptional co-activators (CoA). These co-
activators recruit histone acetyltransferases (HAT), which acetylate the histone amino-
terminal tails and, thereby, induce chromatin decondensation and transcription.  
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Embryological studies investigating the effects of loss of retinoic acid have 
demonstrated that RA is essential for the development of many organs, including 
the pancreas, and is essential for life; mice with no RALDH2 (the earliest and 
most frequently expressed isoform) or RALDH3 were non-viable at E9.5 or 
birth, respectively279. Two studies investigating the effects of RA in early 
pancreas development demonstrated that RALDH2 was expressed in the dorsal 
pancreatic mesenchyme and that the dorsal pancreatic bud was not correctly 
specified when this expression was removed in RALDH2 knockout mice. 
Additionally, mutant embryos did not express the homeodomain transcription 
factor Pdx1, which is required for pancreatic specification in the posterior 
foregut, suggesting that RA could be the mesenchymal signal required for Pdx1 
expression and, therefore, early pancreas development173, 174. In zebrafish, RA 
has also been shown to act as a posteriorising factor in the endoderm, with 
exogenous RA treatment resulting in anterior ectopic expression of all pancreatic 
markers (Pdx1, islet1, insulin, somatostatin and trypsin), at the expense of 
anterior endodermal derivatives such as thyroid and pharynx291. In addition to 
the important role of RA in defining the pancreatic field within the developing 
endoderm, RA may also play a role later in pancreas development and specify 
exocrine differentiation via epithelial-mesenchymal interactions292. These studies 
not only show that RA plays an important role in pancreas development but also 
that it acts primarily in a paracrine manner.  
 
The knowledge that RA is important for (pancreas) organogenesis, in a well-
orchestrated balance with other developmental signalling molecules, such as 
FGF, bone morphogenic proteins (BMPs), Hedgehog and Wnt, has resulted in an 
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increasing interest in its role in differentiation and regeneration290, 293, 294. In 
peripheral nerves, which can slowly regenerate after injury, RA has been shown 
to be induced and stimulate neuronal regeneration, possibly through its anti-
inflammatory effects and the inhibition of macrophage invasion. Based on these 
findings, supplementary RA, or upregulation of RARβ, the main RA receptor 
involved, has been tested to stimulate the neural regeneration as a treatment for 
stroke or spinal cord injury294. Moreover, embryonic stem cells, haematopoietic 
stem cells and neural stem cells have been shown to differentiate into various 
types of neurons and glial cells upon exposure to RA; a feature tested in vivo to 
generate new neurons for treatment of Parkinson’s disease, Huntington’s disease 
or stroke290. The importance of RA signalling in pancreas development has also 
been exploited in efforts to derive pancreatic progenitors from embryonic stem 
cells, in particular in relation to the development of stem cell therapy for diabetes 
mellitus295-297. For example, the differentiation of human embryonic stem cells 
has been shown to follow embryological pathways, in which early RA signalling, 
combined with inhibition of BMP (by treatment with the BMP antagonist 
noggin) and Hedgehog (through KAAD-cyclopamine) signalling, and late 
induction of FGF signalling, was crucial for a pancreatic fate295, 296. 
Additionally, if exposed to conditioned medium of pancreatic rudiments from 
mouse embryos, mouse embryonic stem cells differentiated into cells expressing 
markers of exocrine lineage (Pdx1 and amylase), in which retinoic acid was 
shown to be involved in the specification of an exocrine phenotype297.  
 
Besides these significant functions of RA signalling in cell differentiation, in 
conjunction with other signalling pathways, RA also plays an important role in 
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regulating cell proliferation and apoptosis298; functions all important in 
preventing neoplastic growth. Hence, RA has been of great interest in developing 
cancer therapy, with first studies for a possible role in pancreatic cancer already 
reported more than a decade ago299, 300. The paradigm for successful therapy 
with RA is treatment of acute promyelocytic leukaemia (APML) with all-trans 
RA (ATRA). APML is caused by a chromosomal translocation generating a 
fusion protein involving RARα and, most commonly, the promyelocytic 
leukaemia gene, resulting in enhanced repression by HDACs and several co-
repressors leading to a block of differentiation at the promyelocytic stage. ATRA 
can bind to the fusion protein (RARα kept its ligand binding domain in the 
translocation), dissociate the co-repressor complex and initiate the normal, 
physiological, transcription programme285. In addition to APML, in which RA 
combined with anthracyclines cures 70-80% of patients, RA is used in the 
treatment of precancerous lesions (leukoplakia, actinic keratosis and cervical 
dysplasia), preventing the progression to carcinoma, and is undergoing clinical 
evaluation for treatment of various other cancers301. 
 
Unlike other vitamins, the concentration of vitamin A is strictly regulated in 
order to prevent either deficiency or toxicity. The size and number of lipid 
droplets in hepatic stellate cells is dependent on dietary intake, thereby keeping 
the total circulating plasma concentration of retinol constant302. In addition to 
hepatic stellate cells, pancreatic stellate cells (PSCs) store up to 10% of total 
body retinol. However, upon activation, as seen in the stroma of pancreatic 
cancer, PSCs rapidly lose their retinol stores98. Additionally, in pancreatic cancer 
there is a relative deficiency of all fat soluble vitamins due to a lack of biliary 
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and pancreatic secretions, raising the question whether depletion of vitamin A 
plays a more active role in the desmoplastic reaction in pancreatic cancer. 
Therefore I hypothesised that retinoic acid treatment could restore the quiescent 
state in activated PSCs and offer a novel therapeutic strategy for pancreatic 
cancer. 
 
4.2.2. Phenotypic effects of retinoic acid treatment on pancreatic stellate 
cells 
Preliminary experiments done by Mr Hemant Kocher, testing different retinoids 
(9-cis retinoic acid (9-RA), 13-cis retinoic acid (13-RA) and all-trans retinoic 
acid (ATRA)) at different doses, different substrates (Matrigel or plastic) and 
different treatment intervals), have shown that the most consistent results were 
obtained using a daily treatment of cells on plastic with 1 µM ATRA for 7 days. 
With this treatment schedule PS1 cells changed from spindle shaped cells to a 
more rounded form with fibrillar processes and obvious accumulation of lipid 
droplets that contained vitamin A (Figure 4.3). These morphological changes 
were associated with a reduction in cell numbers (nearly 50%), an increase in 
cell size (nearly 1 µm, trypsinised cells in suspension) and a shift from the G2/M 
phase toward the G1 phase of the cell-cycle (Figure 4.4; these experiments were 
done by Mr Hemant Kocher). 
  
Additionally, PS1 cells treated with ATRA demonstrated an increased expression 
of desmin and GFAP, markers of quiescent stellate cells, a decreased total 
expression of vimentin and a change in the distribution of αSMA from along 
straight fibres to a more globular deposition; a change in keeping with the 
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phenotypic changes in cell shape (Figure 4.5). Hence, all these findings suggest 
that stellate cells are rendered quiescent, at least in two-dimensional cultures, by 
treatment with 1 µM ATRA. 
 
 
 
Figure 4.3 Retinoic acid treatment changes morphology of stellate cells. 
Representative bright-field microscopy picture shows that after 7 days of treatment with 
either vehicle (A) or 1 µM ATRA (B), the pancreatic stellate cells, PS1, show a marked 
change in morphology in response to ATRA. This is characterised by transition from a 
spindle shape to a more rounded morphology with fibrillar processes and fat globule 
deposition (arrowheads), which is confirmed by a positive Oil red O stain.  
Scale bar, 5 µm. 
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Figure 4.4 Retinoic acid (RA) treatment leads to PSC quiescence. 
There was a reproducible change in cell size (A) and cell counts (B) in response to 
treatment of PS1 cells with various retinoic acids, when plated either on Matrigel (right 
on graph) or plastic (left on graph) as compared to respective controls (white bars). 
Changes were most consistent when stellate cells were treated with 1 µM ATRA. 
Alterations in cell-cycle progression are shown in (C), demonstrating a marked shift to 
the G1 phase of the cell-cycle on exposure to ATRA and 9-RA but not to 13-RA, 
irrespective of culture of PS1 cells on plastic or Matrigel. Histograms are representative 
of data from 3 biological repeats each containing at least 3 technical replicates. Mean ± 
SEM; *, p<0.05, Student’s t-test, 2-tailed, unequal variance.  
Data provided by Mr Hemant M Kocher. 
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Figure 4.5 RA mediates cytoskeletal change in pancreatic stellate cells. 
On treatment with 1 µM ATRA there were changes in total protein concentrations and 
distribution of the key markers of PSC, as detected by Western blot and 
immunocytochemistry. P, culture on plastic and M, culture on Matrigel, both at 1 µM 
ATRA; C, vehicle control. Whilst there was no change in αSMA total protein, immuno-
fluorescence images show a change in the pattern of deposition of αSMA to a more 
globular pattern, after treatment with ATRA (A). There was a decrease in vimentin, 
which was more marked in cells on plastic than those on Matrigel (B), and an increase in 
desmin (C) and GFAP (D) on treatment with ATRA. HSC70 was used as a loading 
control (E). Quantification of densitometry from these blots is shown in the adjacent 
graphs, with all values normalised against HSC70 and respective vehicle-treated control 
band in the blot; each blot is one of three independent repeats showing similar changes. 
Mean ± SEM; *, p<0.05, Student’s t-test, 2-tailed, equal variance. Scale bar, 10 µm. 
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4.2.3. Effects of retinoic acid treatment on gene expression in pancreatic 
stellate cells (by Mr Hemant Kocher) 
In order to investigate the effects of ATRA treatment on gene expression in 
stellate cells, gene expression microarrays were performed with RNA extracted 
from stellate cells treated for 7 days with ATRA, at 1 µM or 10 µM and cultured 
on plastic or Matrigel as well as with RNA extracted from stellate cells cultured 
on plastic and treated with 1 µM ATRA for different period of times 
(investigation at 30 minutes, 4, 12, 24 or 168 hours); results were compared with 
gene expression in vehicle-treated stellate cells.  
 
Upon exposure to ATRA there was a marked difference in gene expression, 
which was broadly similar between cells cultured on plastic or Matrigel and a 
maximal numbers of genes deregulated after treatment for 7 days (a list of 
differently expressed genes according to dose-response (1 or 10 µM ATRA) or 
change in culture conditions (on plastic or Matrigel) is shown in Table A.1 in 
Appendix I). The differentially expressed genes then were interrogated for their 
possible cellular function and canonical pathways using Ingenuity Pathway 
Analysis, which highlighted profound effects on key cellular functions, such as 
cell-cycle, cell proliferation, cell morphology and cell movement, across 
different treatment conditions (Figure 4.6). Furthermore canonical signalling 
pathways, such as ‘stellate cell activation’ (de-activation in our case) and 
‘retinoic acid signalling’, were changed dramatically, thus validating the 
experimental conditions and microarray data. Interestingly the ‘Wnt/β-catenin’, 
‘IL-8’ and ‘Hedgehog’ pathways comprised the other top canonical pathways 
affected; pathways increasingly recognised as being de-regulated in pancreatic 
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cancer40, 91, 303, 304 (Figure 4.7). For a subset of genes their changes in 
transcriptional activity were confirmed by me, using quantitative real-time PCR 
(Figure 4.8).  
 
 
 
 
 
Figure 4.6 Change in transcriptome in RA-treated pancreatic stellate cells, 
cellular functions affected. 
The range of p-values (plotted as –log(p-value)) for each individual component of the 
key cellular and biologic functions as interrogated by Ingenuity Pathway Analysis, for 
various treatment conditions with ATRA (P, culture on plastic treated with 1 µM ATRA, 
black; M, culture on Matrigel treated with 1 µM ATRA, grey; 10, culture on plastic 
treated with 10 µM ATRA, white) are shown. P-values were calculated by right tailed 
Fisher’s exact test with Benjamini-Hochberg correction for multiple comparisons. The 
ranges of p-values plotted in the graph (as depicted by the length of each individual bar) 
indicate the distribution of the p-value of all the individual sub-functions of that 
particular biological function. The threshold for significant p-value is 0.05, which 
translates to –log (p-value) of 1.3. All cellular functions shown were significantly 
altered, with cell proliferation and movement being the functions that were affected the 
most. Figure provided by Mr Hemant M Kocher. 
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Figure 4.7 Change in transcriptome in RA-treated pancreatic stellate cells, 
canonical pathways affected. 
This graph demonstrates the top four of the many significantly affected key canonical 
pathways across various treatment conditions as discussed in Figure 4.6. ‘Stellate cell 
activation’ (de-activation is seen in this instance but the labelling for the canonical 
pathways remains the same) and ‘RAR activation’ were, reassuringly, the top canonical 
pathways common in all treatment conditions, confirming the use of our experimental 
set-up against previously published data. Interestingly, we discovered that ‘Wnt/β-
catenin’ and ‘IL-8’ signalling were affected significantly in at least two of the three 
treatment conditions tested. X-axis crosses Y-axis at a threshold of p<0.05 and therefore 
any bars below the threshold are not significant.  
Figure provided by Mr Hemant M Kocher. 
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Figure 4.8 Validation of gene expression by quantitative real-time PCR. 
Quantitative real-time PCR results independently validate microarray data. Two random 
clusters of genes were explored and normalised to 18S expression. Those upregulated on 
treatment were RARβ (retinoic acid receptor β) and ITGA1 (integrin α1); downregulated 
genes were FGF9 (fibroblast growth factor 9) and DKK1 (Dickkopf 1). There is almost 
uniform up- or downregulation as expected from the microarray data with respect to 
dose or substrate on which the treatment was performed (C, control; P, plastic and M, 
Matrigel at 1 µM; 10 is plastic at 10 µM). Mean ± SEM; *, p<0.05, Student’s t-test, 2-
tailed, unequal variance. 
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4.2.4. Effects of retinoic acid treatment on protein expression in pancreatic 
stellate cells 
In addition to the effects of ATRA treatment on gene expression, alterations in 
protein expression are being analysed by proteomic analysis in collaboration 
with Dr Mark Weeks (Veterinary Laboratories Agency Weybridge, Addlestone). 
Experiments were set up to subject full cell lysates as well as supernatants from 
PS1 cells, treated for 7 days with 1 µM ATRA, to mass spectrometry. The initial 
experiment however yielded a very low protein concentration of the supernatant 
samples (Figure 4.9A). Therefore it was decided to pool all replicates from this 
first experiment and continue with TMTtag labelling and tandem mass 
spectrometry (MS/MS) to get a first impression of the secretome, while in the 
meantime new experiments were set up to collect enough supernatant for three 
replicates. In the media samples, 709 proteins were identified. However, a large 
majority of these were albumin (even though cells were washed two times with 
serum free medium before supernatant was collected).  
 
Hence, in the new experiment, which included thirty 175 cm2 dishes per 
treatment, cells were washed extensively (4x) with serum free medium before 
being incubated with 12 ml serum free medium for 4 hours (initial collection of 
supernatant was planned after 8 hours, but at 4 hours the cells looked so stressed 
that it was decided to collect supernatant). Supernatant was collected and 
concentrated to 500 µl using 3 kDa MWCO (molecular weight cutoff) spin 
filters; concentrates from 10 dishes were pooled (resulting in three replicates per 
treatment condition), desalted and protein concentrations were determined. 
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Disappointingly, all replicates again had an extremely low protein concentration, 
indicating a protein content of approximately 100-150 µg in total.  
 
Since we reasoned that the stellate cells could have become too stressed with the 
extensive washes and without any serum, the experiment was repeated but now 
using a well defined medium called CTL Test medium, containing injection 
grade water supplemented with insulin, transferrin, testosterone, glucose, fatty 
acids and buffers in a proprietary composition (Cellular Technology Ltd). Cells 
were treated for 7 days with 1 µM ATRA or vehicle control, washed twice in 
serum free medium and subsequently cultured for 24 hours in CTL Test medium. 
Supernatant was collected, processed as described above and protein assay now 
resulted in approximately 100 times more protein compared to the earlier 
experiments (Figure 4.9B). These samples have been processed for MS/MS 
analysis, with initial results again suggesting albumin contamination (Table 4.1). 
Although more stringent and quantitative analysis is carried out at the moment, 
which will identify truly altered protein expression and provide information 
regarding the up- or downregulation of differentially expressed proteins in 
quiescent versus activated stellate cells, this abundant detection of albumin may 
not only reflect contamination from cell culture medium, since a role for albumin 
in the formation of lipid droplets in pancreatic stellate cells recently has been 
suggested305. Other differentially expressed proteins that will be of interest to 
explore in more detail are for example vimentin, tissue inhibitor of 
metalloproteinase 1 (TIMP1), TIMP2 and S100 calcium binding protein A11 and 
A4 (Table 4.1). 
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Figure 4.9 Protein assay of supernatant collected for proteomic analysis. 
(A) Demonstrates the protein concentration (mg/ml) of three replicate serum free 
DMEM:F12 supernatant samples from stellate cells treated with ethanol (C1, C2 and 
C3) or 1 µM ATRA (P1, P2, P3). The protein concentration increased significantly 
when cells were incubated in CTL medium, as can be seen in (B). These supernatant 
samples have been subjected to mass spectrometry, which results are currently being 
analysed (provisional results shown in Table 4.1). Mean ± SD.  
Data provided by Dr Mark Weeks.  
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Table 4.1 Results tandem mass spectrometry. 
Differential expression of proteins in supernatant of stellate cells treated with 1 µM ATRA, as compared to supernatant of vehicle-treated stellate cells, 
identified by tandem mass spectrometry (MS/MS) analysis with active albumin exclusion. Quantitative analyses regarding up-or downregulation upon ATRA 
treatment are ongoing. Data provided by Dr Mark Weeks. 
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4.2.5. Morphological and proliferative responses of tumour cells cultured 
with pancreatic stellate cells on organotypic gels treated with all-
trans retinoic acid (ATRA) 
To investigate if ATRA could have an anti-tumour effect by rendering stellate 
cells quiescent, cancer cells (AsPc1 or Capan1) were mixed with PS1 stellate 
cells in a 2:1 ratio (cancer cells:stellate cells) and cultured on top of a 
collagen:Matrigel gel, supplemented with 1 µM ATRA or ethanol. Gels were 
raised to a grid (air-liquid organotypic model, Figure 2.2E) and treated daily for 
10 days with 1 µM ATRA or vehicle control (0.1% ethanol). In order to be able 
to distinguish between a direct effect of ATRA on cancer cells or an indirect 
effect via changes occurring in PS1 stellate cells, the results were compared with 
those obtained using a mono-culture of cancer cells on top of extracellular matrix 
gels. In addition to these physiologically relevant 3D cultures, mono- and co-
cultures of cancer cells and PS1 stellate cells also were performed in 2D culture 
conditions.  
 
Immunostaining for markers of proliferation and apoptosis, Ki67 and cleaved 
caspase-3, respectively, revealed that, after 10 days of ATRA treatment of cancer 
cells and stellate cells in organotypic 3D co-culture, there was significantly less 
proliferation and more apoptosis of cancer cells (p<0.005, Mann-Whitney U-test) 
(Figure 4.10). Additionally it was noticed that cancer cells, especially in the 
AsPc1 co-cultures, exhibited a much looser organisation after treatment with 
ATRA (Figure 4.10). These observed changes in cancer cell proliferation, 
apoptosis and cellular arrangement were due to effects of ATRA on PS1 stellate 
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cells, as treatment of cancer cells alone in 3D cultures did not result in any 
change in these parameters (Figure 4.11).  
 
4.2.6. Invasion of pancreatic cancer cells and pancreatic stellate cells and 
the effects of ATRA 
Confirming earlier observations, when cancer cells and stellate cells were 
cultured in different ratios on top of gels (Figure 3.16), dual staining of the 
ATRA or vehicle-treated organotypic cultures with pan-cytokeratin (green, 
cancer cells) and vimentin (red, pancreatic stellate cells), demonstrated that, in 
the vehicle-treated co-cultures, stellate cells invaded the ECM gel first, followed 
by cancer cells (Figure 4.12). Stellate cells could be seen throughout the gel with 
a single cell layer thickness of stellate cells at the tumour-extracellular matrix 
interface (Figure 4.12). In contrast, in the ATRA-treated gels there was a 
significant increase in the thickness of the stellate cell layer at the tumour-gel 
border, which was associated with diminished invasion of stellate and cancer 
cells into the gel (Figure 4.12B, C, D). Thus, quiescent, less invasive, stellate 
cells appeared to form a “wall” due to crowding at the tumour-gel interface, 
thereby preventing the invasion of cancer cells into the underlying gel, possibly 
due to a decrease in the formation of invasion-promoting tracts by pancreatic 
stellate cells137.  
 
In order to confirm these observations, the invasion of cancer cells and stellate 
cells was studied using Transwell invasion assays, in which the ability of cells to 
invade, through a microporous membrane coated with Matrigel towards a 
chemoattractant in the bottom chamber, can be quantified. Compared to the 
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invasion of cancer cells towards serum, conditioned medium from vehicle-
treated PS1 cells significantly increased the invasion of AsPc1 and Capan1 cells, 
which could be inhibited by supernatant from ATRA-treated PS1 cells (Figure 
4.13A). These results confirm the observations in organotypic cultures, as well as 
previously published data that stellate cells stimulate tumour cell invasion103, and 
show, for the first time, that this invasion-promoting effect can be inhibited by 
rendering stellate cells quiescent with ATRA (Figure 4.13A). When studying the 
effects of ATRA treatment on stellate cell invasion, there was minimal invasion 
of stellate cells towards serum, which was not affected by ATRA (Figure 4.13B). 
A similar observation of minimal invasion of PS1 cells cultured without cancer 
cells has been made when cancer cells and stellate cells were cultured in different 
ratios on top of organotypic gels (Figure 3.14). Interestingly then, and in keeping 
with the organotypic culture models, there was marked invasion of stellate cells 
when cancer cells were grown in the bottom chamber, which significantly 
decreased upon treatment with ATRA (Figure 4.13B, C).  
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Figure 4.10 RA treatment of organotypic cultures: changes in tumour cell 
proliferation and apoptosis. 
There was a decrease in proliferation, indicated by a positive Ki67 staining (arrows) in 
(A) and an increase in apoptosis, indicated by a positive staining for cleaved caspase-3 
(arrows) in (C), of cancer cells when co-cultured with PS1 stellate cells on top of 
organotypic gels and treated with 1 µM ATRA (P), as compared to vehicle control (C). 
Respective boxed areas are magnified and shown on the right. Only one cancer cell type 
is illustrated (AsPc1 for proliferation in (A) and Capan1 for apoptosis in (C)), but 
similar observations were made with the other cell line tested, which can be seen in the 
quantification of the percentage Ki67 positive (B) and cleaved caspase-3 positive (D) 
cells per field, across cell lines and experimental conditions. Graphs show median and 
raw data, *, p<0.005, Mann-Whitney U-test. Scale bar, 100 µm.  
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Figure 4.11 RA treatment of cancer cells alone on extracellular matrix gels. 
There were no changes in the morphology, proliferation (positive Ki67 staining) or 
apoptosis (cleaved caspase-3 staining) of cancer cells when cultured alone on top of 
organotypic gels and treated with vehicle (C) or ATRA at 1 µM (P). Graphs below show 
the percentage of Ki67 and caspase-3 positive cells as median and raw data, Mann-
Whitney U-test. Scale bar, 100 µm.  
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Figure 4.12 RA treatment of organotypic cultures: changes in morphology 
and invasion. 
(A) Dual stain for cytokeratin (green, for cancer cells) and vimentin (red, for PSC) 
demonstrates that there are more cancer cells in vehicle-treated organotypic cultures 
than in these treated with ATRA (see DAPI stain for nucleus and cytokeratin stain), 
thereby confirming that there is a change in proliferation and apoptosis. Interestingly, 
more cancer cells had migrated through the gel in the vehicle-treated situation 
(arrowheads, cytokeratin stain, quantification in (B)). The vimentin stain clearly 
demonstrates a reduction in vimentin expression upon ATRA exposure, with PSC 
invading less distance into the gel (arrows, quantification in (C)) and forming a thicker 
layer at the interface of the gel (yellow dotted lines, quantification in (D)). Graphs 
demonstrate median and raw data for both cell lines treated with vehicle control (C) or 1 
µM ATRA (P); *, p<0.005, Mann-Whitney U-test. Inset from panel (A) is magnified in 
(E) to demonstrate the tract laid down by PSC, which the cancer cells follow into the 
gel, in vehicle-treated organotypic cultures (as also seen in Figure 3.16).  
Scale bar, 100 µm. 
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Figure 4.13 Invasion of cancer cells and stellate cells in Transwell invasion 
assays.  
(A) Transwell invasion assays across Matrigel demonstrated an increased invasion of 
cancer cells towards conditioned medium from activated (vehicle-treated) stellate cells 
(C), as compared to invasion towards 10% FBS, which was reduced by treating PSC 
with ATRA, as shown by the decreased invasion of cancer cells towards conditioned 
medium from ATRA-treated PSC (P). (B) PSC invasion towards serum was minimal 
and not affected by ATRA treatment. However, there was marked increase in invasion 
of PSC towards pancreatic cancer cells (in bottom chamber), which was reduced in 
quiescent, ATRA-treated PSC. Illustration of vehicle and ATRA-treated PS1 cells, 
invaded through the Transwell membrane towards Capan1 cancer cells and stained with 
Crystal Violet, is shown in (C). Mean ± SEM; *, p<0.05, Student’s t-test, 2-tailed, 
unequal variance, all compared with supernatant from vehicle-treated PSC (C). 
 185 
4.3. Canonical Wnt-signalling in pancreatic cancer: changes upon 
ATRA treatment 
4.3.1. Background 
Wnts are secreted, relatively insoluble, lipid-modified signalling molecules 
characterised by a high number of conserved cysteine residues. There are 19 
different human Wnt genes, which are defined by sequence rather than by 
functional properties306. Wnts have pleiotropic effects with important roles 
during embryogenesis and adult tissue homeostasis, including mitogenic 
stimulation, cell fate specification and differentiation307. The main receptors for 
Wnts are the Frizzled (Fz) proteins, seven-pass transmembrane receptors with a 
long extracellular N-terminal extension called a cysteine rich domain (CRD); 
Wnts bind directly to this CRD domain. There are 10 human Fz receptors and a 
single Wnt can bind to multiple Fz receptors and vice versa308. Fz receptors 
cooperate with a single-pass transmembrane receptor, the low-density lipoprotein 
receptor-related proteins 5 or 6 (LRP 5/6). Although it has not been clearly 
demonstrated that Wnts mediate an interaction between Fz and LRP and form a 
trimeric complex, the presence of both receptors is required to initiate canonical 
Wnt signalling309.  
 
There are three different pathways that can be activated upon binding of Wnts to 
their receptors: the canonical Wnt/β-catenin cascade, and the non-canonical or β-
catenin independent planar cell polarity (PCP) pathway and the Wnt/Ca2+ 
pathway. The central player in the canonical pathway, which is the best 
understood cascade and has been studied here, is β-catenin. β-Catenin functions 
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as a transcription co-factor with the T cell factor/lymphoid enhancer factor 
(TCF/LEF) family of DNA-bound transcription factors. Additionally, β-catenin 
is an important structural adaptor protein that links the cytoplasmic tail of type I 
cadherins, via α-catenin, to the actin cytoskeleton243, 310. When Wnt receptors 
are not engaged, the concentration of β-catenin not bound to cadherins is kept 
low through phosphorylation of β-catenin by a so called “destruction complex”. 
Two scaffolding proteins in this complex, adenomatous polyposis coli (APC) and 
Axin, bind newly synthesised β-catenin, which is subsequently phosphorylated 
by the serine/threonine kinases casein kinase 1 (CK1) and glycogen synthase-3β 
(GSK3β) at a series of highly conserved serine/threonine residues near its N-
terminus; CK1 phosphorylates β-catenin at serine 45, resulting in subsequent 
phosphorylation by GSK3β at threonine 41 and serine 37 and 33. These 
phosphorylation sites (serine 37 and 33 in particular) form a binding site for the 
E3 ubiquitin ligase β-TrCP, which targets β-catenin for proteasomal 
degradation244.  
 
Once Wnts bind to Fz and LRP, the kinase activity of the destruction complex is 
inhibited through a cascade of events, including binding of Dishevelled (Dvl) to 
Fz and the recruitment of Axin to the phosphorylated cytoplasmic tail of the 
LRP5/6 co-receptor. The regulation of Dishevelled is still poorly understood, but 
the current model is that, upon binding of Wnt to the Frizzled receptor, 
Dishevelled is phosphorylated and, although the exact role of this 
phosphorylation remains unclear, the Axin-GSK3β complex is recruited to LRP5 
or 6, resulting in the phosphorylation of the co-receptors by GSK3β and CK1306. 
As a consequence, β-catenin phosphorylation is inhibited and non-
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phosphorylated β-catenin can accumulate in the cytoplasm and translocate, via 
unknown mechanisms, to the nucleus where it binds to the N-terminus of 
TCF/LEF transcription factors, activating transcription of target genes307, 308, 311.  
 
TCF/LEF proteins are members of the high mobility group (HMG) box-protein 
family, which induce DNA bending and thereby bring distant DNA regions 
together312. Four different TCF genes have been identified in vertebrates, TCF1, 
LEF1, TCF3 and TCF4, which bind to Wnt response elements through a highly 
conserved binding site between all four TCF proteins, CCTTTGXX (X 
represents either T or A). This core consensus sequence has been used to 
generate reporter plasmids to measure Wnt-signalling, such as the pTOPFlash 
reporter, by cloning concatemers of 3 to 10 of these binding motifs upstream of a 
minimal promoter214, 306. In the absence of Wnt signalling, TCF proteins interact 
with TLE1 (Groucho in Drosophila), a chromatin repressor that functions with 
histone deacetylases (HDACs) to inhibit transcription. The mechanisms of target 
gene activation upon binding of β-catenin to TCF, as well as the actions of nuclear 
β-catenin, are still not completely understood. However, in order to activate 
transcription, β-catenin binds to TCF, which seems to displace TLE1, and recruits 
multiple activating co-factors, including the histone acetyltransferase proteins 
CBP/p300313, 314, Pygopus/Bcl9 complexes315, the chromatin remodeller Brg1316 
and the kinase TNIK317.  
 
A plethora of Wnt target genes has been identified, of which an updated list is kept 
at the Wnt homepage (www.stanford.edu/group/nusselab/cgi-bin/wnt/), with 
diverse and cell- and context specific functions. Some of these target genes include 
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components of the pathway (for example Axin2, the most uniformly expressed 
target gene308, Fz, LRP6, TCF1 or Dickkopf 1, among others), thereby constituting 
either a negative feedback loop or a positive feedforward loop. Activation of Wnt 
signalling is further controlled by secreted Wnt-antagonists, which include 
members of the secreted frizzled-related protein and Dickkopf family; this will be 
discussed in more detail in paragraph 4.4. A cartoon of Wnt signalling is shown in 
Chapter III, Figure 3.18. 
 
4.3.2. Pancreatic cancer cells demonstrate active Wnt-signalling  
In order to understand whether Wnt signalling could be important in pancreatic 
cancer, I tested the expression of Wnts (Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, 
Wnt4, Wnt5a, Wnt5b and Wnt7b), the receptors (Frizzled1-10 and LRP5 and 6), 
nuclear transcription factors (TCF1, TCF3 and TCF4) and a well established 
target gene (Axin2), in pancreatic cancer cells and stellate cells by RT-PCR. 
Expression varied, but genes necessary for active Wnt signalling were expressed 
in pancreatic cancer cell lines as well as in pancreatic stellate cells (Figure 4.14, 
4.15). Of note is that there was a strong expression of Axin2 in Capan1, AsPc1, 
HPAF and PaCa3 cells, suggesting active, autocrine Wnt signalling (Figure 
4.15), and that some Wnts (Wnt1, 2 and 3) appeared to be downregulated in 
pancreatic stellate cells treated with ATRA (Figure 4.14).  
 
Although this initial screening gave me a general impression, in order to 
quantitatively analyse the degree of canonical Wnt/β-catenin signalling in 
pancreatic cancer cells, I used a β-catenin/TCF reporter, which has a TCF 
optimal consensus binding site multimer that confirms β-catenin responsiveness 
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to a luciferase reporter  (pTOPFlash)214. Data were analysed relative to 
pFOPFlash luciferase activity, which has 10 mutated, or “far from optimal”, TCF 
binding sites (to control for Wnt independent, basal activity of the reporter 
construct) and both pTOPFlash and pFOPFlash luciferase activity were 
normalised to an internal Renilla control (to control for transfection efficiency). 
Especially AsPc1, HPAF and Capan1 cells demonstrated significant pTOPFlash 
activity, with average TOP/FOP ratios of 13, 10 and 6.6, respectively; Wnt3a 
conditioned medium and/or 5 mM lithium chloride, an inhibitor of GSK3318, 
were used as positive controls. CFPAC and Panc1 demonstrated minimal activity 
(average TOP/FOP ratios of 2.4 and 1.7, respectively). The pTOPFlash luciferase 
activity of a colon cancer cell line carrying activating mutations in β-catenin, 
LS174T, however is roughly 200 times more than the luciferase activity in 
pancreatic cancer cells, which don’t harbour mutations in β-catenin or APC 
(Figure 4.16). 
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Figure 4.14 RT-PCR of Wnt ligands. 
Semi-quantitative RT-PCR, with the housekeeping gene GAPDH as loading control, to 
detect the expression of various Wnt ligands in PS1 cells treated with ethanol (C) or 
ATRA (P) and in pancreatic cancer cells. Cancer cells and stellate cells demonstrate a 
different expression pattern, with a decrease in expression of Wnt1, Wnt2 and Wnt3 by 
stellate cells treated with ATRA, as compared to vehicle control.  
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Figure 4.15 RT-PCR of receptors, transcription factors and target genes. 
Semi-quantitative RT-PCR, with the housekeeping gene GAPDH as loading control, to 
detect the expression of different Frizzled (Fz) and LRP (co)receptors, TCF transcription 
factors and Axin2 target gene in PS1 cells treated with ethanol (C) or ATRA (P) and in 
pancreatic cancer cells. Note the strong Axin2 expression in cancer cells. These data, 
combined with Figure 4.14, demonstrate active Wnt signalling in pancreatic cancer cells 
and stellate cells.  
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Figure 4.16 Pancreatic cancer cells demonstrate autocrine Wnt signalling. 
Pancreatic cancer cells demonstrate active Wnt/β-catenin signalling, as shown by the 
activation of the pTOPFlash reporter. Treatment for 48 hours with Wnt3A conditioned 
medium or 5 mM LiCl, used as positive controls, significantly enhanced the luciferase 
activity, i.e. Wnt signalling, in cancer cells. pTOPFlash (10 optimal TCF binding sites) 
luciferase activity is shown relative to pFOPFlash luciferase activity (10 mutated TCF 
binding sites), both normalised to an internal Renilla control, as mean ± SEM. *, p<0.05, 
Student’s t-test, 2-tailed, unequal variance.  
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4.3.3. Modulation of β-catenin expression in pancreatic cancer cells 
cultured on organotypic gels with pancreatic stellate cells treated 
with ATRA 
In keeping with the observations made in the submerged organotypic model 
(increased β-catenin expression in cancer cells in the presence of stellate cells), 
cancer cells co-cultured with PS1 stellate cells in vehicle-treated organotypic 
cultures demonstrated enhanced membranous, cytoplasmic and nuclear 
expression of β-catenin (Figure 4.17). In contrast, when the organotypic cultures 
were treated with ATRA this increased β-catenin expression reduced 
significantly and no nuclear β-catenin could be detected (Figure 4.17). 
Interestingly, the β-catenin expression in stellate cells did not change. Cancer 
cells cultured alone in organotypic culture expressed β-catenin moderately, 
which did not change upon ATRA treatment (data not shown).  
 
4.3.4. Effects of pancreatic stellate cells on Wnt-signalling in pancreatic 
cancer cells 
To analyse if this increase in nuclear β-catenin expression, and a decrease upon 
ATRA treatment, indeed was reflecting alterations in Wnt-signalling, AsPc1 and 
Capan1 cells transfected with the pTOPFlash (or pFOPFlash) reporter were 
exposed to either conditioned medium from stellate cells or to direct co-culture 
with PS1 stellate cells. Interestingly, conditioned medium from vehicle-treated or 
activated stellate cells (treatment for 7 days) significantly increased the 
pTOPFlash activity, which was reduced by treatment with conditioned medium 
from ATRA-treated, quiescent PSC (Figure 4.18). I was however unable to 
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detect similar changes when cancer cells and stellate cells were directly co-
cultured; in contrast, there seemed to be a trend towards a stimulatory effect of 
ATRA (Figure 4.18). This may be a reflection of the relatively small number of 
stellate cells, since, in order to maintain an interpretable transfection efficiency, I 
could not co-culture cancer cells and stellate cells at the same ratio as in the 
organotypic co-cultures (cancer cell:stellate cell ratio 2:1).  
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Figure 4.17 Expression of β-catenin in organotypic cultures treated with 
retinoic acid. 
Immunofluorescent staining for β-catenin demonstrates an overall decrease in β-catenin 
expression in the cancer cells upon exposure to ATRA as compared to vehicle-treated 
gels (only AsPc1 is shown, similar results were obtained with Capan1). Insets in top row 
are enlarged in bottom row, to demonstrate sub-cellular localisation. Nuclear β-catenin 
expression, shown by arrowheads, is noted only in the vehicle-treated gels. Arrows point 
to stellate cell layer. Scale bar, 10 µm. Only AsPc1 is illustrated, quantification of the 
number of nuclei with β-catenin localisation, for both cancer cell lines, is shown as 
median and raw data in graphs below; n = 45 fields across 6 gels for each condition. 
Mann-Whitney U-test; *, p<0.005.  
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Figure 4.18 Effects of pancreatic stellate cells on Wnt signalling in cancer 
cells. 
The autocrine Wnt/β-catenin signalling in cancer cells increased when cancer cells were 
exposed to conditioned medium (CM) from vehicle-treated PSC (C), which was reduced 
by treatment with conditioned medium from ATRA-treated PSC (P), as shown by the 
activation of the pTOPFlash reporter. Interestingly, direct co-culture of cancer cells with 
vehicle-treated (C) or ATRA-treated (P) stellate cells did not produce any significant 
effect. pTOPFlash luciferase activity is shown relative to pFOPFlash luciferase activity, 
both normalised to an internal Renilla control, as mean ± SEM. *, p<0.05, Student’s t-
test, 2-tailed, unequal variance.  
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4.4. Changes in expression of secreted frizzled-related protein 4 
(sFRP4) in response to ATRA treatment 
4.4.1. Background 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19 Secreted antagonists of the Wnt signalling pathway. 
Extracellular inhibitors of Wnt-signalling can be divided in two classes, those that can 
bind Wnts, thereby preventing Wnt-Frizzled interactions, and a Dickkopf (Dkk) class, 
which interacts with the LRP5/6 co-receptor. The first class includes secreted frizzled-
related proteins (sFRP) which contain a cysteine-rich domain (CRD) that shares 
homology with the CRD in the Frizzled receptors, Wnt-inhibitory factor 1 (WIF1) and 
Cerebrus (Cer). Since ligand binding of Frizzled receptors is required for both canonical 
and non-canonical Wnt-signalling, these inhibitors antagonise both pathways. In 
contrast, Dickkopf proteins form a complex with their receptor Kremen and LRP5/6, 
thereby initiating the endocytosis of the LRP5/6 receptor and making it unavailable for 
interaction with Frizzled receptors, required to induce canonical Wnt/β-catenin 
signalling. Non-canonical signalling is not dependent on the interaction between LRP5/6 
and Frizzled and therefore not inhibited by Dickkopf. 
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Wnt signalling can be inhibited by extracellular Wnt antagonists, which prevent 
ligand-receptor interactions by two different mechanisms. A first group of 
secreted antagonists include the secreted frizzled-related proteins (sFRPs), Wnt-
inhibitory factor 1 (WIF1) and Cerebrus, which bind directly to Wnts thereby 
preventing their interaction with the Fz receptor319. sFRPs contain a CRD 
(cysteine rich domain) sharing 30-50% sequence homology with the CRD of Fz 
proteins and can therefore antagonise Wnt signalling by capturing Wnt ligands as 
well as by forming nonfunctional complexes with Fz. Five sFRP family members 
have been identified, of which, on the basis of sequence homology, sFRP1, 
sFRP2 and sFRP5 form a subgroup as do sFRP3 and sFRP4320.  
 
A second class of secreted Wnt antagonists includes certain members of the 
Dickkopf (Dkk) family, a family comprised of 4 Dkk proteins (Dkk1-4) and a 
Dkk3 related protein named Soggy (Sgy). Dkk1 in particular acts as a Wnt 
inhibitor through binding to LRP5/6 and the single-pass transmembrane proteins 
Kremen1 and Kremen2321, 322. The complex of Dkk1, LRP5/6 and Kremen 
promotes the internalisation of LRP, making it unavailable for Wnt ligands323. 
Not all Dkk family members inhibit Wnt signalling; currently it is understood 
that Dkk4 is indistinguishable from Dkk1, Dkk3 and Sgy have no effect on Wnt 
signalling and the inhibitory function of Dkk2 depends on the presence of 
appropriate Kremen protein (inhibiting Wnt in presence of Kremen2, no effect in 
presence of Kremen1)324. As the non-canonical Wnt signalling pathways are not 
dependent on an interaction between LRP and Fz325, the Dkk proteins only 
inhibit the canonical Wnt pathway, whereas the sFRP class can inhibit both, 
canonical and non-canonical Wnt signalling (Figure 4.19).  
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4.4.2. sFRP4 expression by pancreatic stellate cells treated with ATRA 
The gene expression microarray documented a persistent and consistent increase, 
across all experimental conditions and time-points, in transcripts for secreted 
frizzled-related protein 4 (sFRP4), an important negative regulator of the Wnt/β-
catenin signalling pathway. Although a retinoic acid response element has not 
been identified in the sFRP4 gene, the increase in sFRP4 expression could be 
confirmed by RT-PCR and by quantitative real-time PCR (Figure 4.20A, B). 
Additionally, at protein level there was an increase in sFRP4 secretion in the 
supernatant of 2D treated stellate cells (mono-culture), as detected by Western 
blot analysis, with a protein 10 kDa larger than full cell lysates of the positive 
control (the human keratinocyte cell line HaCaT), suggesting post-translation 
glycosylation prior to secretion, a phenomenon reported previously326 (Figure 
4.21).  
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Figure 4.20 mRNA expression of sFRP4 by pancreatic stellate cells. 
(A) Semi-quantitative RT-PCR, with the housekeeping gene HPRT as loading control, 
demonstrates the expression of transcripts for secreted frizzled-related proteins by PSC 
(PS1) treated with ethanol (C) or ATRA (P) and by pancreatic cancer cells. The level of 
sFRP3 and sFRP4 expression was increased in PSC treated with ATRA, as compared to 
vehicle-treated PSC. (B) Real-time quantitative RT-PCR confirmed the enhanced sFRP4 
expression by stellate cells treated with ATRA, in all culture and treatment conditions 
analysed in gene expression microarray (C, vehicle control; P and M, culture on plastic 
(P) and Matrigel (M) treated with 1 µM; 10, cultured on plastic treated with 10 µM).  
 
 
 
 
 
 
 
 
 
Figure 4.21 Secreted sFRP4 in supernatant of pancreatic stellate cells.  
Western blots of the supernatants of PSC (mono-culture in 2D) demonstrate that, after 
treatment with 1 µM ATRA, there was a significant increase in the amount of sFRP4 in 
the supernatant medium, as compared to vehicle-treated PSC. The band observed was 10 
kDa higher than that for positive control (HaCat cell lysate) since the protein is 
glycosylated prior to secretion. C, control; P and M, culture on plastic (P) and Matrigel 
(M) at 1 µM ATRA; 10, plastic and 10 µM ATRA. Blot is representative of three such 
blots with quantification of densitometry of the bands shown in the graph as mean ± 
SEM. *, p<0.05, Student’s t-test, equal variance.  
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4.4.3. Impact of changes in sFRP4 expression on pancreatic cancer cell 
behaviour 
Immunofluorescence of non-permeabilised 2D cultures of cancer cells alone, 
demonstrated no sFRP4 expression; not even after treatment with ATRA. 
Contrastingly, in 2D co-cultures of stellate cells and cancer cells, sFRP4 was 
found on stellate cells, with an increase after treatment with ATRA, indicating 
that stellate cells were the source of sFRP4 (Figure 4.22). Interestingly, when co-
cultured in the 3D organotypic cultures and treated with ATRA, there was an 
increased sFRP4 expression on stellate cells as well as cancer cells compared to 
co-cultures treated with vehicle alone (Figure 4.23).  
 
To analyse any functional effects of the increased sFRP4 secretion, sFRP4 
expression in stellate cells was silenced using a pool of siRNA duplexes. A time-
course investigating the duration of efficient knockdown revealed that even 7 
days post transfection, there still was a significant inhibition of sFRP4 mRNA 
expression (Figure 4.24). Hence, stellate cells could be transfected and 
subsequently be treated for 7 days with ATRA or vehicle control followed by 
collection of supernatant for functional assays.  
 
Supernatant from stellate cells with silenced sFRP4 expression significantly 
increased the pTOPFlash luciferase activity in AsPc1 and Capan1 cancer cells, as 
compared with supernatant from stellate cells transfected with a pool of non-
targeting siRNA duplexes, suggesting that the observed alterations in Wnt 
signalling are, at least in part, mediated by an increased secretion of sFRP4 by 
quiescent stellate cells (Figure 4.25). Additionally, alterations in sFRP4 secretion 
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and Wnt/β-catenin signalling have significant biological consequences, since 
knockdown of sFRP4 increased the invasion of pancreatic cancer cells (Figure 
4.26).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22 sFRP4 expression in 2D cell cultures. 
Cancer cells (AsPc1 or Capan1) cultured alone in 2D and treated for 7 days with ATRA 
or vehicle control demonstrated no expression of sFRP4. However, on co-culture of 
AsPc1 or Capan1 cells with PS1 stellate cells, there was a marked upregulation of 
surface sFRP4 after treatment with ATRA. There was little expression of sFRP4 on 
cancer cells. These coverslips were stained on non-permeabilised cells, therefore the 
sFRP4 staining detects surface sFRP4. Scale bar, 50 µm. 
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Figure 4.23 sFRP4 expression in organotypic cultures. 
Isotype control (top left) and ethanol-treated AsPc1 and PS1 gels (bottom left) were 
negative for sFRP4. In contrast, ATRA-treated gels (middle top and bottom) 
demonstrated a positive staining for sFRP4 in both cancer cells and stellate cells 
(arrowheads). Respective insets are enlarged in the right top and bottom, respectively. 
The sections are not permeabilised and therefore sFRP4 staining is surface staining. 
Scale bar, 10 µm. 
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Figure 4.24 siRNA mediated silencing of sFRP4 expression. 
Quantitative real-time PCR demonstrates an increase in sFRP4 expression upon 
treatment with 1 µM ATRA (as seen in Figure 4.20), with a significant knockdown of 
sFRP4 mRNA expression when PSC are transfected with a pool of sFRP4 siRNA 
duplexes, as compared to a pool of non-targeting (NT) siRNA, and treated with either 
vehicle control or 1 µM ATRA for 2 or 7 days. Mean ± SEM; *, p<0.05, Student’s t-test, 
2-tailed, unequal variance. 
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Figure 4.25 Wnt signalling in cancer cells in response to sFRP4.  
Conditioned medium from ATRA-treated PSC with silenced sFRP4 expression 
significantly increased the pTOPFlash reporter activity in pancreatic cancer cells, as 
compared to conditioned medium from ATRA-treated PSC transfected with a pool of 
non-targeting (NT) siRNA. The induced pTOPFlash reporter activity by conditioned 
medium from vehicle-treated PSC transfected with NT siRNA was significantly reduced 
by treatment with conditioned medium from ATRA-treated PSC transfected with NT 
siRNA (internal control). PSC were transfected with siRNA and treated with 1 µM 
ATRA or vehicle control for 7 days; supernatant was collected and cells were lysed for 
analysis of sFRP4 expression by quantitative real-time PCR. pTOPFlash luciferase 
activity is shown relative to pFOPFlash luciferase activity, both normalised to an 
internal Renilla control, as mean ± SEM. *, p<0.05, Student’s t-test, 2-tailed, unequal 
variance.  
 
 
 
 
 
 
 
 
Figure 4.26 Invasion of cancer cells in response to sFRP4. 
Transwell invasion assays across Matrigel demonstrated a decreased invasion of cancer 
cells towards conditioned medium from ATRA-treated PSC, transfected with a pool of 
non-targeting (NT) siRNA, as compared to conditioned medium from vehicle-treated 
PSC. This reduction in invasion was abrogated when conditioned medium was used 
from PSC in which the sFRP4 expression was silenced by siRNA. Mean ± SEM; *, 
p<0.05, Student’s t-test, 2-tailed, unequal variance, all compared with ATRA-treated 
PSC, transfected with non-targeting siRNA. 
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4.4.4. sFRP4 and β-catenin expression in pancreatic cancer tissues 
As I observed a strong β-catenin expression associated with a low sFRP4 
expression in vehicle-treated organotypic co-cultures, compared to low β-catenin 
and high sFRP4 expression in ATRA-treated gels, I sought to determine if I 
could find a similar relationship in human tissue samples. Normal pancreatic 
ducts, centro-acinar cells and stellate cells demonstrated a strong staining of 
sFRP4, and interestingly, precisely those cell types had minimal β-catenin 
expression. Conversely, cancer and stromal cells demonstrated a strong β-catenin 
(membranous, cytoplasmic and nuclear) and a very weak sFRP4 staining in 
primary cancer as well as in sites of perineural invasion and lymph node 
metastasis (Figure 4.27). Hence, human tissue samples of normal and malignant 
pancreas confirmed the observations of the relationship between sFRP4 and β-
catenin differential expression.   
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Figure 4.27 β-Catenin and sFRP4 expression in patient samples.  
(A) In the normal pancreas β-catenin is expressed in the acinar cells (*) but not in PSC (S) or ducts (D). Cancer cells express β-catenin at the membrane, in 
the cytoplasm (arrowheads) and in the nucleus (arrows) in the primary tumour, during perineural (N) invasion and within lymph node (LN) metastasis. (B) In 
the normal pancreas, PSC (S), ductal cells (D) and centro-acinar cells (*) express sFRP4, which is absent in cancer tissues both in cancer cells as well as in 
stromal cells (in the primary tumour, during perineural (N) invasion and within the lymph node (LN) metastasis). Scale bar, 50 µm. 
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4.5. Discussion 
4.5.1. Rendering stellate cells quiescent with retinoic acid 
Stellate cells were rendered back into their quiescent phenotype by treatment 
with ATRA and, to a lesser extent 9-cis RA, but not by treatment with 13-cis 
RA. Two other studies have demonstrated similar effects when treating rat 
stellate cells with retinol or retinoic acid (9-cis RA and ATRA), albeit at higher 
doses217, 218. A third study reported an important role of albumin, which is 
endogenously expressed in quiescent PSCs, in the formation of vitamin A lipid 
droplets; treatment with 10 µM retinol could increase the albumin synthesis in 
activated PSCs and reduce the expression of αSMA, suggesting that PSC were 
rendered quiescent305. However, all these studies used either 10 µM ATRA or 10 
µM retinol (shown to have toxic effects in our study and a much higher 
concentration than the physiologically levels of circulating retinol, on average 
1.7 µM213, 302) and did not investigate the role that these quiescent stellate cells 
could subsequently have on pancreatic cancer cells.  
 
The direct effects of RA on pancreatic cancer cells have been studied for nearly 
two decades, demonstrating variable responses depending on RA isoform, the 
concentrations used and the pancreatic cancer cell line tested (Table 4.1)299, 300, 
327-331. The growth inhibitory effects of RA in pancreatic cancer have been 
attributed to an increase in apoptosis, either via altered expression of Bcl2 family 
members, activation of caspases330 and/or by upregulation of the tumour 
suppressor p53, possibly mediated via RA-induced expression of the chromatin 
modifying protein Chmp1A327. Moreover, RARβ, whose RARβ2 isoform is 
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considered to function as a tumour suppressor285, was aberrantly methylated in 
20% of pancreatic cancer tissues or cell lines332, with the loss of RARβ 
expression shown to be associated with the degree of cellular differentiation299.  
 
However, despite the overall conclusion that RA may inhibit pancreatic cancer 
growth and induce apoptosis in vitro and in vivo (xenograft models), a pilot 
phase II clinical trial treating patients with unresectable PDAC with gemcitabine 
and 13-cis RA did not reveal any improvement in response compared to 
treatment with gemcitabine alone333. Additionally, RAR antagonists have been 
suggested to decrease metastatic behaviour in pancreatic cancer, possibly via 
suppression of the RA-responsive expression of the metastasis promoting 
microRNA-10A334. Although the pancreatic cancer cell lines I used in my 
studies, AsPc1 and Capan1, have been shown to express all RAR and RXR 
isoforms300, 331, I did not observe any effect of 1 µM ATRA when cancer cells 
were cultured alone in the, physiologically relevant, organotypic cultures, 
confirming the important role of the tumour microenvironment and pancreatic 
stellate cells; a characteristic that all other studies to the effects of RA on 
pancreatic cancer cell behaviour did not take into account. Interestingly, when 
cancer cells were cultured in 2D (monoculture) and treated with 1 µM ATRA 
they were driven into a more proliferative state, as shown by an increase in the 
G2/M phase of the cell-cycle (Figure 4.28). It should also be noted that 13-cis 
RA, the only RA isoform tested in a clinical setting for treatment of pancreatic 
cancer, did not induce quiescence in pancreatic stellate cells, which may explain 
the failure of this isoform in pancreatic cancer therapy333.  
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Figure 4.28 Effects of RA-treatment on cancer cells cultured in 2D. 
Cell-cycle analysis of AsPc1 and Capan1 cancer cells treated with 1 µM ATRA 
demonstrated the opposite effects as those seen in pancreatic stellate cells (Figure 4.4 
and 5.1); both cancer cell lines seemed to be driven into mitosis upon ATRA treatment, 
as shown by a shift to the G2/M phase of the cell-cycle. C, vehicle control; P, cultured 
on plastic and treated with 1 µM ATRA. Histograms are representative of data from 3 
biological repeats each containing at least 3 technical replicates. Mean ± SEM; *, 
p<0.05, Student’s t-test, 2-tailed, unequal variance.  
Data provided by Mr Hemant M Kocher. 
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These different responses of cancer cells and stellate cells to RA highlight the 
complexity of RA signalling. RA can modulate transcription either through 
retinoic acid response elements (RARE) or by interaction with other signalling 
pathways, including retinoid-receptor mediated transrepression of AP1 
(activating-protein 1) and activation of TRAIL (tumour necrosis factor-related 
apoptosis-inducing ligand) receptor signalling, via transcriptional activation of 
interferon regulatory factor-1 (IRF1)285, 335. In fact, the synergistic effects of RA 
signalling and the interferon pathway have been tested in many clinical studies to 
date and have been shown to improve survival rates in patients with lymphoid 
malignancies336 and various solid tumours, including prostate cancer337, 
squamous cell carcinoma of head and neck301 and renal cell carcinoma338, albeit 
in many situations the (sometimes modest) effects were accompanied by a high 
degree of toxicity.  
 
Based on preclinical observations that 13-cis RA and interferon-α (IFNα) exerted 
anti-proliferative effects on pancreatic cancer cells, a pilot phase II clinical trial 
of a combination therapy of 13-cis RA and IFNα in patients with advanced 
pancreatic carcinoma, yielded some promising median survival rates, with 
approximately 65% of patients demonstrating stable disease for at least 5 
months, irrespective of tumour stage339. However, the subsequent clinical trial 
testing 13-cis RA in combination with gemcitabine did not reveal any merit in 
the addition of 13-cis RA333. In contrast, recent studies have shown that RA 
signalling and IFNγ synergistically induce the expression of mucin 4 (MUC4), a 
large transmembrane glycoprotein which is aberrantly expressed in pancreatic 
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cancer, mediated in part via RA-induced expression of TGFβ and upregulation of 
signal transducer and activator of transcription 1 (STAT1) by IFNγ340. 
 
In addition to RAR, RA has also been shown to bind the peroxisome proliferator-
activated receptor (PPAR) isotype PPARβ/δ, which, like RAR, forms a 
heterodimer with RXR but activates the transcription of a distinct set of genes 
mediating anti-apoptotic and pro-proliferation processes298. Elegant work by 
Noy and co-workers has demonstrated that the opposing effects of ATRA on cell 
growth (inhibition or promotion of cell proliferation/survival) result from the 
activation of either RAR or PPARβ/δ, controlled by the ratio of cytoplasmic RA 
binding protein II (CRABP-II) and fatty-acid binding protein 5 (FABP5) in the 
cytoplasm341. Upon binding of RA, CRABP-II translocates to the nucleus and 
delivers RA to RAR, whereas FABP5 targets RA to PPARβ/δ. Since the binding 
affinity of the CRABP-II/RAR pathway for RA exceeds that of the FABP5/ 
PPARβ/δ route, RA signalling through RAR will predominate in most cells with 
the activation of PPARβ/δ occurring only in cells that exhibit a low CRABP-
II/FABP5 ratio. Accordingly, tumour development in a RA-resistant mouse 
model of breast cancer was accompanied by a decreased CRABP-II/FABP5 ratio 
and RA induced PPARβ/δ signalling, which could be diverted to RAR mediated 
signalling and reduced tumour growth by increasing the CRABP-II/FABP5 
ratio342. Signalling through PPARβ/δ and alterations in CRABP-II/FABP5 ratio 
may, in part, explain the increase in the G2/M phase of the cell-cycle that I 
observe when cancer cells cultured in 2D were exposed to 1 µM ATRA, with a 
switch to RAR signalling if cultured in the presence of quiescent stellate cells in 
a 3D environment.  
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In summary, differential expression of the retinoic acid and retinoid X receptors, 
with different RARE and non-RARE mediated transcriptional regulation, may 
help explain the diverse phenotypic responses in pancreatic cancer cells 
(inhibition versus stimulation of proliferation)327, 330, 333, 334, pancreatic stellate 
cells (different expression levels of αSMA)217, 218, hepatic stellate cells (different 
effects of 9-cis RA, ATRA and RAR or RXR agonists on hepatic stellate cell 
proliferation and collagen secretion)343 or in pancreatic embryonic development 
(suppression versus promotion of exocrine differentiation)292, 344; an overview of 
the various effects of retinoic acid is given in Table 4.1. 
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Table 4.2 Diverse effects of retinoic acid 
Cell type tested Treatment Effects Reference 
PDAC cells (Capan1, 
Capan2, Panc1) ATRA (5-10 µM) 
More differentiated phenotype, growth inhibition in vitro and in vivo (subcutaneous xenografts in 
nude mice) Rosewicz 1995
300 
PDAC cells (AsPc1, 
Capan2) ATRA (5-10 µM) 
Dose-dependent stimulation of anchorage independent growth in AsPcl cells and growth 
inhibition in Capan2 cells, with differential expression of PKCα (increased expression in AsPc1, 
decreased expression in Capan2) 
Rosewicz 1996331 
PDAC cells (T3M4, 
BxPc3, AsPc1, A818-4) 0.5 µM 9-cis RA 
Increased apoptosis in BxPc3, T3M4 and AsPc1, but not A818-4, with a decrease in the  
Bcl2/Bax ratio Pettersson 2002
330 
PDAC cells (Panc1, 
KP2) 
9-cis RA or ACR 
(both 0.1-100 µM) 
and gemcitabine  
Growth inhibition and increased apoptosis, synergistically with gemcitabine, in vitro and in vivo 
(subcutaneous xenografts in nude mice) Nakagawa 2009
328 
PDAC cells (Panc1, 
Capan2) ATRA (20 µM) Growth inhibition, possibly mediated via increased expression of Chmp1A and p53 Li 2009
327 
PDAC cells (PaTu8988S 
and PaTu8988T) 
RARα antagonist  
Ro-41-5253 (0.2 µM) 
and ATRA (1 µM) 
ATRA induced miRNA-10A expression, RARα antagonist reduced miRNA-10A expression and 
inhibited migration, invasion and metastasis in vitro and in vivo (zebrafish xenotransplantation 
model) 
Weiss 2009334 
PDAC cells 
(CD18/HPAF-SF) 
Combination IFNγ 
(0-50 ng/ml) and 
ATRA (0-100 nM) 
Increased MUC4 expression (mRNA and protein expression in vitro) 
Andrianifahanana 
2005340 
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Rat PSCs ATRA (1-10 µM) Decreased proliferation, diminished collagen production, no changes in αSMA expression, 
transrepression of AP1 Jaster 2003
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Rat PSCs Retinol, ATRA, and 9-cis RA (all 10 µM) 
Decreased cell proliferation, reduced expression of collagen type I, fibronectin, laminin and 
αSMA, decreased phosphorylation of all three classes of MAPKs (ERK1/2, JNK and p38 kinase) McCarroll 2006
218 
Rat PSCs Retinol (10 µM) Cytoplasmic lipid droplets, increased albumin synthesis, reduced αSMA expression Kim 2009305 
    
E11.5 mouse whole 
pancreas or isolated 
pancreatic epithelia 
9-cis RA (1 nM -  
1 µM), diverse RAR 
and RXR agonists 
and antagonists 
Dose dependent inhibition of acinar cell differentiation (decrease in amylase-positive cells) with 
increased ductal differentiation and no effect on insulin-positive cells, mediated through RARα 
signalling and upregulation of laminin; ductal differentiation was not induced in absence of 
mesenchyme 
Kobayashi 2002292 
Dorsal buds from E11.5 
mouse embryos ATRA (0.1-1 µM) 
Dose dependent inhibition of exocrine differentiation (decrease in amylase-positive cells), with 
increased formation of islet-like structures and suppressed branching morphogenesis (1 µM 
ATRA), possibly due to early upregulation of Pdx1 in the endocrine cell clusters, increased 
laminin expression and enhanced apoptosis of acinar cells 
Shen 2007344 
    
Embryoid bodies  
(3D cell clusters formed 
by culture of mouse 
embryonic stem cells in 
suspension) 
ATRA (1 µM) Upregulation of p48 and elastase; mRNA expression of insulin and Pdx1 was not affected  Skoudy 2004297 
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Human embryonic  
stem cells ATRA (2 µM) 
RA signalling combined with BMP and Hedgehog antagonism and late induction of FGF 
signalling resulted in pancreatic cell differentiation, as shown by a high expression of FOXA2 
and Pdx1 with very low expression of markers for hepatocyte differentiation (albumin and AFP) 
Mfopou 2010296 
    
Clinical trial in patients 
with advanced, 
unresectable PDAC 
13-cis RA with IFNα 22 patients included, combination therapy with 13-cis RA and IFNα was well tolerated, 
approximately 60% of patients demonstrated stable disease with a median duration of 5 months Brembeck 1998
339 
Clinical trial in patients 
with advanced, 
unresectable PDAC 
13-cis RA with 
gemcitabine 
30 patients included, co-treatment with 13-cis RA and gemcitabine was well tolerated, but with 
response rates and median survival equivalent to single-agent gemcitabine treatment, the activity 
was limited 
Michael 2007333 
 
Table 4.2 Diverse effects of retinoic acid. 
The response to RA (retinoic acid) by pancreatic ductal adenocarcinoma (PDAC) cells, pancreatic stellate cells (PSCs), during pancreas development and by 
patients in clinical trials is variable dependent on study type. It should be noted that many studies have investigated the role of RA signalling in pancreatic 
cancer or pancreas development, with this table only highlighting a few reports to demonstrate the different and multiple effects of RA. ACR, acyclic retinoid 
(synthetic retinoid); IFN, interferon; PKC, protein kinase C; MUC, mucin; AP1, activating-protein 1; MAPK, mitogen activated protein kinase; ERK1/2, 
extracellular regulated kinases 1 and 2; JNK, c-Jun N terminal kinase; BMP, bone morphogenetic protein; FGF, or fibroblast growth factor; FOXA2, forkhead 
box A2, AFP, alpha-fetoprotein.    
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4.5.2. Changes evoked in pancreatic cancer cells by stellate cells treated 
with ATRA 
4.5.2.1. Morphological, proliferative and invasive behaviour of cancer cells 
Rendering stellate cells quiescent with 1 µM ATRA had significant anti-tumour 
effects by reducing the proliferation and increasing the apoptosis of cancer cells 
as well as changing the pattern and degree of invasion into extracellular matrix 
gels (Figure 4.10 – 4.13).  Of note is the observation that rendering stellate cells 
quiescent can have detrimental effects on tumour cells, may have a much broader 
application than pancreatic cancer only, since stellate cells have been 
demonstrated in other organs as part of a diffuse stellate cell system100. For 
hepatic and pancreatic stellate cells it already has been shown that they bear 
many genomic and phenotypic similarities; thus if effective targeting of stellate 
cells in one organ were possible, such a strategy could be extrapolated to other 
organ systems and diseases99. 
 
4.5.2.2. Modulation of Wnt/β-catenin signalling 
There are numerous plausible mechanisms for the cross-talk between the cancer 
cells being modulated by RA, however, previous observations in organotypic 
cultures (Chapter III) and results of gene expression profiling led me to 
investigate the Wnt/β-catenin signalling pathway. Upon ATRA treatment, total 
(membranous, cytoplasmic and nuclear) β-catenin expression decreased 
significantly in cancer cells with a concurrent increased expression of sFRP4.  
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Although mutations in β-catenin or APC typically are absent in pancreatic ductal 
adenocarcinoma, recent studies have shown that altered Wnt signalling may be 
important in pancreatic cancer40, 43, 176, 192, 303, 345. Embryological signalling 
pathways, including FGF, Hedgehog, Notch and Wnt signalling, commonly are 
reactivated or deregulated in cancer in general, and in pancreatic cancer 
specifically8, 40, 268. Therefore pancreatic developmental studies can give 
valuable insights into the pathogenesis of pancreatic cancer, and the role of Wnt 
signalling herein.  
 
Wnt ligands (Wnt2b, 5a, 5b, 7b and 11), Frizzled receptors (Frizzled2 – 9) and 
sFRPs (sFRP1 – 4) have been shown to be expressed in the developing pancreas 
in a spatial and temporal manner; Wnts were expressed mainly in the pancreatic 
mesenchyme, with a decrease in expression between E15 and E17, when the 
amount of mesenchyme decreases, Frizzled receptors and sFRPs were expressed 
in both epithelial and mesenchymal compartments346. In early pancreas 
development, hyperactivation of Wnt signalling prevents pancreas 
organogenesis. Expression of Wnt1 and Wnt5a, driven by the Pdx1 promoter346, 
and expression of mutated, activated β-catenin in Pdx-creearly mice192 (see more 
detailed description below) result in pancreatic agenesis or severe hypoplasia. 
Later in pancreas development, when the pancreatic epithelium branches in the 
surrounding mesenchyme, Wnt/β-catenin signalling has been indicated with 
pancreas growth and proliferation of pancreatic progenitors192, 193. Four loss of 
function studies, using different Pdx-Cre deletor mice driving the expression of 
either dominant-negative Frizzled 8 receptor347 or deleting the β-catenin gene, 
CTNNB1348-350, resulted in different phenotypes. Whereas in one model 
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conditional β-catenin deletion resulted in a reduction in endocrine cell numbers 
without a change in gross morphology349, the other three models with either 
conditional knockout of β-catenin348, 350 or a partially blocked canonical Wnt-
signalling via a dominant-negative Frizzled 8 receptor347, reported pancreatic 
hypoplasia mainly affecting the exocrine pancreas. The most likely explanation 
for this discrepancy is the use of different mice strains, all mediating Cre-
recombination under control of the Pdx promoter but generated with different 
promoter fragments resulting in different Cre-recombinase activity; the 
importance of which has elegantly been shown by the Hebrok laboratory176, 192, 
194. 
 
Using 2 transgenic mice that both express Cre-recombinase under control of the 
Pdx-promoter but with a different temporal and spatial activity, Heiser et al 
demonstrated that robust β-catenin expression during early organogenesis, in all 
three pancreatic lineages (driven by “Pdx-Creearly”), resulted in a severe reduction 
of pancreas mass. In contrast, inducing the stabilised form of β-catenin at a later 
time of pancreas development by using a “Pdx-Crelate” driver line with a more 
mosaic Cre-activity, which was restricted to acinar and endocrine cells, led to 
outgrowth of pancreatic tissue and increase in organ size, mainly due to 
increased proliferation of acinar cells, but without pancreatic tumour formation 
in mice up to 1 year of age (Table 1.3)192. Postnatal pancreatomegaly, with 
increased acinar proliferation, also was seen in mice with Pdx-Crelate mediated 
deletion of APC, the crucial member of the destruction complex, and thus with 
stabilised β-catenin and enhanced Wnt/β-catenin signalling, possibly due to 
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increased expression of the Wnt-target gene C-MYC; yet also these mice did not 
develop any tumours by 1 year of age193.  
 
Since in these studies mainly acinar cells were affected, a subsequent study 
aiming to induce stabilised β-catenin expression in duct progenitors, investigated 
the expression of phosphorylated β-catenin under control of the p48 promoter. 
This resulted in the development of “ductal associated lesions” at birth and large, 
well encapsulated tumours resembling human solid pseudopapillary neoplasm 
(SPN) of the pancreas by the age of 3 months (Table 1.3)176. Interestingly, when 
these mice were crossed with KRASG12D mice to analyse the effects of aberrant 
KRAS activation in the context of active β-catenin signalling, the pancreata of 
p48-Cre;CTNNB1exon3 fl/+;LSL-KRASG12D mice were smaller, as compared with 
p48-Cre;CTNNB1exon3 fl/+ or p48-Cre;KRASG12D littermates, with lesions 
suggestive of acinar to ductal metaplasia, a strong desmoplastic reaction and 
tumours similar to rare human intraductal tubular tumours; no PanIN lesions 
were noticed176. Hence, Wnt/β-catenin signalling is important for exocrine cell 
proliferation and can induce transformation but, unlike other cancers such as 
colon cancer, does not seem to be able to initiate pancreatic ductal 
adenocarcinoma; in contrast, simultaneous activation of the β-catenin and KRAS 
signalling pathways in the developing pancreas seemed to block the development 
of PanIN lesions.  
 
Further evidence for an important role of Wnt/β-catenin signalling in acinar-
ductal metaplasia and progression to PanIN and PDAC was shown in a third 
study by the Hebrok laboratory, investigating the mechanisms that allow 
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oncogenic KRAS to drive acinar to ductal metaplasia and PanIN formation194, as 
shown by Guerra et al.190 and Habbe et al.191 (see paragraph 1.6.2 and Table 
1.3), among others8. Using an acute, caerulein pancreatitis model with oncogenic 
KRAS driven by the Pdx or p48 promoter as well as by an inducible Elastase-
ERT2Tg/+ promoter (to confirm the acinar source of ductal lesions), it was shown 
that upon pancreatic injury, acinar cells transiently obtained a ductal phenotype 
with upregulation of developmental signalling pathways including Pdx1, Notch 
signalling and Wnt/β-catenin signalling. However, in the presence of mutant 
KRAS, this transition to a ductal phenotype became fixed, with persistent 
expression of the marker of ductal differentiation CK19 and embryonic markers 
such as Pdx1 and Notch, but with a weak expression of β-catenin, resulting in the 
rapid development of PanIN lesions194. Wnt/β-catenin signalling seemed to be a 
crucial regulator of acinar regeneration with activated β-catenin signalling in the 
normal, transient de-differentiation of acinar cells or a blocked β-catenin 
signalling in persistent ductal reprogramming and PanIN formation. Moreover, 
similar to earlier findings176, increased β-catenin signalling could antagonise the 
ability of KRAS to reprogramme acini into ductal metaplasia with PanIN 
lesions194. However, in contrast to the weak expression in damaged exocrine 
tissue of mice with mutated KRAS (2 days after caerulein treatment), the 
developed PanIN lesions demonstrated a strong increase in membranous and 
cytoplasmic β-catenin expression, with upregulation of target genes (3 weeks 
after caerulein treatment), suggesting a role for Wnt/β-catenin signalling in 
supporting pancreatic cancer maintenance; which is confirming additional 
studies with human tumours and pancreatic cancer cell lines (discussed below)40, 
43, 303, 345.  
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Hence, Wnt/β-catenin signalling, shown to be involved in epithelial-
mesenchymal interactions in many developing organs351, also has multiple 
important roles in pancreas development, where strict temporal regulation is 
essential for cell differentiation, tissue morphogenesis and function352. This 
tuned, temporal expression is also important for the development of pancreatic 
cancer, in which the opposing roles of β-catenin signalling in PanIN initiation 
versus PDAC maintenance or progression may be mediated via reactivation of 
other developmental signalling pathways such as Notch or Hedgehog signalling8.  
 
Supporting evidence for deregulation of Wnt-signalling in pancreatic cancer has 
come from detailed genetic analysis of 24 pancreatic cancer samples, which were 
sequenced and analysed for homozygous deletions and amplifications. All 
mutations could be classified in a set of 12 core signalling pathways and 
processes, including the Wnt signalling pathway, which was altered in all tumour 
samples analysed40. Additionally, analysis of 136 human PDAC samples 
revealed up to 13% of patients with a nuclear localisation of β-catenin and 65% 
with cytoplasmic expression of β-catenin, a percentage slightly higher than the 
35.2% I observed when analysing 51 patient samples (Figure 3.12, Table 3.3). 
Functional evidence of a role for aberrant Wnt/β-catenin signalling in pancreatic 
cancer was shown via the inhibition of activated Wnt/β-catenin signalling in 
human pancreatic cancer cells by the endogenous Wnt inhibitor Icat, by a 
dominant-negative form of LEF1 or by siRNA directed against β-catenin, which 
resulted in a decrease in proliferation (measured by BrdU incorporation) and 
enhanced apoptosis (measured as numbers of fragmented nuclei as well as by 
FACS using an anti-cleaved caspase-3 antibody) of pancreatic cancer cells43.  
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Another gene recently shown to be associated with pancreatic cancer and 
stabilisation of β-catenin is the ataxia-telangiectasia group D complementing 
(ATDC) gene, whose overexpression, due to unexplained mechanisms, led to 
increased Wnt/β-catenin signalling in pancreatic cancer via its interaction with 
Dishevelled303. In addition to activation of Wnt/β-catenin through inhibition of 
the destruction complex303, activation downstream of Hedgehog signalling has 
been reported43, 176, 192 as well as activation via cues from the stroma345, 353, 354. 
Autocrine Wnt signalling has recently also been reported in breast, ovarian353 
and multiple myeloma cells354, in which it has been shown to be regulated at the 
level of interaction with cell surface receptors via signals from the tumour 
microenvironment. This may be mediated by extracellular sulphatases, shown to 
be upregulated in pancreatic cancer and modulate interactions of Wnts with cell 
surface receptors via heparan sulphate proteoglycans345. Alternatively, and more 
relevant in my studies, stromal cells could be a source of Wnt ligands354 or 
demonstrate an altered expression pattern of secreted inhibitors of the Wnt 
pathway. I show that stellate cells secrete sFRP4, a capacity that they lose upon 
activation in a cancer microenvironment but which can be restored by rendering 
stellate cells quiescent (Figure 4.20, 4.21). The increased expression of sFRP4 by 
quiescent stellate cells results in a decrease in Wnt-signalling, which was 
confirmed by siRNA mediated knockdown of sFRP4 (Figure 4.25). Moreover, 
altered expression of Wnts by activated stellate cells could also play a role in the 
increased Wnt signalling observed in pancreatic cancer cells, since the initial RT-
PCR results suggested a possible decrease in the expression of various Wnts by 
quiescent, ATRA-treated stellate cells (Figure 4.14).  
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Surprisingly, the detected increase in pTOPFlash activity upon treatment with 
conditioned medium from vehicle-treated stellate cells, and a decrease if 
conditioned medium from ATRA-treated stellate cells was used, could not be 
seen when cancer cells and stellate cells were co-cultured in a 24-well plate. 
When cancer cells and stellate cells were cultured in different ratios on top of 
organotypic gels, β-catenin expression in cancer cells increased in conjunction 
with the increase of stellate cells (observations by Dr Raghu Kadaba). However, 
due to experimental difficulties, in particular very low transfection efficiency of 
the pTOPFlash reporter constructs in cancer cells upon co-culture and high cell 
densities, I was not able to co-culture cancer cells and stellate cells at the same 
ratio as in the organotypic cultures (cancer cells:stellate cells 2:1). The 
pTOPFlash activity in cancer cells co-cultured with stellate cells as shown in 
Figure 4.18 was with a cancer cell:stellate cell ratio of 10:1, a ratio that 
demonstrated minimal alterations in β-catenin expression in organotypic co-
cultures. Additionally, it has recently been reported that cells don’t respond to 
absolute levels of β-catenin but to changes in the fold-change of β-catenin, 
defined as the ratio of β-catenin level after and before Wnt stimulation, with a 
certain region in which they can withstand naturally occurring variation355. This 
may suggest that when cancer cells and stellate cells were co-cultured in order to 
analyse the effects on the pTOPFlash activity in cancer cells, the used cancer 
cell:stellate cell ratio of 10:1 could not alter the fold-change of β-catenin above a 
certain threshold and therefore not alter downstream transcription.  
Of interest is that the gene expression microarray also demonstrated a significant 
downregulation of another secreted Wnt antagonist, Dickkopf-1 (Dkk1), in 
quiescent ATRA-treated pancreatic stellate cells, which was confirmed by 
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quantitative real-time PCR (Figure 4.8). Although mostly known for its 
inhibition of Wnt-signalling through direct binding to LRP5/6321-323, Dkk1 
expression has been reported to be upregulated in pancreatic cancer, in which it 
was associated with invasive activity of pancreatic cancer cells356. The role of 
Dkk1 in pancreatic cancer, and the implication of the decreased expression by 
stellate cells treated with ATRA, will need to be further elaborated. The awaited 
results from the proteomic analyses of the secretome of stellate cells treated with 
vehicle control and ATRA may shed some more light on this initial observation.  
 
4.5.2.3. Alterations in sFRP4 expression 
One of the mechanisms resulting in the increase in Wnt-signalling in cancer cells 
in the presence of stellate cells, which can be reduced by rendering stellate cells 
back into their quiescent phenotype with retinoic acid, is shown to be the 
different sFRP4 expression by activated versus quiescent stellate cells. The RA-
mediated upregulation of sFRP4 expression, which has been reported in one 
previous study in human embryonal carcinoma cells treated with 10 µM 
ATRA357, is most likely an indirect effect, since to date no retinoic acid response 
element has been identified in the sFRP4 gene.  
 
Based on their ability to block Wnt signalling, either by direct interaction with 
secreted Wnts or by forming non-functional complexes with the transmembrane 
Frizzled receptors, sFRPs have been postulated to act as tumour suppressors319. 
In keeping with this hypothesis, loss or downregulation of sFRP expression, 
either due to epigenetic silencing (sFRP1, sFRP2, sFRP4 and sFRP5 have dense 
CpG islands that flank their first exon) or deletion and loss of heterozygosity (in 
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particular sFRP1 and 3 loci), can be seen in a variety of malignancies, including 
breast cancer358, prostate cancer359, hepatocellular carcinoma360, colon cancer361, 
362 as well as in pancreatic cancer363. Even in the presence of downstream 
mutations in APC, restoration of sFRP expression in colon cancer cells resulted 
in reduced Wnt signalling362. sFRP4 expression in particular has been associated 
with a decrease in endothelial cell migration and tumour vascularity in a 
subcutaneous mouse model of ovarian serous cystadenocarcinoma364, high 
membranous sFRP4 expression was associated with improved survival of 
patients with prostate cancer326 and in a study investigating the methylation 
status of sFRP genes in 60 human pancreatic cancer tissues, sFRP4 was 
methylated in 60% of tissues, as compared to 10% in ‘normal’ adjacent tumour 
tissue363.  
 
On the other hand however, sFRPs have been associated with tumour growth as 
well as with stimulation of Wnt signalling365. Although initially identified 
through their sequence similarity with Frizzled receptors366, a separate study, 
published the same year, reported two secreted apoptosis-related proteins, 
SARP1 and SARP2, which were identical to sFRP2 and sFRP1, respectively367. 
Interestingly, sFRP1 and sFRP2 demonstrated opposing functions on MCF7 
breast cancer cells, with sFRP1 stimulating cell death and decreasing levels of 
cytoplasmic β-catenin, whereas sFRP2 overexpressing cells demonstrated an 
increase in cytoplasmic β-catenin and enhanced resistance to apoptosis367. 
Hence, it is possible that sFRPs can stimulate tumour growth, most likely via 
effects in apoptosis, and stimulate Wnt signalling as well, possibly by different 
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sFRPs neutralising one another’s activity or by forming a heteromeric complex 
with Wnts and Frizzled receptor that promotes signal transduction365.  
 
In contrast with the tumour suppressive role of sFRP4 that I report, sFRP4 was 
first reported to be upregulated in the stroma of endometrial and breast 
carcinoma, with only stromal cells, and not epithelial cells, expressing sFRP4368. 
Later, the observation that sFRP4 was consistently overexpressed in tumours 
associated with osteomalacia, has revealed that sFRP4 plays an important role in 
the regulation of inorganic phosphate (Pi)369.  Infusion  of  sFRP4 in the rat 
resulted in reduced surface expression of Na+-Pi cotransporter in proximal 
tubules, thereby inhibiting renal re-absorption of Pi, with an increase in renal β-
catenin phosphorylation, and blocked the compensatory increase in vitamin D 
synthesis, necessary for intestinal absorption369.  
 
In addition to a role in bone homeostasis, sFRP4, along with other sFRPs, has 
been reported to have a role in modulating fibrosis and the extracellular matrix. 
In a rat model of ischaemic heart injury, sFRP4 treatment resulted in hearts with 
significantly less fibrosis and thicker walls370. In contrast, sFRP2 has been 
shown to increase cardiac fibrosis by enhancing procollagen C-proteinase 
activity of Tolloid-like metalloproteinases, which cleaves the C-propeptide from 
procollagen before mature triple-helical collagen molecules can be released into 
the extracellular matrix371. Additionally, sFRP5 has recently been shown to 
control the microenvironment of white adipose tissue in conditions of metabolic 
stress by neutralising non-canonical JNK (c-Jun N-terminal kinase) activation by 
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Wnt5a in macrophages and adipocytes, resulting in a decrease in macrophage-
mediated inflammation372.  
 
In summary, the precise mechanisms by which sFRPs influence tumour growth, 
cell proliferation or apoptosis remain poorly understood. The different and 
contradictory effects might reflect the presence of a different repertoire of Wnts, 
different affinities of sFRPs for Wnts, relative concentration of sFRPs, structural 
differences within the sFRP family or tissue specific responses to growth or 
apoptotic signals. In addition, it is becoming increasingly clear that sFRPs can 
bind to different signalling molecules, unrelated to Wnt signalling, such as 
fibronectin, receptor activator for nuclear factor kappa B ligand (RANKL) and 
BMP1/Tolloid metalloproteinases320, 365.  
 
The observations however, that I could confirm an inverse relationship of β-
catenin and sFRP4 expression in organotypic cultures as well as human 
pancreatic tissues and was able to reverse the inhibitory effects of ATRA-treated 
stellate cells with siRNA against sFRP4, suggest that sFRP4 plays an important 
role in mediating Wnt signalling and cancer cell invasion in pancreatic cancer. 
Additional studies to the exact mechanisms of downregulation of sFRP4 
expression in pancreatic cancer stroma/activated pancreatic stellate cells, as well 
as a better understanding of functions of sFRPs and different Wnts involved, 
would further illuminate the role of sFRP4 in pancreatic cancer.  
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4.6. Conclusion 
Retinoic acid induces quiescence in stellate cells, which indirectly can modulate 
the morphology and behaviour of co-cultured cancer cells. The model in Figure 
4.29 illustrates the key findings of the cross-talk between pancreatic stellate cells 
and cancer cells, modulating the Wnt/β-catenin pathway in pancreatic cancer 
cells, their invasion and the role of retinoic acid herein. The observations are 
consistent with the often cited, but unproven, hypothesis that modulation of 
stroma can be of benefit in cancer treatment. Selective targeting of stromal cells, 
by inhibiting pathways such as the Hedgehog pathway, has been shown to be 
therapeutically beneficial in genetically engineered mouse models91. However 
this benefit was transient, with tumours developing resistance by bypassing 
inhibition of a single pathway. ATRA holds the promise of restoring PSC 
quiescence and their normal physiological activity. Thus the quiescent stellate 
cells may influence tumour behaviour via affecting multiple signalling cascades 
in the tumour-stroma cross-talk, including Wnt/β-catenin signalling which I have 
studied. This could be most relevant in cancers with an intense desmoplastic 
reaction, such as pancreatic cancer; a tumour highly resistant to conventional 
chemotherapy. 
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Figure 4.29 Summary model. 
In normal pancreas, stellate cells have a key homeostatic role on ductal as well as 
centro-acinar (and perhaps acinar) cells via secretion of paracrine factors including 
sFRP4. In cancer, there is abnormal proliferation of cancer cells as well as activation and 
proliferation of stellate cells. Cancer cells follow tracts laid down by activated stellate 
cells within the stroma. Absence of sFRP4 secretion by stellate cells in a cancer 
microenvironment increases the β-catenin expression in the cancer cells in all sub-
cellular compartments: cell membrane, cytoplasm and nucleus, resulting in enhanced 
Wnt/β-catenin signalling. ATRA-induced quiescence of stellate cells produces not only 
alteration of matrix composition but also restores sFRP4 secretion, which, along with 
changes in expression of other cytokines, results in a decrease in proliferation, increase 
in apoptosis and decreased β-catenin in all sub-cellular compartments leading to reduced 
Wnt/β-catenin signalling. In addition there is a change in morphology of cancer cells 
with fewer invasive events and trapping of cancer cells in a wall of stellate cells. 
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4.7. Future challenges 
Although the organotypic culture models provide a physiologically relevant 
means to study tumour-stroma interactions, and the modulation thereof with 
potentially new therapeutic agents, they are still a simplified representation of the 
complex in vivo situation. With the generation of mice that express mutant KRAS 
and TP53 alleles in pancreatic cells, Tuveson and colleagues have created an 
excellent mouse model of pancreatic cancer184. These so called “KPC” mice 
develop tumours with strong similarities to human PDAC, including the 
progression from PanIN lesions to invasive cancers with a ductal morphology 
and a strong desmoplastic stroma. Hence, the next step, before a clinical trial, 
will be to test the therapeutic potential of ATRA in pancreatic cancer by treating 
these KPC mice with ATRA or with ATRA combined with gemcitabine. The 
additional results will give a reliable prediction of the clinical response and 
possibly identify ATRA as a new therapeutic strategy for patients with pancreatic 
cancer373, perhaps in conjunction with standard cytotoxic agents or with other 
interventions that can enhance the effects of ATRA, such as HDAC inhibitors or 
recombinant TRAIL. 
 
Considering the mechanisms of transcriptional regulation of retinoic acid 
response elements, with binding of histone deacetylases (HDAC), via co-
repressors, to RAR-RXR heterodimers resulting in gene silencing, one can 
reason that HDAC inhibition could restore retinoic acid signalling. Indeed, too 
much HDAC activity is the basis of APML and pharmacological doses of RA, 10 
to 100 times higher than physiological levels, are needed to dissociate the HDAC 
complexes and recruit co-activator/histone acetyltransferase (HAT) complexes to 
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initiate gene transcription301. APML patients with an alternative chromosomal 
translocation resulting in a RARα - promyelocytic leukaemia zinc finger fusion 
protein with two co-repressor interaction surfaces for binding of HDACs, don’t 
respond to treatment with RA. However, in combination with an HDAC 
inhibitor, this complex becomes retinoic acid sensitive and RA signalling is 
activated. Similar effects have been seen in other RA-insensitive APML patients 
and combined treatment of RA with HDAC inhibitors will be interesting to either 
lower the required pharmacological dose of RA, and thereby reduce toxicity, or 
to restore retinoid signalling in RA-resistant cells374.  
 
To investigate any potential benefit of HDAC inhibitors in the treatment of 
pancreatic cancer, pancreatic cancer cells and stellate cells have been treated 
with the pan-HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid 
(SAHA) and with the HDAC2 inhibitor valproic acid by Dr Mohammed Ghallab, 
who will continue this research question. Initial results look promising and may 
give us additional insights into novel therapeutic strategies for pancreatic cancer.  
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5.CHAPTER V  CONCLUDING REMARKS 
 
5.1. Pancreatic stellate cell, PS1 
The availability of the hTERT immortalised human pancreatic stellate cell, PS1, 
has enabled me to develop and use the described organotypic culture model, for 
which large amounts of stromal cells are required. Since isolated primary human 
pancreatic stellate cells can only be passaged for a limited number of times 
before undergoing senescence, obtaining primary human stellate cells in 
sufficient quantities has been proven to be difficult98; when I tried to isolate 
stellate cells, stellate cells were already senescent a few days after their 
outgrowth from the tissue blocks. Although the immortalised pancreatic stellate 
cell line I used, which was isolated from a normal human pancreas, continued to 
demonstrate all the characteristics of a true pancreatic stellate cell and imparted 
multiple tumour-promoting effects in pancreatic cancer cells, the effects of 
stellate cells isolated from pancreatic cancer tissue (from different patients) have 
not been investigated. Nevertheless, the relevance of the results obtained with 
PS1 cells can be confidently interpreted for several reasons. First, the effects of 
ATRA were analysed in different human and murine stellate cells by Mr Hemant 
Kocher, which demonstrated similar effects as the described results in PS1 cells, 
specifically a marked shift to the G1 phase of the cell cycle on exposure to 
ATRA (Figure 5.1). Second, a recent paper by the Apte group, comparing 
stellate cells isolated from normal pancreas and from pancreatic cancer tissue in 
their ability to stimulate tumour growth and progression in vivo, did not 
demonstrate any difference in their tumourigenic effects, suggesting that normal 
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pancreatic stellate cells were rapidly activated when in contact with pancreatic 
cancer cells104. Similar observations were made in organotypic cultures of 
oesophageal squamous cell carcinoma (OSCC), in which foetal oesophageal 
fibroblasts were activated when cultured in organotypic cultures with OSCC 
cells and stimulated cancer cell invasion to a similar extent as cancer associated 
oesophageal fibroblasts. Moreover, OSCC cells did not invade into the ECM 
when foetal skin fibroblasts were embedded into the gel, demonstrating the 
importance of the source of fibroblasts143, 144.  
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Effects of RA-treatment on pancreatic stellate cells. 
In addition to the immortalised PS1 stellate cell line, all four other stellate cells available 
in our laboratory (FS, primary normal human stellate cell; SAMK, SV40 immortalised 
rat stellate cell line; SIPS1, spontaneously immortalised rat stellate cell line; HPSC, 
primary human pancreatic stellate cells from cancer patient) were rendered back into a 
quiescent phenotype upon treatment with 1 µM ATRA, as demonstrated by a marked 
shift to the G1 phase of the cell cycle. In contrast, ATRA did not have any effect on 
primary human pancreatic fibroblasts (HPF), which were used as controls. C, vehicle 
control; P, cultured on plastic and treated with 1 µM ATRA. Histograms are 
representative of data from 3 biological repeats each containing at least 3 technical 
replicates. Mean ± SEM; *, p<0.05, Student’s t-test, 2-tailed, unequal variance. Data 
provided by Mr Hemant M Kocher. 
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5.2. From bench to clinic 
Predicting drug response in cancer patients remains a major challenge; currently 
only about 5% of new anti-cancer drugs that are being tested in clinical trials will 
ultimately be approved by the FDA375. Preclinical models selecting these 
possible new agents include 2D in vitro assays to study the functional effects on 
tumour cell behaviour and subsequent confirmation in xenograft models, in 
which tumour cells are injected subcutaneously or orthotopically in 
immunocompromised mice. One major drawback of these models is that the 
desmoplastic stroma is not well represented. Hence, better preclinical models are 
sorely needed. With the development of the Pdx1-Cre;LSL-KRASG12D;LSL-
TP53R172H (KPC) mice the pancreatic cancer research field has the availability of 
a genetically engineered mouse model that faithfully recapitulates human 
pancreatic cancer184. The relevance of this model to test novel therapeutic agents 
has recently been shown by Olive et al, who demonstrated that the tumour’s 
response to gemcitabine in KPC mice was similar to that observed in patients, 
i.e. a high resistance to the drug, whereas all xenograft mouse models 
demonstrated a significant reduction in tumour volume. This could be explained 
by a poor drug delivery to the tumours; KPC and human tumours demonstrated a 
decreased blood vessel density with vessels embedded in the intense 
desmoplastic stroma and tumour cells widely spaced from the blood vessels, 
resulting in undetectable levels of the active gemcitabine metabolite in the KPC 
tumours. Interestingly, drug delivery was significantly enhanced when the 
tumour stroma was disrupted by means of inhibition of the Hedgehog signalling 
pathway. Combining gemcitabine with an inhibitor of Smoothened, the 
transmembrane receptor that triggers the activation of Hedgehog signalling, 
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resulted in a significant decrease of the prominent desmoplastic stroma, an 
increase in vessel density with elevated intratumoural concentrations of active 
gemcitabine metabolites, a decrease in liver metastasis and a significantly better 
survival91. Thus, this study elegantly highlights the importance of a 
representative tumour model, the significant role of the tumour stroma in the 
delivery and efficacy of therapeutic agents, and that targeting this stroma is an 
effective approach in tumours with a strong desmoplastic stroma such as 
pancreatic cancer.  
 
Although these genetically engineered mouse models are excellent models to 
preclinically test novel therapeutics, they are expensive and time consuming. 
Since in vitro models are the first step in the selection of compounds that are 
tested in clinical trials, 3D in vitro models that more accurately model a human 
tumour will have a higher predictive value for their effect in genetically 
engineered mouse models and patients, as compared to the traditional 2D in vitro 
assays, thereby dramatically improving the current paradigm of preclinical drug 
screening. Valuable information can be obtained early in the whole process and 
only relevant drugs will be first tested in expensive, but representative, 
genetically engineered mouse models (and thus reduce the need of many animal 
experiments) and ultimately in patients, hopefully resulting in a better outcome 
of clinical trials.  
 
A recent comprehensive genetic analysis of 24 pancreatic cancer samples, 
demonstrated that the genetic basis of pancreatic cancer is extremely complex 
with a heterogeneous pattern of genetic alterations. Although on average 
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pancreatic cancers contained 63 genetic alterations (mostly point mutations), in 
which the specific genes altered in each tumour were largely different, they could 
be confined to a set of 12 cellular signalling pathways and processes that were 
genetically altered in 67 to 100% of the tumours40. This suggests that treatment 
of pancreatic cancer should target these complex and overlapping signalling 
pathways rather than their individual gene components. Until a more 
individualistic approach is feasible, this would entail a combination of targeted 
therapy and conventional chemotherapy (or radiotherapy). The advantage of 
differentiation therapy, such as ATRA, herein is that cells are rendered back into 
their physiological state, thereby affecting multiple signalling cascades and 
prevent possible escape or adaptation mechanisms of tumour cells leading to 
resistance.  
 
The increased understanding of the biology and genetic basis of pancreatic 
cancer with the recognition of the active, oncogenic, role of the tumour 
microenvironment is opening new avenues for treatment of pancreatic cancer. 
Good preclinical models will bridge the large gap that currently exists between 
preclinical results in 2D in vitro and xenograft models and the actual efficacy in 
patients, resulting in an improved (and faster) discovery of new treatments for 
cancer patients. Combined with research efforts to earlier detect pancreatic 
cancer by innovative imaging and/or new biomarkers, this may ultimately lead to 
a better perspective for patients with this deadly disease.  
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Table A.1 Differentially expressed genes upon ATRA treatment. 
Microarray data for significantly up- or downregulated genes according to dose-response (1 or 10 µM ATRA) or change in culture conditions (on plastic or 
Matrigel). Genes which differential expression has been confirmed by quantitative real-time PCR are highlighted in blue. C, control; P, plastic and M, 
Matrigel at 1 µM; 10, plastic at 10 µM. 
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8.APPENDIX II – LEGENDS TO SUPPLEMENTARY MOVIES 
Supplementary Movie 1 (attached on CD) 
Animation of z-stack of confocal images of E-cadherin staining of the 
organotypic cultures with or without stromal cells, as specified in the movie. 
Blue colour is DAPI stain for the nucleus, green stain is for E-cadherin. The 
stack is played at 1 frame per second through the full section and is on average 1-
2 cells thick. This movie demonstrates the loss of E-cadherin focally amongst 
cancer cells in the presence of stromal cells, as opposed to robust expression 
when there are no stromal cells.  
 
Supplementary Movie 2 (attached on CD) 
Animation of z-stack of confocal images of ezrin staining of the organotypic 
cultures with or without stromal cells, as specified in the movie. Blue colour is 
DAPI stain for the nucleus, green stain is for ezrin. The stack is played at 1 frame 
per second through the full section and is on average 1-2 cells thick. In some 
images the extracellular matrix is located at the top, which is specifically 
mentioned. This movie demonstrates the presence of ezrin positive processes 
arising from cancer cells, only in the presence of stromal cells. 
 
